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Summary
Smoking is now recognized as the single largest avoidable cause of premature death 
and disability in Britain and probably the greatest avoidable threat to public health 
worldwide. There are several therapies available to combat nicotine addiction ranging 
from psychological therapy to pharmacological interventions such as Nicotine 
Replacement Therapy. However, success rates for these therapies individually and 
mixture of therapies together, are still low and can be improved. A new strategy in 
helping quit rates is immunotherapy. This research project has focused on targeting 
cotinine, the major metabolite of nicotine, to produce a vaccine as a cessation method. 
The effect of cotinine on nicotine-evoked dopamine release was first examined using 
96-well plate assay in chapter 2. Cotinine was shown to decrease nicotine - evoked 
dopamine release, probably by desensitising the nAChRs. a6p2*, a4p2 receptor 
subtypes were implicated, using competitive antagonists. Trans-4-thiol cotinine was 
produced as a viable derivative and conjugated to ovalbumin in the appendix and 
chapter 3. Vaccination of rats generated anti-cotinine antibodies, although mid-point 
titres were low. Improvements were made in chapter 4 which increased the mid-point 
antibody titres. The improvements included change of carrier molecule to Tenatus 
Toxoid, allowing for 15 derivative attachments per carrier molecule, and change of 
adjuvant. The best concentration of conjugate to be used in vaccination was 
determined to be 5 pg which produced specific antibodies towards cotinine. Blood 
nicotine and cotinine concentrations after chronic nicotine treatment showed 
vaccination resulted in the retention of cotinine in the blood, presumably reducing the 
concentration reaching the brain, in chapters 4 and 5. Similar results were also 
obtained after acute nicotine treatment in chapter 5. The effect of vaccination on 
nicotine - evoked dopamine release was studied in chapters 4 and 5; an increase in 
nicotine-evoked dopamine release was observed in vaccinated animals. This suggests 
the retention of cotinine in the blood and the consequent reduction of antagonism of the 
actions of nicotine by cotinine, allowed nicotine to have a larger effect. Nicotine- 
induced locomotor activity was not affected by vaccination, however future work is 
needed to give conclusive results.
These results have provided preliminary proof of concept for this immunotherapy 
approach. Future in vivo experiments will elucidate the actions of this vaccine on 
addiction mechanisms and facilitate the development of this approach as a therapy to 
help people overcome nicotine addiction.
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1.1 Overview of smoking
1.1.1 History of tobacco
In 1962, the Royal College of Physicians published its first report on the effects of 
smoking on health, drawing attention to the strong relationship between cigarette 
smoking and lung cancer. The report concluded that this association was probably 
causal, that smoking may also cause other diseases including chronic bronchitis and 
coronary heart disease, and that smokers may be addicted to nicotine. In the years 
since that report was published, the true scale of the harm caused by smoking has 
become apparent. Smoking is now recognized as the single largest avoidable cause of 
premature death and disability in Britain and probably the greatest avoidable threat to 
public health worldwide.
The tobacco plant, nicotians tabacum, is native to the American continent. It is 
believed to have begun growing around 6000 BC and the American Indians started to 
use tobacco as early as 1st Century BC for medicinal and ceremonial purposes. 
Christopher Columbus was given tobacco, among other gifts, by American Indians in 
October 1492. Tobacco seeds and leaves were then brought back to Europe for the 
first time. However, tobacco smoking remained almost exclusively a male habit, at 
least in public, until the 19th Century. Although in 1571 a Spanish doctor, Nicholas 
Mondardes, claimed tobacco could cure 36 health problems, including toothache and 
cancer, in 1604 King James I produced a damning report entitled ‘Counterblast to 
Tobacco’ in which he said that smoking is a;
“Custome loathsome to the eye, hateful to the nose, harmful to the brain, [and] 
dangerous to the lungs.”
However by mid-1660s trade in tobacco between America and Europe had become a 
major business and by 1770 England’s role as a major tobacco trade centre between 
America and Europe had been established. In 1761 Dr John Hill performed possibly 
the first clinical study of tobacco’s effects, and noted that snuff users were vulnerable to 
cancers of the nose. In 1826 the pure form of nicotine was isolated. The invention of 
manufactured cigarettes transformed tobacco smoking into a truly mass habit when the 
first cigarette factory opened in England in 1856. It was still unacceptable for women to 
smoke until the suffragette movement in the 1920s, when a significant number of 
women started smoking; by the 1940s the British tobacco smoking epidemic was in full 
force (Kiernan 1991).
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1.1.2 Trends in smoking prevalence in Britain
Published data released by the Office for National Statistics shows smoking prevalence 
is on the decline and in 2004 was at 26% for men and 24% for women. However, 
inspection of age-specific rates in adults reveals that smoking prevalence has in fact 
been stable or increasing in recent years amongst most of the younger age groups, 
particularly in women. The rate at which new smokers are joining the prevalent 
smoking population has therefore been increasing for some years, making it likely that 
unless cessation rates begin to increase, the overall prevalence of smoking in the UK 
will soon begin to rise. Therefore better methods for effective smoking cessation are 
needed, hence the incentive for the research described in this thesis.
1.1.3 Risk factors and determinants of cigarette smoking
Risk factors and determinants of cigarette smoking come in several categories. The 
effect of gender on the likelihood of being a smoker is changing from being 
predominantly a male habit to becoming equal between the genders and may be 
overtaken by the female population (Freeth, Office for National Statistics 1998). Age is 
a major determinant of smoking behaviour with 28% of boys and 33% of girls of 15 
being regular smokers. Among adults, the 20-24 age group show the greatest smoking 
prevalence, thereafter decreases progressively with age (Department of Health 1998). 
Socio-economic status is also a significant determinant of smoking behaviour. In 1996 
the lowest consumers of tobacco were the professionals at 12% and the highest were 
the semi-skilled manual occupation groups at 39% (Department of Health 1998). 
However other measures of relative poverty or deprivation, including housing tenure, 
crowding, living in rented accommodation, being divorced or separated, 
unemployment, low educational achievement, and in women, single parent status, are 
also independently associated with an increased risk of smoking amongst adults (Royal 
College of Physicians 1992). Data for NHS Regional Office areas of England reveal 
that highest prevalence is in the North West Region at 30% and lowest in the South 
and West Regions at 25% therefore region of residence is also a determining factor 
(Department of Health 1998). Risk factors for smoking in children aged 11-15 in 
England include low educational achievement, living with parents who smoke and 
having siblings who smoke. Additional potential risks include low socio-economic 
status and having friends and teachers who smoke (Royal College of Physicians 1992).
1.1.4 Morbidity and mortality caused bv smoking
The cost of smoking to health is vast. A report by Callum for Health Education 
Authority (1998) said, smoking is responsible for approximately one in every five
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deaths in Britain which translates to 2300 people killed by smoking every week. When 
looking at individual causes of deaths, smoking caused 84% of all lung cancer and 
chronic obstructive lung disease deaths, 17% of ischaemic heart disease and 10% of 
strokes. Other diseases related to smoking include various forms of cancer such as 
kidney, bladder, stomach, pancreas and myeloid leukaemia. Other circulatory 
diseases include aortic aneurysm, myocardial degeneration and atherosclerosis. 
Diseases in the digestive system such as ulcers are also causes of death related to 
smoking. Overall, approximately one in every two smokers will die prematurely as a 
result of their smoking. However, the total loss to the community also depends on how 
premature their deaths are. Based on the distribution of deaths from smoking by age 
and mortality risks in never-smokers, it is estimated that in 1997 cigarette smoking 
accounted for the loss of 205000 years of life under age 65 and 551000 years of life 
under age 75 (Callum 1998).
1.1.5 The costs of smoking
There is also the monetary cost of smoking to society. These can be divided into two 
groups (Parrott et al 1998):
• The cost of the harmful effects of passive smoke exposure in non-smokers
• The costs imposed by smokers on the wider community, through the use of 
scarce health service resources or by lower productivity in the workplace. The 
total estimated cost was £1.5 billion for England in 1997.
1.2 Acetylcholine Receptors (AChR)
Addiction is a complex issue with many different factors contributing to the causes and 
effects of the condition. Ultimately, drug addiction begins with molecular interactions 
that alter the activity and metabolism of the neurons that are sensitive to that drug. 
Over time, this alters the properties of individual neurons and circuits, which leads to 
complex behaviours such as dependence, tolerance, sensitisation, and craving 
(Mansvelder et al 2002). Nicotine is the principle addictive component of cigarettes, 
which interacts with specific membrane receptors in the nervous system known as 
neuronal nicotinic acetylcholine receptors (nAChRs).
1.2.1 Classes of Acetylcholine Receptors
There are two classes of AChRs, the metabotropic muscarinic receptors and the 
ionotropic nicotinic receptors. In 1914, Sir Henry Dale, observed that the action of the 
esters of choline could be mimicked by some tissues by an alkaloid from Nicotiania 
tabacum (nicotine) and in other tissues by another alkaloid from Amanita muscaha
19
(muscarine). In doing so, Dale proved that the same substance (now known to be 
acetylcholine) could mediate distinctive responses in tissues through different 
molecules, therefore defining the existence of different receptor subtypes. However, 
the characterization of the nAChR became possible after the discovery that the electric 
organs (electroplax) of the sea dwelling rays of the Torpedo species contained huge 
amounts of nAChRs that led to the purification of milligrams of the protein (Changeux & 
Edelstein 1998). Research since then has propelled the nAChR group to be one of the 
most studied receptor groups. Both classes of receptor are present throughout the 
brain, with the smaller portion lying in the nicotinic group. From this section I will talk 
about the more relevant nicotinic acetylcholine receptors.
1.2.1.1 Nicotinic Acetylcholine Receptors
nAChRs respond to the neurotransmitter acetylcholine and have been implicated in a 
variety of physiological processes, including mediation of muscle contraction, neuronal 
development, neuroprotection, autonomic transmission and cognitive function 
(Lindstrom et al 1996, Role & Berg 1996, Changeux et al 1998, Dajas-Bailador et al 
2000). The nAChRs are ligand gated ion channels from a supergene family containing 
the inhibitory GABAa, GABAc and glycine receptors and the excitatory 5HT3 receptors 
(Ortells & Lunt 1995). The nAChR family is divided into two groups: neuronal nAChRs 
and muscle nAChRs.
1.2.1.2 nAChRs located at the neuromuscular junction
The nAChR located at the neuromuscular junction has a subunit composition of 
(a1 )2Pi5/ey (Ortells & Lunt 1995). These can form two different subtypes; the (a1 fePiSy 
are found before innervation (developmentally) or after nerve damage, and the adult 
(a1)2p8s are found over the muscle surface with the same composition as in Torpedo 
electroplax. After innervation, nAChRs are concentrated at the endplate, with the e 
subunit replacing y in adult muscle, altering both single channel conductance and 
channel kinetics (Mishina et al 1986, Camacho et al 1993). Due to the lack of subtype 
diversity, accessibility and straightforward functional role, synthesis and structure, the 
function of the muscle-type nAChR has been characterized in relative detail compared 
to the neuronal nAChR group. The neuromuscular junction is a remarkably robust 
structure, which rarely fails, however myasthenia gravis is one of the very few disorders 
that specifically affect it (Drachman 1981, Graus & De Baets 1993). This disease 
affects about 1 in 2000 individuals, who show muscle weakness and increased 
fatigability resulting from a failure of neuromuscular transmission. This is caused by
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the reduction of the amplitude of the endplate potential so that it often fails to reach 
threshold. Functionally, this results in the inability of muscles to produce sustained 
contractions, of which the characteristic drooping eyelids is a sign. In myasthenic 
muscle the number of receptors per endplate is on average, only about one-third of 
normal. An immunological explanation of the disappearance of receptors from the 
neuromuscular junction emerged in 1974, when the presence of antibody directed 
against the AChR protein was discovered in the serum of myasthenic patients 
(Drachman 1994). Myasthenia gravis can therefore be classified as an autoimmune 
disease.
1.2.1.3 Neuronal nAChR
The heterologous neuronal nAChRs are thought to contain 2 ‘a ’ subunits and 3 ‘non-a’ 
subunits; the latter comprise of p and a5 subunits (Cooper et al 1991). These 
receptors show a high affinity for nicotine (Clark 1985). The 12 types of neuronally 
expressed nAChR subunits, a2-10 and (32-4, can potentially give rise to thousands of 
nAChR subtypes. However, this is not thought to be the case, as it is now known that 
the assembly of the nAChR follows certain combinatorial rules (Elgoyhen et al 2001, 
Galzi & Changeux 1995, Sargent 1993). When heterologously expressed the a7, a8 
and a9 nAChR subunits can produce homopentamers (Elgoyhen et al 1994, Gotti et al 
1994). These receptors show a high affinity for a-bungarotoxin (Schoepfer et al 1990, 
Elgoyhen et al 2001). The a2-6 and a10 nAChR subunits only form complexes with (3 
subunits or other a subunits (Elgoyhen et al 2001, Le Novere et al 1996, Ramirez- 
Latorre et al 1996, Vernallis et al 1993). The pentameric structure of nAChRs is 
shown in figure 1.1.
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Figure 1.1: Pentameric structure o f the neuronal nAChR
The five subunits are arranged around a central channel in a pseudosymmetric manner. The 
pentamer consists of 2 a subunits and 3 non-a subunits. There is a large extracellular domain 
containing two acetylcholine binding sites that are mainly confined to the a subunits, with some 
contribution at the interfaces from neighbouring subunits, (picture by Dr Amy Bradley)
The subunits contain two major domains, the N-terminal extracellular domain, which 
contains the agonist-binding site, and the transmembrane domain that contains the ion 
channel. The most recent model shows flattened subunits, rather than rod-like, which 
are arranged around the pore like the blades of a pinwheel with a clockwise torsion 
(LeNovere et al 1999).
The large extracellular N-terminal domain contains putative glycosylation sites, a 
disulphide-linked cysteine-loop between residues homologous 128 and 142 of all a  or 
P subunits, which contains 13 amino acids, and the interface for agonist binding 
(Corringer et al 2000). It has been suggested that the cysteine-loop is involved in the 
assembly of the receptor from component subunits; in particular a conformational 
change in the cysteine-loop of the a subunit enables the association of a second 
subunit (Green & Wanamaker 1997).
The N-terminal region is glycosylated with up to 4KDa of carbohydrate polymers. There 
are four membrane-spanning regions (M1-M4) with a large cytoplasmic loop between 
M3 and M4 and a short C extracellular carboxyl terminus. The transmembrane
Extracellular Ions pats through
Po»(Na+ & C a2+eo in. 
A g o n is t





domains contain both p sheets and a helices. The second transmembrane segment, 
TM2 is orientated to line the channel producing a wide region at the extracellular 
surface narrowing towards the cytoplasmic face. High magnification imaging confirmed 
an a-helical conformation on TM2 (Revah et al 1990, Unwin 1995). The other 3 
transmembrane domains contain a helical regions but also contain a large degree of p 
strand conformation (Unwin et al 2003).
1.2.1.4 The acetylcholine binding protein (AChBP)
Although electron microscopy has resolved the structure (9.6 A), high resolution detail 
achieved by crystallographic methods has not been possible. However, this is 
circumvented for the ACh binding site by the recent discovery of the acetylcholine 
binding protein (AChBP) from the mollusc lymnaea stagnalis. The AChBP is produced 
by glial cells and is excreted into the extracellular space where it binds to free ACh, 
effectively lowering the concentration of ACh at synapses (Smit et al 2001). The 
AChBP is a homopentameric soluble protein, which appears to be analogous to the 
extracellular portion of the nAChR, with highest homology to a7-9 homopentamers. 
The cysteine-loop is present although the 13 amino acids between cysteines are not 
conserved. The high-resolution crystal structure demonstrated that the pentamer is 80 
A in diameter, 62 A in height with an 18 A channel through the centre. The subunits 
form an immunoglobulin-like fold and are arranged in a pin-wheel conformation (Brejc 
et al 2001).
The crystal structure confirmed the positions of the residues in the binding pocket, 
consisting of 3 loops (A, B, and C) contributed by the a subunit and 3 loops (D, E and 
F) from the neighbouring subunit. The contribution of loop E appears to be responsible 
for difference in agonist affinities between p2* and p4* nAChRs (Changeux & Edelstein 





Figure 1.2: Representation of the ligand-binding site viewed from the extracellular face of 
the protein.
The binding site is formed at the interface of the a  subunit and the complementary subunit, y or 
Sin muscle receptors, a  or f i in neuronal receptors. Acetylcholine (orange orb) binds between 6 
loops, 3 contributed from the a  subunit, A, B and C, and 3 from the complementary subunit, D,
E, and F. Loop C contains vicinal cysteines 192 and 193, (Cys), the majority of the other 
residues on the 6 loops are aromatic amino acids (Adapted from Changeux & Edelstein 2001,
Le Novere et al 2001). (Picture by Dr Amy Bradly).
1.2.1.5 Sequential model or concerted allosteric model?
It was first thought that the nAChR opened and closed in a manner similar to that of an 
enzyme, binding of an agonist causing the receptor to open, called the ‘sequential 
model’. However, in 1965 Monod, Wyman & Changeux proposed the ‘concerted 
allosteric model’. In this model the nAChR spontaneously isomerises between discrete 
states via a series of allosteric transitions, where binding of the ligand is at a site 
distinct from the site of activity i.e. the ion channel (for reviews see Corringer et al 
2000, Changeux & Edelstein 2001).
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Figure 1.3: Diagram representing the minimal four state model of allosteric transitions of 
the nAChR.
From rapid mixing experiments performed on Torpedo membranes rich in nAChR, a model with 
a minimum of four states was developed. R is the low-affinity resting state that occurs in the 
absence of agonist, A represents the active receptor state, and D and I are desensitised states. 
For the Torpedo nAChR, the timescales of some of the transitions are as follows: R to A = ps to 
ms, towards D = ms to 100 ms, towards I = up to a minute.
Figure 1.3 shows that upon agonist binding, nAChRs undergo an allosteric transition 
from the closed, resting conformation to an open state which conducts the cations 
sodium, potassium and calcium. In the active (open) conformation, the nAChR binds 
agonists with low affinity. The continued presence of agonist leads to ion channel 
closure and receptor desensitisation. Although the receptor shows higher affinity for 
agonist binding in this condition, it is refractory to activation. A multiplicity of 
desensitised states is proposed to exist. The rates of desensitisation and recovery 
differ between subtypes with a7 displaying very rapid desensitisation. Prolonged 
agonist exposure may produce an inactivation state, from which recovery is very slow. 
Transitions between resting, open and desensitisation states are reversible and 
different ligands may stabilise different receptor states: agonists initially stabilise the 
activated state whereas competitive antagonists preferentially stabilise the closed 
state, either the resting or desensitised configuration (Sharpies & Wonnacott 2001 
Tocris report). So from a physiological point of view, a pulse of acetylcholine into the
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synaptic cleft would stabilise the active state before proceeding to stabilise the higher 
affinity desensitised and inactive states. However, a low concentration of acetylcholine 
would match the high affinity of the inactive and desensitised states thus shifting the 
equilibrium in that direction. In this way acetylcholine could act as both an activator or 
inhibitor depending on the concentration present at the nAChR. This is important on 
the actions of nicotine in addiction and smoking.
1.3 Pharmacology and pharmacokinetics of nicotine





Figure 1.4: Chemical structure of nicotine molecule. Nicotine is a water and lipid soluble drug, which 
in free base form, is readily absorbed via respiratory tissues, skin and gastrointestinal tract.
Nicotine is a tertiary amine which exists in two sterioisomers; (S)-nicotine is the active 
isomer which binds to nACh receptors and is found in tobacco. Small quantities of (R)- 
nicotine are found in cigarette smoke after racemisation during smoking, which acts as 
a weak agonist on nAChRs.
A concise and accurate description of cigarette smoke was found in the Royal College 
of Physicians report 1997 which says: Cigarette smoke is composed of volatile and 
particulate phases. 500g gaseous compounds including nitrogen, carbon monoxide, 
carbon dioxide, ammonia, hydrogen cyanide and benzene have been identified in the 
volatile phase which accounts for about 95% of the weight of cigarette smoke; the other 
5% consists of particulates. There are about 4000 different compounds in the 
particulate phase, of which the major one is nicotine. Other alkaloids include 
nornicotine, anatabine and anabasine. The particulate matter without its alkaloid and 
water content is called tar. Many carcinogens including polynuclear aromatic 
hydrocarbons, N-nitrosamines and aromatic amines, have been identified in cigarette 
tar.
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1.3.2 Absorption of nicotine from tobacco products
When a cigarette is smoked, small droplets of tar containing nicotine are inhaled and 
deposited in the small airways and alveoli. As nicotine is a weak acid, at pH 5.5 (same 
as smoke from cigarettes) it is mostly ionized and does not freely cross cell 
membranes. This is why it is not absorbed through the buccal mucosa. In contrast, 
nicotine delivered through pipes and cigars, which have an alkaline pH of 8.5, is mostly 
unionized and well absorbed from the mouth (Russell et al 1981, Russell et al 1986). 
Once cigarette smoke reaches the small airways and alveoli, it is buffered to 
physiological pH and rapidly absorbed into the pulmonary alveolar capillary and venous 
circulation leading to the systemic arterial blood. This allows for rapid distribution 
around the body, only taking 10-19 seconds to reach the brain (Russell et al 1981). At 
this time the arterial blood perfusing the brain contains levels of nicotine which exceed 
venous levels by a factor of 2-6 fold allowing for rapid absorption into the brain. The 
nicotine levels in plasma and brain decline rapidly due to distribution to peripheral 
tissues, excretion and elimination.
The plasma nicotine levels of smokers who smoke multiple cigarettes during the day 
follow a pattern of oscillations between peak and trough. As nicotine has a half-life of 
only 4 hours, nicotine accumulates over 6-8 hours reaching levels in the plasma 
ranging from 20-40ng/ml (Russell 1990). This then falls progressively during the night. 
Different people seem to have a different tolerance to the levels of nicotine in their 
blood which makes the smoker regulate their intake of nicotine by self-titration, from a 
cigarette to achieve and maintain a desired level of nicotine. Thus circumventing the 
negative physiological effects caused by high nicotine levels, whilst preventing 
symptoms of withdrawal (review by Russell 1990). This can be done in a number of 
ways including changing the puff volume or number of puffs (Hasenfratz et al 1993). 
The rapid absorption of nicotine from cigarettes and the high arterial levels reaching the 
brain enhance the behavioural reinforcement from smoking. When the levels of 
nicotine fall, the nAChRs are allowed to resensitise between cigarettes. Tolerance to 
the toxic effects of nicotine such as nausea, rapidly develop and persist. Nicotine has 
a number of toxic or adverse effects, some of which are potentially relevant in disease 
pathogenesis. These include acute systemic effects such as headache and dizziness, 
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Figure 1.5: The metabolic pathway o f nicotine in mammals.
Solid arrows show established pathways, broken arrows indicate unconfirmed reactions 
(Kyerematen & Vesell 1991).
Following administration, nicotine is extensively metabolised in the liver but also to a 
small extent in the lung and brain. Nicotine undergoes extensive hepatic 
biotransformation via a number of phase I and II metabolic pathways (figure 1.5) 
(Kyerematen et al 1991). It is established that regular smokers metabolise nicotine 
more slowly than non-smokers. Several cytochrome P450 enzymes and flavin mono­
oxygenase have been reported to play a role in nicotine metabolism. However, 
CYP2A6 has been shown to be the main enzyme involved, especially in converting 
nicotine to cotinine via the route shown in figure 1.5. The principle metabolite of
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nicotine is cotinine which has a much longer half-life (16-21 h) than nicotine (4h), with 
average cotinine levels 15 times higher than those of nicotine (Benowitz 1996). In one 
study (Kyerematen et ai 1990) the six most abundant species recovered in the urine of 
smokers following an intravenous dose of racemic nicotine (190pg) were 3- 
hydroxycotinine glucuronide (16.6%), cotinine (15.6%) with a half life of 16-20 hours, 
nicotine (14.9%), demethylcotinine enamine (11.3%), demethylcotinine (9.3%) and 
cotinine-N-oxide (7.4%). There were also small amounts of 3-norcotinine (2.7%), 3- 
hydroxycotinine (1.6%) (found in urine) and nicotine-1-N-oxide (0.7%). Other 
metabolites that have been identified in urine following nicotine administration to 
human volunteers include 4-oxo-4-(3-pyridyl) butanoic acid (14% of total nicotine) 
(Hecht et al 1999), nicotine glucuronide (3%) and cotinine glucuronide (17%) (Byrd et 
al 1992). Ethnic differences in nicotine metabolism have been studied and these show 
that African-Americans metabolised cotinine more slowly than Caucasians by slower 
oxidation to trans-3’-hydroxycotinine and N-glucuronidation (Benowitz et al 1999). 
Therefore, smokers who metabolise nicotine more rapidly may need to take in more 
cigarette smoke and are therefore at higher risk of smoking-related illness. Pianezza et 
al (1998) speculated that the presence of a CYP2A6*v1 mutant allele, reflecting slower 
than normal nicotine metabolism, may be associated with a lower risk of progression 
from experimental to addictive smoking. This study however is not conclusive. 
Continine levels are most strongly correlated with nicotine dose and to a lesser extent, 
fractional conversion of nicotine to cotinine and cotinine clearance (Benowitz et al 
1997). Renal clearance of nicotine, which in turn controls partly the nicotine levels in 
plasma, depends on urine pH, being higher in acidic urine and lower in alkaline urine, 
and accounts for 2-35% of total nicotine clearance (Benowitz et al 1985). Other factors 
as mentioned before which influence nicotine levels in plasma and brain are distribution 
to peripheral tissues, excretion and elimination.
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Figure 1.6: The origin o f CNS metabolites of nicotine after peripheral nicotine
administration (Crooks & Dwoskin 1997).
Figure 1.6 shows the current understanding of the origin of nicotine metabolites present 
in brain after peripheral nicotine administration. Little is known about the metabolism of 
nicotine in human brain. Pharmacokinetic studies have determined the amount of 
nicotine in brain after various routes of administration in several animal species 
(Nordberg et al 1989, Plowchalk et al 1992). Nicotine, cotinine, nornicotine, norcotinine 
and two minor unidentified metabolites appear in brain after a single dose of nicotine 
(Crooks et al 1995, 1997, Ghosheh et al 1999). Brain half-lives for cotinine, nornicotine 
and norcotinine were 6, 3 and 4 times longer, respectively, than the half-life of 52 
minutes determined for nicotine, demonstrating that these biotransformation products 
have longer brain residence times compared with nicotine. Considering the chronicity 
of nicotine exposure during tobacco smoking and the relatively longer brain residence 
time of the metabolites, the possibility exists that after repeated peripheral nicotine 
administration, the metabolites of nicotine may accumulate in brain and reach 
pharmacologically significant concentrations (Ghosheh et al 1999).
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1.4 Nicotine addiction
Addiction is a complex behavioural phenomenon with causes and effects that range 
from molecular mechanisms to social interactions. Ultimately, the process of addiction 
begins with molecular interactions that alter the activity and metabolism of the neurons 
that are sensitive to that drug. Over time, this alters the properties of individual 
neurons and circuits, which leads to complex behaviours such as dependence, 
tolerance, sensitisation and craving (Koob eta! 1997, Nestler & Aghanjanian 1997). 
Various neural pathways and transmitter systems have emerged in research as 
compelling candidates for the processing of the psychoactive and addictive properties 
of nicotine.
1.4.1 Neuronal pathways associated with nicotine addiction
The ventral tegmental area (VTA) is located in the midbrain and has been shown to be 
involved in the rewarding and motivational effects of many addictive drugs, including 
cocaine (Philips et al 2003), and nicotine (Laviolette & Van der Kooy 2003, Corrigall et 
al 2000, Nisell et al 1994). The principle excitatory inputs to the VTA DA neurons are 
glutamatergic projections from the prefrontal cortex (kalivas et al 1989, Johnson et al 
1992, Sesack & Pickel 1992, Taber et al 1995, Carr & Sesack 2000). The principle 
inhibitory inputs to VTA neurons are GABAergic including local interneurons and 
projections from Nacc and the ventral pallidum (Kalivas et al 1993). Cholinergic 
projections to the VTA come from brain stem nuclei, the pedunculopontine and 
tegmental nucleus (PPTg) and the lateral dorsal tegemental nucleus (LDTg). 
Ultrastructural analysis has shown that cholinergic boutons within the VTA contact 
postsynaptic structures with low levels of dopamine transporter expression (Garzon et 
al 1999). Numerous other neurotransmitters and neuromodulators influence the 
activity of the VTA including serotinine, norepinephrine and endogenous opiods 
(Tzschentke 2001), however I will only focus on GABA and glutamate inputs into the 
VTA DA neurons. DA release from VTA projections is caused by the balance of 
excitatory and inhibitory inputs and the intrinsic activity of the DA neurons. Nicotinic 
receptors of various subtypes are expressed by DA and GABA neurons and by the 
axon terminals of glutamatergic inputs and play an important physiological role in the 
modification of synaptic transmission within the VTA (figure 1.8).
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Figure 1.7: Sagittal section through the rat brain depicting the anatomical pathways 
implicated in the reinforcing effects of drugs of abuse. Projections of the mesolimbic 
dopaminergic system to the nucleus accumbens (NAcc) are in orange, and are thought to be 
critical for psychomotor stimulation reward. They originate in the ventral tegmental area (VTA) 
and project to the NAcc, olfactory tubercle (OT) and ventral striatal domains of the caudate 
putamen (CP). Green pathways indicate opioid peptide containing neurones that may be 
involved in opiate and ethanol reward. GABAa receptor brain areas are shown in blue, and are 
thought to mediate some of the sedative/hypnotic rewards of ethanol. VP, ventral pallidum; SNr, 
substantia nigra pars reticulata; DMT, dorsal medial thalamus; PAG, periaqueductal gray; FC, 






Figure 1.8: Schematic showing the DA and GABA neuronal populations within the VTA.
GABA neurons send descending projections to the TPP and provide inhibitory input to DA 
neurons. Both neuronal populations are activated by nicotine and receive excitatory 
glutamatergic inputs, which can regulate the relative activity of DA and GABA in the VTA 
(Picture taken from Laviolette & van der Kooy 2004).
Dopamine neurons of the VTA express the a2-a7 and 02-04 subunits (Charpantier et 
al 1998, Klink et al 2001). From these subunits, at least three pharmacologically 
distinct subtypes can be formed including the homomeric a7, which is preferentially
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localized in the VTA in the midbrain, adjacent to the substantia nigra (Woolterton et al 
2003). Most nAChRs of the GABA neurons in the VTA contain a4 and p2 subunits, 
which are blocked by mecamylamine and DHpE (Mansvelder et al 2002) and less than 
25% of these neurons express the a3, a5, a6 and p4 subunits (Klink eta! 2001).
Many addictive drugs including nicotine cause an increase in dopamine levels in the 
nucleus accumbens (NAcc) at the same concentrations that are achieved in serum 
during self-administration in rodents and humans (Nisell et al 1994, Imperato et al 
1986, Stolerman & Jarvis 1995, Dani & Heinemann 1996, Picciotto et al 1998, Dani & 
De Biasi 2001). Within physiological range of plasma nicotine concentrations that are 
obtained by smokers (~0.5pM), nicotine potently activates DA neurons of the VTA, 
which is followed by desensitisation of nAChRs after continued exposure to nicotine 
(Pidoplichko et al 1997). This indicates that the acute excitatory actions of nicotine on 
DA neurons might signal its reinforcing reward effect, the long-lasting desensitisation of 
VTA nAChRs might represent a cellular basis of nicotine tolerance. This may explain 
reports from heavy smokers, that they enjoy most the first cigarette of the day (at a 
time when nAChRs would not be in a state of prolonged desensitisation). The Nacc 
levels have been shown to be important in reward by VTA lesion studies and 
microperfusion of the Nacc with DA receptor antagonists, mecamylamine and DHpE, 
both of which result in reduced self-administration of nicotine (Nisell et al 1994, Balfour 
1991, Corrigall et al 1992, 1994, Louis & Clarke 1998). Therefore, while systemic 
administration of nicotine affects nAChRs in many brain regions such as Nacc, 
hippocampus and cortex, it is the nAChRs in the VTA that mediate the rewarding 
effects of nicotine. Although some drugs of abuse alter the activity of the VTA neurons 
to enhance DA release, preferentially in mesoaccumbens but not the nigrostriatal 
system (Imperato etal 1986, Benwell & Balfour 1997).
1.4.2 Functional properties of nAChRs in nicotine addiction
As nicotine influences neuronal activity, synaptic communication and behaviour 
through its effects on nicotinic receptors, it is important to discuss the functional 
properties of these receptors. There is great diversity in the sensitivity of the different 
receptor subtypes to nicotine and different affinities lead to different channel activation 
and subsequent desensitisation in the continued presence of the drug. Nicotinic 
receptor upregulation is where the receptor sensitivity and binding levels increase 
following nicotine pre-exposure, but this is not associated with changes in mRNA and is 
thought to reflect increased assembly (Olale et al 1997, Wang et al 1998).
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Physiologically relevant nicotine concentrations have been shown to upregulate a4p2 -  
containing receptors (Buisson & Bertrand 2001). Upregulation has also been shown 
with higher nicotine concentrations in some cells (Rogers & Wonnacott 1997, Molinari 
et al 1998). There are some reports of an increase in ligand binding following nicotine 
pre-exposure (Rowell & Wonnacott 1990, Buisson & Bertrand 2001), while others have 
found a decrease in function (Marks et al 1993). These differences may be a result of 
different assays being used. However nicotine self-administration may enhance 
nAChR responses as pre-exposure to nicotine has been shown to sensitise animals to 
its locomotor and self-administration effects (Shoaib et al 1997). It is still not clear 
whether nicotine self-administration induces receptor upregulation in vivo, although 
high [3H] nicotine binding in brain tissue from post-mortem smokers have been reported 
(Court et al 2000, Patterson & Nordberg 2000).
1.4.3 Excitation of nAChRs in nicotine addiction
In brain slice recordings from VTA DA neurons, glutamatergic transmission onto these 
neurons is enhanced by low concentrations of nicotine which is unaffected by TTX, 
which blocks action potential firing, suggesting that nAChRs mediating this effect are 
situated locally in the VTA, on the presynaptic glutamatergic terminals (Mansvelder & 
McGehee 2000). These nAChRs are sensitive to MLA, which is a selective inhibitor of 
a7 subunits (Alkondon & Albuquerque 1993). These subunits are well situated for 
modulating synaptic transmission as they have a high calcium permeability, and this 
calcium flux occurs at resting membrane potential when activated by agonists 
(McGehee & Role 1995).
In a cholinergic synapse, the Ach concentration rises within milliseconds to millimolar 
concentrations (Kuffler & Yoshikami 1975). However the nicotine concentration profile 
of a smoker’s blood during cigarette smoking is very different and shows blood nicotine 
levels reaching 300-500nM several minutes after the initiation of smoking and 
concentrations close to 250nM are sustained for 10 minutes or more (Henningfield et al 
1993, Gourlay & Benowitz 1997). The high affinity nAChRs including a4J32 and a3p2 
subtypes have measurable activity at these concentrations on VTA DA neurons 
(Picciotto et al 1998) but with nicotine concentrations of 100-500nM, the somatic 
nAChRs desensitise within minutes (Dani et al 2000). However, in vivo studies show 
that a single systemic injection of nicotine enhances DA release in the Nacc for more 
than an hour (Di Chiara 2000). Therefore other mechanisms following activation of 
nAChRs must induce the long-term potentiation of the excitatory glutamatergic input,
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and nicotine-induced depression of GABAergic transmission (Mansvelder & McGehee
2000).
Nicotine receptors are present on both the presynaptic glutamatergic terminals and DA 
neurons. When nicotine arrives in the VTA, it stimulates both directly, which can mimic 
the paired electrical stimulation of pre- and postsynaptic partners. Presynaptic a7 
nAChRs provide rapid means to increase intracellular calcium presynaptically as these 
channels will gate the resting membrane potential (Seguela et al 1993), and 
simultaneous activation of the nAChRs on postsynaptic DA neurons will increase the 
likelihood of NMDA receptor activation due to depolarisation and relief of magnesium 
block. In mutant mice lacking the p2 containing subunit, there is no long-term 
activation of the DA system by nicotine, and the mice do not self-administer (Picciotto 
et al 1998). This suggests that without p2 containing nAChRs, nicotine does not 
depolarise the DA neuron enough to relieve magnesium block of NMDA receptors 
(Mansvelder & McGehee 2002).
1.4.4 Inhibitory control of nAChRs in nicotine addiction
In addition to excitatory inputs, GABAergic inputs into the VTA DA neurons provide 
inhibitory control. When nicotine reaches the VTA, nAChRs expressed by GABA 
neurons are activated and cause an increase in the firing rate of these neurons (Yin & 
French 2000). These are most likely to be of the non-a7 type that contain a4 and p2 
subunits. When nicotine is applied to these receptors there is a transient increase in 
inhibitory inputs to DA neurons in the VTA. This effect would likely offset some of the 
excitatory effects of nicotine during the time of enhanced GABA transmission. These 
nAChRs on the GABA neurons desensitise rapidly causing a decrease of GABA 
neuron activity and the inhibitory input to the DA neurons diminish resulting in an 
increase in their action potential firing. The nAChRs on the GABA neurons recover 
very slowly from desensitisation. In the first 15 minutes after nicotine is present, GABA 
neurons do not respond at all to the next nicotine application and this takes 
approximately 1 hour to reach normal levels of nicotine sensitivity (Mansvelder et al
2002). The recovery of endogenous cholinergic transmission would require a similar 
time course. During this time DA neurons are therefore more active.
Although a7 receptors on the glutamatergic terminals also desensitise rapidly, the low 
nicotine concentrations associated with tobacco use induce much less desensitisation 
of these receptors. A 10 minute exposure to 250nM nicotine completely desensitises
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the nAChRs on GABA neurons, however the enhancement of glutamatergic 
transmission does not show significant desensitisation. Thus excitatory inputs to VTA 
DA neurons are enhanced by nicotine while inhibitory GABAergic inputs are depressed 
(Mansvelder et al 2002). In addition, if DA neuron is depolarised sufficiently, the 
enhancement of glutamatergic transmission can induce long-term potentiation of these 
inputs.
1.4.5 Does a reduction in VTA GABAergic transmission actually contribute to 
nicotine addiction?
Rats and mice will readily self-administer GABAa receptor antagonists when they are 
locally infused into the VTA (David et al 1997), which also increases DA levels in the 
Nacc (Ikemoto et al 1997). Therefore it is likely that the reduction in GABAergic 
transmission following nAChR desensitisation in the VTA contributes to the reinforcing 
effects of nicotine. p2 subunits which mediate the effect of nicotine on GABA neurons 
have been shown to be necessary for the maintenance of nicotine self-administration in 
knock-out mice (Picciotto et al 1998, Grottick et al 2000). These mutant mice also 
showed a strong reduction in nicotine induced conditioned taste aversion indicating that 
this receptor is also implicated in the aversive effects of nicotine. I will talk about the 
aversive effects of nicotine later. Pre-treatment with specific antagonists of D1 and D2 
DA receptor subtypes strongly attenuated nicotine self-administration (Corrigall et al 
1991). Lesions of the mesolimbic DA system caused by 6-hydroxydopamine, a 
molecule that selectively destroys DA neurons, also attenuated nicotine self­
administration (Corrigall et al 1992). Also, microinfusion of DHpE directly into the VTA 
attenuated nicotine self-administration but not the reinforcing effects of food or cocaine, 
implicating that the mesolimbic DA projections from the VTA are a crucial mediator of 
the reinforcing effects of nicotine (Corrigall et al 1994).
1.4.6 Role of Nacc shell vs core in nicotine addiction
Another issue to consider is the fact that the Nacc is a heterogeneous structure, which 
is composed of a shell that lies ventral and medial to the accumbal core. These two 
principle subdivisions of the accumbens are anatomically distinct, have different 
projection fields and are thought to subserve different functions (Heimer et al 1991, 
Zahm & Brog 1992). Subsequent studies showed that the acute injections of nicotine 
stimulate DA overflow in the medial shell of the accumbens, whereas they have no 
significant effect on extracellular levels of DA in he accumbal core (Benwell & Balfour 
1992, Cadoni & Di Chiara 2000, lyaniwura et al 2001). However, if rats are treated
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repetitively with daily injections of nicotine, the DA response in the medial shell tends to 
diminish, significantly so in the study reported by Cadoni & Di Chiara (2000), whereas 
nicotine pre-treatment results in a regionally selective sensitisation of the response in 
the accumbal core (Benwell & Balfour 1992, Cadoni & Di Chiara 2000, lyaniwura et al
2001).
The core of the accumbens sends projections to areas of the brain concerned with the 
control of motor activity (Zahm & Brog 1992). Initially therefore, it was assumed that 
the sensitised DA response to nicotine observed in the core of the accumbens of 
nicotine pre-treated rats, mediated the sensitised locomotor responses to the drug also 
observed in rats pre-treated with nicotine prior to the test day (Benwell & Balfour 1992, 
Cadoni & Di Chiara 2000). However some studies have revealed a dissociation 
between the sensitised increase in DA overflow in the accumbal core and the increase 
in locomotor activity evoked by nicotine in nicotine pre-treated rats. The sensitised DA 
response to the drug is inhibited by the prior administration of an antagonist of NMDA 
glutamatergic receptors, whereas the sensitised locomotor response is unaffected by 
these drugs (Shoaib et al 1994, Balfour et al 1996, Benwell et al 1996).
The microdialysis probes which are used in many studies to investigate the effects of 
drugs of dependence on extracellular DA in the NAcc do not directly measure the 
changes in DA release into the synaptic cleft, but detect changes in the DA 
concentration in the interstitial space between the cells. The increase in DA overflow, 
evoked by systemic injections of nicotine, appears to be mediated predominantly by 
receptors located on or close to the cell bodies of the VTA that influence impulse flow 
to the terminal field (Balfour et al 1998, 2000). Nicotine injections increase the 
proportion of midbrain DA neurons that exhibit burst firing (Nisell et al 1996), and there 
is evidence that increased burst firing of these neurons evokes a substantial increase 
in the DA concentration in the extracellular space sampled by a dialysis probe (Gonon 
1997, Nissbrandt et al 1994). This led to the conclusion that the increases in 
extracellular DA found in both the accumbal medial shell and core of nicotine treated 
rats reflect the increase in burst firing of dopaminergic neurons evoked by the drug 
(Balfour et al 2000).
1.4.7 Hedonic properties on behaviour by nicotine
Microdialysis studies have shown that the presentation of natural rewards, such as 
palatable food or sucrose increase DA overflow in the medial shell when compared 
with the core in the NAcc. Whereas the presentation of a stimulus such as the odour
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of food selectively stimulates DA overflow in the accumbal core (Hajnal & Norgren 
2002, Bassareo & Di Chiara 1999). It also elicits sensitisation of the DA response to 
the core if the animals are subsequently permitted access to the food. One hypothesis 
by Balfour (2004), to explain the data derived from studies with both natural rewards 
and drugs of dependence, is that the major role of the DA projections to the medial 
shell is to confer hedonic properties on behaviours, rather than their outcomes, that are 
paired with increased extracellular DA in this subdivision of the structure. Therefore 
the behaviours themselves acquire reinforcing properties, which are related to the 
magnitude of the increase in extracellular DA in the medial shell. This increases the 
probability that behavioural responses that deliver a pleasurable reward will be 
repeated and learned efficiently. Psychostimulant drugs of dependence such as 
nicotine, evoke sustained and substantial increases in DA overflow in the accumbal 
medial shell, by acting directly on the neurons that project to the subdivision of the 
accumbens. Therefore behaviours and stimuli associated with delivery of the drug 
acquire powerful reinforcing characteristics that may be disproportionate to, or indeed 
independent of, the rewarding properties of the drugs per se.
Hedonia
RewardNicotineBehaviour
Increased DA overflow in 
the accumbal shell
Figure 1.9: The role o f increased dopamine overflow in the accumbal shell on 
responding to a reward.
Proposed circuitry by which a reward such as nicotine increases DA overflow in the acumbal 
medial shell. This increased DA overflow is hypothesised to confer hedonic characteristics on 
behaviour such as lever-pressing response that results in presentation of reward. Nicotine is 
illustrated to greatly enhance the hedonia associated with the behaviour by directly increasing 
extracellular DA in the accumbal medial shell. (Diagram and hypothesis from Balfour (review) 
2004).
Some tests have shown that responding reinforced by injections of psychostimulant or 
the presentation of food are also associated with increased DA overflow in the 
accumbal core (Ito et al 2000, Bassareo & Di Chiara 1999). Balfour (1994) suggested 
that increased DA overflow in the core of the accumbens may also promote and 
maintain compulsive drug-seeking behaviour in animals in which the behaviour is
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reinforced by delivery of the primary reward. This may suggest that sensitisation of this 
response plays a pivotal role in the transition to dependence. The sensitised increase 
in DA overflow in the accumbal core enhances the probability of compulsive drug- 
seeking behaviour in response to drug-associated stimuli, whereas the increase in DA 
overflow in the medial shell serves to amplify these effects on behaviour by enhancing 
the hedonic value of the behaviour itself. These two effects serve to make drug- 











Figure 1.10: The putative role o f hedonia and conditioned rein forcers in nicotine-seeking 
behaviour.
The figure summarises the mechanisms that have been proposed to explain how increased DA 
overflow in the medial shell and core of the NAcc, evoked by an injection o f nicotine, play 
complementary roles in the expression o f nicotine-seeking behaviour. The hypothesis suggests 
that in both subdivisions of the accumbens, extracellular DA serves to promote or amplify the 
signals that project from or through the structure. Stimulation o f the projections to the medial 
shell of the accumbens enhances the hedonia value of the behaviour itself and of sensory and 
environmental stimuli associated with the delivery of nicotine. Stimulation of the projections to 
the accumbal core promotes the effects of conditioned reinforcers or stimuli on nicotine-seeking 
behaviour. These conditioned responses can be amplified further by stimulation of the DA 
projections to medial shell through which neurones from the core project. (Diagram and 
hypothesis from Balfour (review) 2004).
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1.4.8 Aversive effects of nicotine on nicotine addiction
Nicotine however does not have powerful “euphoriant” properties and in some 
circumstances has potent aversive effects. Nicotine can produce powerful anxiogenic 
effects systemically and centrally (File et al 2000) through activation of nAChRs that 
contain p2, a4 and a7 subunits (Tucci et al 2003). The noxious effects felt by people 
include nausea, dizziness and coughs on their initial experience with tobacco 
(Kozlowski & Hartford 1976), however tolerance develops to these aversive effects with 
repeated exposure (Shoaib & Stolerman 1995). The precise neurological mechanism 
behind this is still unknown but it does indicate that chronic nicotine exposure might 
induce a functional alteration in the neuronal systems that mediate the aversive and/or 
rewarding effects of nicotine. A study using the conditioned place preference model 
(CPP) reported that both rewarding and aversive effects could be measured using the 
same test after microinfusions of nicotine itself onto the VTA (Laviolette & van der Kooy
2003). They showed a dose-dependant, biphasic curve for the motivational effects of 
nicotine in the CNS; whereas a lower nicotine concentration in the VTA produced an 
aversive effect, higher concentrations produced potent rewarding effects. With DA 
receptor blockade systemically or directly in the Nacc there was no attenuation of the 
rewarding effects of nicotine in chronically treated animals, however when the acute 
aversive effects of nicotine are blocked by interfering with mesolimbic DA receptor 
signalling, the rewarding effects of nicotine are potentiated, presumably by the removal 
of an aversive signal (Laviolette & van der Kooy 2003).
A view proposed by Berridge & Robinson (1998, 2001) states that after repeated drug 
exposure, sensitisation of the DA system, which signals the ‘craving’ for the drug, leads 
to compulsive drug seeking and use. Repeated nicotine exposure has been shown to 
sensitise DA pathways (Benwell & Balfour 1992) and increase DA receptor expression 
in the projection areas of the VTA DA system (Le Foil et al 2003) and increase the 
number of nAChR subtypes in the VTA (Ryan & Loiacono 2001). A related possibility 
is that plastic processes that increase DA responsiveness to nicotine within the VTA 
might represent an aberrant form of drug-induced associative learning. Interestingly, 
exposing humans to imagery of stimuli associated with smoking activates neuronal 
regions that are linked to drug-induced DA sensitisation processes such as the 
prefrontal cortex and amygdala (Brody et al 2002). Blockade of this DA-mediated 
incentive learning signal in chronically treated animals does reduce nicotine self­
administration (Corrigall et al 1992, 1994, Picciotto et al 1998, 2002). However this 
does not explain why DA-mediated transmission seems to carry a specific aversive 
signal in the acute phase of nicotine exposure and reinforcing signal after chronic
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nicotine exposure. An explanation by Laviolette & van der Kooy (review 2004) 
suggests that dysregulation of DA-mediated signalling during nicotine dependence and 
withdrawal after chronic exposure might be responsible for the aversive effects of 
nicotine withdrawal, which motivate the smoker to seek nicotine. Whereas, activation 
of nAChRs of DA neurons can signal an aversive effect in the early phases of nicotine 
exposure, the eventual desensitisation of these receptors, which takes place after the 
desensitisation of the nAChRs in VTA GABA neurons might account for the tolerance 
to the aversive properties of nicotine over time.
1.4.9 Prolonged or habitual smoking
As mentioned before, the neuronal nAChRs which mediate the effects of nicotine on 
mesolimbic DA neurons are desensitised by sustained exposure to the drug at 
concentrations significantly lower than those found in the plasma of rats that have self- 
administered nicotine for 1 hr (Benwell et al 1995, Pidoplichko et al 1997, Shoaib & 
Stolerman 1999). This implies that as the concentration of nicotine in the brain reaches 
a level that results in desensitisation of the receptors, subsequent injections of the drug 
may not result in further stimulation of the DA-secreting neurons (Balfour et al 2000). 
In many self-administration studies the animals are trained and tested in discrete daily 
trials of 1 or 2 hours. For the remainder of the day, the animals experience enforced 
abstinence when the blood nicotine concentration will fall to a low level that is unlikely 
to maintain the nicotinic receptors in a desensitised state. The microdialysis results 
predict that at the beginning of each session of self-administration the initial injections 
of nicotine will stimulate DA overflow in the medial shell, and the DA concentrations in 
the extra-cellular space will remain elevated for 1 hour or so afterwards. As a result, 
for most if not all of the trial, the animals will be responding under conditions of raised 
extra-cellular DA. The hypothesis predicts that during this period the behaviour 
response that delivers drug will be reinforced thereby facilitating the acquisition and 
maintenance of responding for nicotine.
If inhaled nicotine exerts a similar sustained effect on DA overflow in the medial shell 
as that evoked in rats that receive daily injections of the drug, the microdialysis results 
suggest that cigarette smoking will increase DA overflow in smokers with low initial 
blood nicotine concentrations. Therefore the behaviour associated with delivery of the 
drug -  cigarette smoking -  and sensory cues associated with its delivery will acquire 
hedonic properties that may be disproportionate to the rewarding properties of the drug 
itself. However, it is also likely that many smokers, allowed to smoke ad libitum, will 
accumulate concentrations of nicotine in the brain that cause prolonged desensitisation
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of the neuronal nAChRs, which mediate the response (Benowitz et al 1990, Balfour et 
al 2000). If this happens, smoking may not be associated with increased DA overflow 
in the medial shell of the accumbens and it becomes necessary to consider the 
reasons why habitual smokers continue to smoke under these circumstances.
One explanation could be that these smokers seek to maintain the brain nicotine 
concentration at a level that prevents withdrawal, therefore avoiding the aversive 
abstinence syndrome. This conclusion is supported by results where rats rendered 
nicotine-dependent by the constant infusion of the drug, show that nicotine 
administration alleviates both somatic and other behavioural signs evoked by its abrupt 
withdrawal (Malin et al 1992). However, the evidence from NRT experiments in 
abstinent smokers is less impressive as withdrawal symptoms are not completely 
alleviated (Foulds et al 1998, West 1998).
An alternative explanation may be that tobacco smoke is likely to be a rich source of 
sensory stimuli in the mouth and bronchi that can acquire the properties of conditioned 
reinforcers when paired with the delivery of nicotine from the smoke. These sensory 
cues play a fundamental role in regulating smoke intake and the craving to smoke 
(Rose et al 1993). These stimuli could also serve as conditioned reinforcers that 
maintain responding during periods when the receptors that mediate the effects of 
nicotine on DA overflow are desensitised and smoking may not result in increased DA 
overflow in the medial shell or core of the accumbens. This is supported by evidence 
that show non-nicotinic sensory-motor factors play a critical role in mediating the 
immediate responses to cigarette smoke that reinforce the habit (Rose et al 2000). 
Thus by smoking heavily the smoker can maintain the blood nicotine concentration at a 
level that prevents withdrawal while continuing to derive some positive reinforcement 
form the conditioned reinforcers present in smoke (Balfour et al 2000).
Due to the complexity of addiction and a large number of pathways involved, which are 
not fully understood, it is very difficult for a smoker to quit. It is often said that quitting is 
one the hardest things a person can do. Quitters relapse due to, in some cases severe 
withdrawal syndromes, and ex-smokers have reported to experience some craving 
even after 10 years. Although there are some strategies to aid smokers to quit 
(explained in section 1.5), there is definate room for improvement to allow for higher 
quit rates over longer periods of time. The immunotherapy approach is a new 
candidate to tackle this issue.
42
1.5 Nicotine Addiction Therapies
Nicotine addiction can be tackled in two ways via non-pharmacological approaches:
• Wide-reach approach.
• Intensive intervention.
These two approaches can work effectively together and on their own (Royal College
of Physicians report 1997).
1.5.1 Wide-reach approach
This consists of interventions which reach the population on a large scale.
1) Comprehensive community-orientated interventions include posters, mass- 
media campaigns, telephone and self-help interventions, ‘quit and win’ contests 
etc. However, these have not been proven to be effective.
2) Self-help interventions such as leaflets and books have been marginally 
effective especially when they also include information about pharmacological 
interventions and are tailored to the individual smoker and their addiction rating. 
These methods have also been shown to be more effective when combined 
with other more intensive therapies.
3) Telephone help-lines have been found to elicit a large number of calls when 
well advertised. Although there is no research as yet showing their efficacy, 
they are a useful tool for referring callers to locally available face-to-face 
treatments.
4) Brief advice by physicians or health professionals has been shown to be 
effective especially with light smokers, although the efficacy is low. This 
however is difficult to initiate and maintain within the patient-doctor relationship.
1.5.2 Intensive interventions
1) Behavioural interventions are often offered in conjunction with pharmacological 
interventions over a series of weekly sessions. Both individual and group 
meetings have been shown to be effective. The large Lung Health Study 
(Anthonisen et al 1994) provides a persuasive confirmation of the effectiveness 
of intensive support combined with NRT, achieving a one-year abstinence rate 
of 35% versus 9% with usual care for hospitalised patients. There are two 
forms of behavioural interventions. One category is for relapse intervention 
which is a major problem causing the fall in success rates of 50-60% at one 
month to 20-30% one year later. This has been shown to be effective even for 
heavy smokers for a period of several weeks but there is no evidence yet of its 
longer efficacy. Social support is the second category which is believed to be
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very important especially in group treatments. The ‘buddying’ system has 
shown a significant short-term effect in the first stages of abstinence. More 
work is needed on designing and evaluating social support treatments on a 
larger scale.
2) Hypnosis and acupuncture are very popular with smokers. The Cochrane 
group has reviewed 9 studies of hypnosis and 16 trials of acupuncture and 
concluded that evidence of specific efficacy is lacking. However, some people 
can be helped by numerous different unproven procedures, via non-specific and 
placebo effects.
1.5.3 Pharmacological approach
These include nicotine replacement therapy and non-nicotine medications.
1.5.3.1 Nicotine Replacement Therapy (NRT1
Acute nicotine withdrawal symptoms are the main short-term difficulty smokers face 
during a quite attempt. NRT works by breaking the quitting process into two phases. 
In the first phase smokers learn to cope with not smoking and the absence of the rapid 
boli of nicotine, whilst protected from the worst withdrawal effects by moderate levels of 
nicotine provided by NRT. The second phase is the gradual withdrawal of nicotine until 
none is used. NRT may make early relapse less rewarding therefore less likely to 
trigger a full-scale relapse. Another possible mechanism could be deconditioning 
because the link between pharmacological reinforcement and smoking behaviour may 
weaken during abstinence accompanied by NRT. The provision of a coping 
mechanism during the use of NRT can also play a crucial role in success rates.
1.5.3.1.1 Nicotine chewing gum
Nicotine gum has been subject to several reviews (Tang et al 1994, Silagy et al 1994). 
There is little doubt that nicotine gum is an effective NRT treatment, although the 
magnitude of the effect versus placebo is low with some trials reporting only a marginal 
or non-significant increase in quit rate compared to placebo. It is likely that during gum 
usage a substantial amount of nicotine is ingested, leading to extensive first pass 
metabolism and formation of metabolites.
There are 2 doses of nicotine gum available at 2mg and 4mg. Nicotine enters the 
blood stream via the buccal mucosa and the plateau blood nicotine level is reached 
after about 30 minutes. Only about 0.9mg nicotine from one piece of 2mg gum and 
1.2mg from 4mg gum reaches the bloodstream. Smokers are recommended to chew
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each piece for 30 minutes and chew one piece per hour not exceeding 15 gums per 
day.
1.5.3.1.2 Nicotine transdermal patch
There are 3 doses of patch available depending on the number of cigarettes smoked 
and time to first cigarette, and is aimed at reducing nicotine dosage over time. The 
highest dose delivers 1mg of nicotine per hour. 16 hour patches are available to avoid 
sleep-time nicotine dosing, however 24 hour patches are useful for preventing urges to 
smoke on waking. Nicotine absorption is slow, taking hours to reach plateau, however 
the simple instructions and ease of use makes the patch the most used NRT product 
(Tonnesen et al 1999, Hajek et al 1999).
1.5.3.1.3 Nicotine nasal spray
This is a bottle of nicotine solution, which is sprayed into a nostril by an air pump 
plunger via a nozzle. It provides the most rapid nicotine absorption rate among NRT 
products as it reaches plateau in just 10 minutes. One spray delivers 0.5mg of nicotine 
absorbed through the nasal mucosa. Smokers are recommended to use one spray in 
each nostril hourly, up to 16 times a day. Despite its initial irritant effects it is most 
effective for heavy smokers who seem to get used to it quickly (Sutherland et al 1992).
1.5.3.1.4 Nicotine inhaler
This consists of a plastic holder and cartridges containing a polythene plug with 
nicotine. A puff from the inhaler delivers nicotine vapour into the mouth and throat 
where it is absorbed. 20 puffs from an inhaler delivers the same amount of nicotine as 
one cigarette. Smokers are advised to use 6-12 cartridges per day, each for 3 puffing 
sessions. The inhaler is designed to replace the behavioural aspects of smoking 
without the harmful effects of cigarettes, however this is not a widely used device 
(Hajek et al 1999).
1.5.3.1.5 Nicotine sublingual tablet
These are designed to be held under the tongue until they dissolve within 20-30 
minutes. They have a similar absorption and dose delivery profile to the gum and 
inhaler although they are also not widely used and their effectiveness has not been 
thoroughly studied.
The persistent presence of nicotine in the body during cigarette smoking is thought to 
be one of the contributing factors to the addictive nature of tobacco use. Conversely
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the low levels of nicotine provided by NRT products attempt to relieve some of the 
withdrawal symptoms people suffer when they quit smoking (Lee et al 1993).
1.5.3.2 Non-nicotine medications
The main non-nicotine medication, which has shown success and is now widely used is 
buproprion. Although other medications such as lobeline, naltrexone and 
mecamylamine have been tested, they have not shown adequate results to boost them 
onto the market on a large scale.
1.5.3.2.1 Buproprion (Zvban)
This drug was originally produced as an antidepressant, but patients found they could 
quickly quit smoking after taking buproprion. This drug has dual action; it is a dopamine 
re-uptake inhibitor and, as rat studies have shown, during withdrawal dopamine levels 
drop, therefore this drug can maintain a more stable level of dopamine. It is also a 
nAchR antagonist, which reduces the effects of nicotine, therefore smokers do not get 
the desired effects of a cigarette (Slemmer et al 2000, Hemby et al 1997). It is given 
one week before cessation for 7-12 weeks. Its efficacy does not appear to be due to its 
antidepressant effects as the drug works equally well in smokers with and without a 
past history of depression. It has shown similar quit rates to NRT (Hughes et al 1999).
Keeping in mind the various nicotine cessation strategies and their efficacies explained 
above, they have only proved to have limited success. There still remains a need to 
enhance and develop therapies which can be more successful. Immunotherapy is a 
new strategy being studied which may prove to show more success in the battle 
against nicotine addiction.
1.6 Immunotherapy
1.6.1 Vaccines under investigation
A new strategy which has grown in popularity in the last few years, has been to target 
the drug rather than the brain through vaccination. This project is committed to the 
study of an immunotherapy approach to combat nicotine addiction, which will be 
explained in more detail later. Bonese et al (1974) were the first people to investigate 
the possibility of using drug-specific antibodies to reduce the effects of drugs of abuse, 
namely heroin. They actively immunized one monkey after it had been trained to self- 
administer both heroin and cocaine. They showed that immunization reduced the self­
administration of heroin but not cocaine. Later Killian et al (1978) went on to transfuse
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two non-immunized monkeys with morphine-specific antiserum from immunized 
monkeys. In this study, altered patterns of heroin self-administration lasted more than 
3 weeks, when the effect of immunization reduced in parallel with antibody titres. 
Later, research was conducted for the treatment of cocaine addiction by Carrera et al 
(1995). They have produced a catalytic antibody to bind to the cocaine molecule in the 
blood before it reaches the brain and it is deactivated by a simple cleavage reaction 
that produces two molecules. The antibody then releases the molecules and is ready 
to bind another molecule. This therefore eliminates the addictive effects of cocaine. 
Results in vaccinated rats that were previously addicted to cocaine have shown that 
they ignore the drug. This concept is still under investigation.
The idea behind vaccination of rats against nicotine is to elicit the production of 
nicotine-specific antibodies which can bind and sequester nicotine in serum and 
extracellular fluid, reduce nicotine distribution to brain, and reduce many of nicotine’s 
physiological and behavioural effects. Some practical features of vaccination such as 
long-lasting effects and avoiding the need for daily medication, may prove attractive. 
Potentially, a positive aspect of immunotherapy is that it does not affect 
neurotransmitters or receptors and should not have many of the adverse effects 
associated with other treatments.
The amount of nicotine reaching the brain, and the rate at which it does so, are 
important determinants of the initiation and maintenance of smoking (Benowitz 1996). 
Within limits, higher doses of nicotine are more rewarding than lower doses, and more 
rapid delivery of nicotine to the brain is more rewarding than slower delivery (smokers 
report cigarettes are more rewarding than a nicotine patch). Therefore the rate and 
extent of nicotine distribution to the brain provide potential therapeutic targets in which 
therapy is directed at the drug rather than the brain. In theory, nicotine vaccines should 
bind to nicotine and the antibody-nicotine complex would be too large to cross the 
blood-brain barrier, so that administered nicotine bound to the antibody is excluded 
from the brain. Therefore, vaccination can potentially alter the amount of nicotine 
reaching the brain. Vaccination may also reduce the rate at which nicotine enters the 
brain, although the mechanism by which this happens is unclear.
In 1997, Pentel group produced the first nicotine vaccine for which a nicotine derivative 
was conjugated to KLH (Heida et al 1997). After immunising rats with the nicotine 
vaccine (3 x 25pg over 5 weeks), antibody titres rose to over 10,000. Competition 
ELISA assays demonstrated that increasing concentrations of nicotine and nicotine
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derivative increased the percent inhibition of antibody binding in a concentration- 
dependent manner, thus demonstrating their ability to bind to the antibody. The 
nicotine metabolites, nicotine-N-oxide and cotinine, did not appreciably bind to the 
antibody with concentrations up to 10'2 mol/L. Anti-nicotine antibodies did not 
recognise the structurally dissimilar compounds propranolol and acetylcholine. The 
nicotine binding capacity of anti-nicotine antibodies after active immunisation (1.3 
pmol/L) exceeded the venous plasma levels of nicotine (up to 0.26 pmol/L) and was 
nearly equal to the arterial plasma levels reported in humans after smoking one or two 
cigarettes (Benowitz et al 1983, Henningfield et al 1993). Fourty minutes after 
intravenous administration of nicotine 0.03 mg/kg, there were 4 to 6 fold greater 
concentrations of nicotine in the plasma of immunised animals but there were no 
differences in brain levels of nicotine. However, when nicotine levels were examined at 
a more clinically relevant time point (3 minutes after intravenous nicotine 
administration), brain nicotine levels were reduced by 36%, while plasma 
concentrations raised 3 to 6 fold (Heida et al 1999). The pharmacokinetics are similar 
even after five repeated doses of nicotine (Keyler et al 1999), or after long-term 
exposure to nicotine before and during immunisation (Heida et al 2000).
To show the effectiveness of anti-nicotine antibodies for altering the behavioural effects 
of nicotine, nicotine polyclonal antibodies (50-150mg) were passively administered to 
rats (Pentel et al 2000). Antibody treatment dose-dependently attenuated nicotine- 
induced increases in systolic blood pressure and completely prevented nicotine- 
induced increases in locomotor activity measured 25 hours later. In nicotine- 
dependent rats, passive administration of 150mg of nicotine antibodies also prevented 
nicotine reversal of abstinence signs (Malin 2001). Malin et al (2002) also showed that 
passive immunization against nicotine attenuated nicotine discrimination. Rats were 
trained in a two lever operant chamber to press different levers after a nicotine or saline 
injection. After passive immunization, the immunized rats performed a significantly 
lower percentage of their lever presses on the nicotine lever compared to the non­
immunized rats. In 2003 they published a paper showing that vaccination reduces 
nicotinic distribution to the brain not only by sequestering nicotine in serum but also by 
redirecting tissue distribution disproportionately away from the brain, such that nicotine 
concentrations are reduced to a greater extent in the brain than in other tissue 
(Satoskar et al 2003). They also showed that maternal vaccination against nicotine 
reduced nicotine distribution to foetal brain in rats (Keyler et al 2003).
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To test the effects of the nicotine vaccine, nicotine-induced seizures were examined in 
rats. Immunisation reduced the incidence of seizures induced by a high (2mg/kg) dose 
of nicotine (Tuncok et al 2001). The nicotine vaccine was even more effective in 
preventing seizures if rats were first pre-exposed to nicotine (1mg/kg/day for 6 days) 
before high dose nicotine challenge. This vaccine was tested in humans in early 2002 
by Nabi Biopharmaceuticals under the trade name Nic VAX.™1. This vaccine is a 
nicotine conjugate vaccine, conjugated to a carrier protein, recombinant exoprotein A 
(rEPA). In the phase I trials, 20 healthy non-smoker adults were randomly assigned to 
receive either an intramuscular injection of 200pg of the vaccine or placebo. Blood 
samples showed that a single dose of the vaccine resulted in a rapid immune response 
(within 7 days of vaccination) and generated substantial amounts of nicotine specific 
antibodies that were maintained or continued to increase through 60 days after 
vaccination. Adverse effects included mild to moderate local reactions to vaccination 
that were temporary and required no therapeutic intervention (Nabi Pharmaceuticals
2002).
At least three other nicotine vaccines are currently under development. Xenova Group 
pic began phase I clinical testing with TA-NIC™ (a nicotine derivative coupled to rec 
cholera toxin B) in September 2001. The vaccine’s safety, tolerability and 
immunogenicity were investigated in 60 Belgian volunteers, and preliminary results in 
both smokers and non-smokers have shown the vaccine to be safe and well tolerated 
both systemically and locally. The vaccine was administered by intramuscular injection 
and investigated at two different dose levels in a variety of dose regimes. The vaccine 
generated a specific anti-nicotine response, which is especially important in preventing 
nicotine from reaching the brain (Xenova.co.uk 2002). Preclinical studies of this 
vaccine produced high titres of nicotine-specific antibodies in mice and altered the 
pharmacokinetic distribution of a nicotine challenge (Kasaian 1998). Specifically one 
minute after an intravenous injection, nicotine levels in the brain decreased while 
plasma levels increased. Therefore, the antibodies may have the capacity to block the 
psychoactive effects of nicotine.
De Villiers et al (2002) have developed a nicotine-KLH conjugate vaccine which 
produced antibodies that recognised nicotine and the minor metabolite nornicotine, but 
not the major metabolites cotinine or nicotine-N-oxide. Immunisation in rats showed a 
reduction in the outflow of dopamine in the NAcc shell. They have also shown that 
immunization against nicotine alters the distribution but not half-life of nicotine (de
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Villiers et al 2004). They also showed that vaccinated rats do not re-instate nicotine 
self-administration behaviour when exposed to nicotine (Lindblom et al 2002).
Whether vaccination will prove clinically useful is still unclear and will hinge upon a 
variety of pharmacokinetic and behavioural factors. In rats, pharmacokinetic effects of 
vaccination are greatest in those with the highest titres of antibodies in serum. 
Therefore it will be important to achieve sustained high antibody titres in humans in 
order for the vaccine to be effective. A key question regarding the use of vaccination is 
whether smokers will attempt to compensate for reduced nicotine effects by increasing 
their smoking, either deliberately or unintentionally. Since vaccination efficacy depends 
upon both the concentration of nicotine-specific antibodies in serum and the magnitude 
of the nicotine dose, compensation may be possible.
In a clinical setting, vaccination against nicotine is not likely to duplicate or replace 
existing medication, as it has no effect on the severity of tobacco withdrawal. The main 
effect of vaccination will be to blunt the rewarding effects of nicotine. Therefore it may 
be useful to use vaccination in conjunction with other therapies. Vaccination may be 
better suited to relapse prevention, in which the goal is to block the priming effect of a 
few puffs or a few cigarettes, than to smoking cessation where the antibody will be 
presented with large cumulative daily doses of nicotine. Vaccination can be achieved 
even in the presence of nicotine so that smokers could be vaccinated while they are 
still smoking, in preparation for a quit attempt (Heida et al 2000). However, this is 
already done in smoking cessation services using NRT while cutting down on nicotine 
consumption with a view to quit. More research needs to be done to study the 
effectiveness of this approach. Another possible role for vaccination is primary 
prevention of smoking among high-risk teens but this will require not only efficacy but 
considerable confidence in vaccine safety.
The immunotherapy approach for nicotine addiction is starting to get some attention. 
More research into the actions of the vaccine in relation to nicotine addiction may prove 
very interesting. For example, does the nicotine vaccine have any effect on the 
addiction pathway? If so, how? Does the decrease in nicotine in the initial stages of 
smoking reduce the aversive effects of nicotine? With lower nicotine concentrations in 
the brain, does tolerance to these aversive effects take place or take longer to occur? 
If so, will addiction only develop in persistent smokers? Is addiction to nicotine 
produced in the smoker with lower levels of nicotine in the brain, as there is less reward 
associated with the hedonic properties instigated by smoking? With already
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established smokers going through withdrawal due to a lower level of nicotine in the 
brain, will other products such as NRT relieve withdrawal? As mentioned before one 
major reason for relapse is the severity of withdrawal symptoms. Perhaps intensive 
counselling will play a larger role in the treatment of nicotine addiction alongside 
vaccination and new relapse prevention methods need to be investigated. With more 
research and a better understanding of its therapeutic use in both animals and humans 
vaccination may become a viable nicotine cessation therapy.
1.6.2 Why target cotinine in an immunotherapy strategy?
Cotinine (Figure 1.5) is the most extensively studied nicotine metabolite. Until recently 
it has been generally accepted that cotinine is devoid of pharmacological activity 
(Benowitz 1986, Benowitz et al 1983). However, some more recent reports have 
suggested that cotinine (or its metabolites) may have some physiologic activity. Details 
of a small clinical study to assess the effect of cotinine in the treatment of cigarette 
smoking have been published as a conference abstract (Liberto 1995). The authors 
conclude that the preliminary data showed that cotinine had efficacy as an aid to 
quitting cigarette smoking. Another publication (Keenan et al 1994) describes a two- 
way crossover study to assess the effects of oral cotinine and placebo on various 
withdrawal symptoms in abstinent smokers. The results showed that for a number of 
subjective withdrawal symptoms (ie restlessness, tension/anxiety) the placebo was 
more effective than cotinine in relieving these symptoms. Somewhat surprisingly this 
study has been recently used to support a US patent application concerning the use of 
cotinine as a smoking cessation aid.
A case study (Benowitz et al 1987) concerning nicotine poisoning following massive 
cutaneous exposure to nicotine provides further evidence that cotinine or other nicotine 
metabolites may have antagonistic activity. The patient presented with nausea and 
recurrent vomiting. Blood levels of nicotine measured between 5 and 12 hours 
following exposure to nicotine remained fairly constant, whereas cotinine levels 
increased from around 400 ng/ml to 800 ng/ml within the same period, however nausea 
was resolved after around 8 hours following exposure to nicotine. It is possible that the 
rise in cotinine concentration (or other metabolite) could have been responsible for the 
abolition of poisoning symptoms.
The development of tolerance to the acute effects of nicotine is well documented 
(Porchet et al 1987), although the reasons for this remain unclear. One group (Porchet 
et al 1988) has produced a pharmacokinetic/ pharmacodynamic model to explain the
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development of tolerance to the acute effects of nicotine. The model developed utilized 
a hypothetical “metabolite” antagonist of nicotine which may be cotinine. A reasonable 
fit was obtained between the observed and predicted data using this approach.
Studies conducted in vivo in rats and mice have shown that the number of nicotine 
receptors in the brain increases after chronic administration of nicotine and induction of 
tolerance (Marks et al 1983). In this paper the authors postulated that nicotine or a 
nicotine metabolite could act directly as an antagonist.
The effects of oral nicotine and subcutaneously administered nicotine have been 
studied in rats (Balfour 1980). Oral nicotine was not an adequate substitute for rats 
made behaviourally dependent upon nicotine injections in a shock avoidance test. 
Furthermore in rats treated with oral nicotine in the drinking water (5.4mg/kg/day) there 
were no changes in plasma corticosterone levels. However this treatment did block the 
increase in plasma corticosterone seen in response to a subcutaneous injection of 
nicotine. Pre-treatment with cotinine was without effect on the changes in corticosone 
levels seen with nicotine injections suggesting that cotinine was not acting as an 
antagonist in this case, however this observation does not rule out putative antagonistic 
activity of other metabolites.
Other recent work has demonstrated that cotinine can antagonize the effects of 
nicotine, for example one study (Vainio et al 1998) demonstrated that cotinine inhibits 
nicotine-induced noradrenaline release in vitro. The authors speculated that cotinine 
may sustain the addictive changes or relieve the abstinence symptoms in smokers by 
antagonizing the effects of nicotine. They have also shown that cotinine and nicotine 
inhibit each other’s calcium responses in bovine chromaffin cells, and cotinine may also 
be desensitising the nicotinic cholinergic receptors, possibly by acting as a low-affinity 
agonist at these receptors. (Vainio et al 2000). Tests done on the nucleus accumbens 
show that cotinine blocks nicotine induced dopamine release (Sziraki et al 1999). This 
can be explained by the findings that cotinine acts as an agonist to evoke dopamine 
release and perhaps causes desensitisation of the nAChRs in the striatum and 
therefore in practice inhibit nicotine induced dopamine release (Dwoskin et al 1999).
As it has been demonstrated here, there is conflicting evidence about the actions of 
cotinine. More evidence shows that cotinine seems to be antagonizing the overall 
effects of nicotine possibly through desensitisation of the nAChRs. With this idea in
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mind cotinine was used as a primary target for the immunotherapy approach in nicotine 
cessation.
1.6.3 Aims of the immunotherapy approach targeting cotinine
The aims of this project are to target cotinine, the major metabolite of nicotine and raise 
antibodies to eliminate it from the blood before it reaches the brain, and proceed on to 
pharmacological tests to find out what effects this has on the brain in relation to 
nicotine addiction.
The rational behind this project is; once a cigarette has been smoked by a vaccinated 
smoker, nicotine will be metabolised to cotinine in the blood. Cotinine will then be 
retained in the blood and eliminated before it reaches the brain via the cotinine 
antibodies. This will in turn stop the antagonistic actions of cotinine (through initial 
agonism causing desensitisation of nicotinic AchRs) on nicotine in the brain. Therefore 
nicotine will have a larger desired effect on the smoker, which in turn will encourage the 
smoker to consume fewer cigarettes. This is better for the health of the smoker and 
also with the aid of other therapies such as NRT, the smoker may have a better chance 
of successfully quitting.
The experimental aims of this project are:
• As there is conflicting evidence in the literature regarding the effects of cotinine 
on nicotine addiction, this will be studied further using dopamine release 
experiments in the striatum.
• The first step in the production of the vaccine will be to produce a derivative of 
cotinine with the feasibility to attach to a carrier molecule. This derivative- 
carrier complex will need to have 10-15 derivatives and expose the cotinine 
molecule to allow for specific recognition by the immune system.
• The derivative-carrier complex will then need to be incorporated with adjuvent 
and injected into rats and the immune response tested.
• The injection regime needs to be optimised to produce the maximal response.
• Appropriate ELISA methods need to be developed to test the immune response 
and its specificity to cotinine.
• Blood nicotine and cotinine levels will then need to be measured to examine 
whether cotinine is retained in the blood.
• Dopamine release in the striatum will be measured to examine whether 
vaccination has an effect.
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• The effect of vaccination will also be examined on nicotine induced locomotor 
activity as a test to see whether vaccination has an effect on the behaviour of 
animals.
This hypothesis is of course not without flaw. There are some factors that may affect 
the outcome of this immunotherapy approach, which will need further examination 
beyond the scope of this project. For example, metabolism of nicotine and cotinine 
may be altered by vaccination. This has not been shown to be the case in a limited 
study by de Villiers et al (2004), however it is an important issue to consider and 
examine. If cotinine is taken up by antibodies in plasma, it may increase rate of shift of 
the metabolism of nicotine into cotinine, thereby increasing the amount of cotinine in 
the blood which may mean that less nicotine is reaching the brain. This may suggest 
that administration of nicotine by NRT and the proposed increase in its effect due to the 
eradication of the antagonism caused by cotinine, as hypothesised in this study, may 
have a reduced effect. Another question to address is whether enough cotinine will be 
kept away from the brain to cause a functional increase in the actions of nicotine in the 
brain. Also, will this increase in effect of nicotine in the brain mean less demand for 
nicotine intake by the smoker in a practical situation?
There are many aspects to nicotine addiction as explained in this chapter, and the 
effect of a cotinine vaccine in this hypothesis is only tackling the effects of smoking on 
the mesolimbic dopimanergic pathway related to reward in a limited manner. 
Questions which will need further investigation following this project include;
• Will the decrease in cotinine in the brain have an effect on excitatory inputs into 
the VTA via glutamatergic transmission from the prefrontal cortex?
• Will the inhibitory inputs into the VTA via GABAergic neurons have an effect on 
the addiction pathways?
• Will the decrease in cotinine and the subsequent larger effect of nicotine show 
different characteristics on the dopamine released in the Nacc shell and core 
and therefore on the hedonic properties of nicotine?
• The aversive effects of nicotine may also be altered with the decrease of 
cotinine and the subsequent increase of nicotine effect in the brain.
As with the nicotine vaccines under investigation, other aspects of addiction such as 
withdrawal and behavioural support also need to be addressed alongside vaccination 
to allow for a robust therapy package for nicotine addiction.
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The rational behind the immunotherapy approach targeting cotinine has been 
explained. In the final section of this introduction I will talk more about the immune 
responses in the body, characteristics of antibodies and what is involved in designing 
the right vaccine fit for the purpose of this immunotherapy approach against nicotine 
addiction.
1.6.4 Overview of immunology
To give an overview of the immunology involved in this project I have used a variety of 
text books (Immunology by Goldsby et al, Biology by Campbell, Antibodies; a 
laboratory manual by Harlow et al).
The body has two defence systems against unwelcome intruders. One system is non­
specific and consists of two lines of defence; the first line of defence is external and 
consists of epithelial tissue that cover and line the body via skin and mucous 
membranes. The second line is internal and is triggered by chemical signals and uses 
antimicrobial proteins and phaygocytic cells that attack any invaders that penetrate the 
body’s outer barriers. The second system, which is specific, is the immune system, 
which comes into play simultaneously with the second line of non-specific defence. 
This includes the production of specific defensive proteins called antibodies as well as 
several different types of cells that are derived from white blood cells called 
lymphocytes. The four key features characterize the immune system are specificity, 
diversity, memory and self/nonself recognition.
1.6.4.1 Passive Immunity
Immunity elicited in one animal can be transferred to another, providing passive 
immunity, by injecting it with serum from the first. Passive immunization does not 
activate the immune system, it generates no memory response and the protection 
provided is transient. Passive immunization can be acquired through several 
processes:
1. Natural maternal antibodies transferred from mother to foetus.
2. Immune globulins which are antibody-containing solution derived from human 
blood, obtained by cold ethanol fractionation of large pools of plasma, available 
in intramuscular and intravenous preparations.
3. Humanized monoclonal antibody.
4. Antitoxins which are antibodies derived from the serum of animals that have 
been stimulated with specific antigens.
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1.6.4.2 Active Immunity
The goal of active immunization is to elicit protective immunity and immunological 
memory. When active immunization is successful, a subsequent exposure to the agent 
elicits a heightened immune response that successfully eliminates the antigen. Active 
immunity can be achieved by natural infection with a microorganism or by artificial 
administration of a vaccine.
1.6.4.3 Humoral and cell-mediated responses
The immune system can mount two different types of responses to antigens: a humoral 
response and a cell-mediated response. Humoral immunity results in the production of 
antibodies, which are secreted by B lymphocytes and circulate as soluble proteins in 
blood plasma and lymph. Cell-mediated response depends on the direct action of cells 
(T lymphocytes) rather than antibodies.
Lymphocytes originate from pluripotent stem cells in the bone marrow or in the foetus, 
mainly in the liver. Lymphocytes that then differentiate into T cells are those that 
migrate to the thymus, and B cells remain in the bone marrow to continue their 
maturation. Mature B cells and T cells are most concentrated in lymph nodes, the 
spleen and other lymphatic organs, where they are most likely to encounter antigens. 
Both have specific antigen receptors on their plasma membranes. The antigen 
receptors on B cells are membrane-bound antibody molecules specific for a certain 
antigen. The antigen receptors on T cells are different than in antibodies but do 
recognize antigens as specifically as antibodies. Any lymphocytes with receptors for 
molecules present in the body are destroyed or are rendered non-functional during 
maturation, leaving only lymphocytes that are reactive against foreign molecules. This 
gives rise to self-tolerance. The self molecules tolerated by an individual's immune 
system are a collection of molecules encoded by a family of genes called the major 
histocompatibility complex (MHC). Two main classes of MHC molecules mark cells as 
self. Class I MHC molecules are located on all nucleated cells. Class II MHC 
molecules are restricted to a few specialized cell types such as macrophages, B cells 
and activated T cells.
Each antigen, by binding to specific receptors, selectively activates a tiny fraction of 
cells from the body's diverse pool of lymphcotyes; this relatively small number of 
selected cells gives rise to a clone of millions of effector cells, all dedicated to
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eliminating the specific antigen that stimulated the humoral or cell-mediated response. 
This reaction upon the first exposure to an antigen constitutes the primary immune 
response. Between initial exposure to an antigen and maximum production of effector 
cells, there is a lag time of 5 to 10 days.
When antigens bind to specific receptors on the surface of a lymphocyte, the 
lymphocyte is activated to divide and differentiate, giving rise to a population of effector 
cells, which defend the body in an immune response. B cells differentiate to plasma 
cells, which secrete antibodies that help eliminate antigens. T cell effector cells include 
cytotoxic T cells (Tc), which kill infected cells and cancer cells, and Helper T cells (TH) 
which secrete protein factors called cytokines to regulate neighbouring cells. Cytokines 
help B cells and T cells therefore act in both the humoral and cell-mediated responses.
The secondary immune response occurs if the body is exposed to the same antigen at 
some later time. This response is faster than in the primary immune response and only 
takes 3-5 days and lasts longer (peaks after 14 days after the second exposure) than 
the primary immune response. The immunological memory is based on long-lived 
memory cells, which are produced along with the relatively short-lived effector cells of 
the primary immune response, however they are not active at this time. These memory 
cells proliferate rapidly when exposed again to the same antigen. This gives rise to a 
new clone of memory cells as well as new effector cells.
In most cases, the selective activation of a B cell to form a clone of plasma cells and 
memory cells is a two-step process. One step as mentioned before is the binding of 
antigen to specific receptors on the surface of the B cell. The other step involves 
macrophages and helper T cells. After a macrophage engulfs pathogens by 
phagocytosis, fragments of the partially digested antigen molecules are bound by class 
II MHC molecules. The two molecules are transported to the plasma membrane and 
displayed on the surface of the macrophage (antigen-presenting cell). A helper T cell's 
specific receptors recognize this self/nonself combination of MHC and a particular 
antigen fragment. This activates the T cell, which proliferates and forms a clone of 
helper T cells. The helper T cells then secrete cytokines, which selectively stimulate B 
cells that have already encountered the particular antigen. After the binding of antigen 
to a B cell, the cell takes in a few of these foreign molecules by endocytosis. The B cell 
then displays antigen fragments bound to class II MHC markers on the cell surface. 
The helper T cell's receptor recognizes and binds this antigen-MHC complex.
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The antigens that evoke the response described above are known as T-dependent 
antigens. Most antigens are T-dependent. T-independent antigens trigger the humoral 
response without involvement of macrophages and T cells. However, the humoral 
response is generally much weaker and no memory cells are generated. These will not 
be discussed further as they are not involved in the immune response generated in this 
project. Once B cells are activated by T-dependent antigens, a clone of plasma cells 
are produced and each of these effector cells secretes as many as 2000 antibodies per 
second for the 4-5 day lifetime of the cells.
1.6.4.4 Antibodies
Antibodies constitute a class of proteins called immunoglobulins (Igs). Every antibody 
has at least two identical sites that bind to the epitope. A typical antibody has four 
polypeptide chains joined to form a Y-shaped molecule: two identical light chains and 
two identical heavy chains. Both heavy and light chains have constant regions which 
are responsible for the antibody's effector function. At the tips of the Y-shaped 
molecule's two arms are the variable regions, which function as the antigen-binding 
sites. The antigen-binding site is responsible for an antibody's recognition function of 
epitopes. There are five types of constant regions which determine the five major 
classes of mammalian immunoglobulins;
IgM - which are the first circulating antibodies to appear in response to an initial 
exposure to an antigen and decline in concentration rapidly. They consist of five Y- 
shaped monomers arranged in a pentamer structure.
IgG - which are the most abundant of the circulating antibodies. They readily cross the 
walls of blood vessels and enter tissue fluids and trigger the action of the complement 
system. These are the immunoglobulins most expected to be present in this project.
IgA - which are produced by cells in mucous membranes to prevent attachment of 
viruses and bacteria to epithelial surfaces.
IgD - which don't activate the complement system and are mostly found on the surface 
of B cells, probably functioning as an antigen receptor.
IgE - which are slightly larger than IgG molecules and are present in blood in small 
concentrations. They cause mast cells and basophils to release histamine and other 
chemicals which cause an allergic reaction.
Antibodies do not destroy an antigenic invader directly. The composition of the 
antigen-antibody complex causes several effector mechanisms. These include 
neutralization, agglutination of particulate antigens, precipitation of soluble antigens
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which forms immobile precipitates that are captured by phagocytes, and activation of 
the complement system.
1.6.4.5 Immunoqenicitv
Immunogenicity is the ability to induce a humoral and / or cell mediated immune 
response:
B cells + antigen = effector B cells + memory B cells 
T cells + antigen = effector T cells + memory T cells
Antigenicity however is the ability to combine specifically with the final products of the 
above responses ie: antibodies and / or cell - surface receptors. Some small 
molecules called haptens are antigenic but incapable, by themselves, of inducing a 
specific immune response. Proteins are the most potent immunogens, and are used 
by immunologists as immunogens in most experimental studies of humoral immunity
and cell-mediated immunity. These proteins include ovalbumin (44 KDa) and tetanus
toxoid (150KDa).
Immunogenicity is determined in part by several properties of the immunogen. In order 
to elicit an immune response, a molecule must be recognized as nonself by the 
biological system. Also, the greater the phylogenic distance between two species, the 
greater the structural disparity between them. There is a correlation between size of a 
macromolecule and its immunogenicity. The most active immunogens tend to have a 
MW of over 100KDa, and the least active are below 5-10KDa. Chemical complexity 
also contributes to immunogenicity for example all four levels of protein organization 
(primary, secondary, tertiary and quaternary) contribute to its immunogenicity. Large, 
insoluble macromolecules are generally more immunogenic than small, soluble ones 
because the larger molecules are more readily phagocytosed and processed.
1.6.4.6 Vaccine design
Several factors must be considered when designing a successful vaccine. The 
development of an immune response does not necessarily mean that a state of 
protective immunity is achieved. What is critical is which branch of the immune 
system, the humoral or the cell-mediated branch, is activated. A second factor is the 
development of immunological memory. For example, a vaccine that induces a 
protective primary response may fail to induce the formation of memory cells, leaving 
the host unprotected after the primary response to the vaccine subsides. For a 
compound to elicit a primary antibody response and a strong secondary response, it
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must contain an epitope that can bind to the cell-surface antibody of a virgin B cell and 
it must promote cell-to-cell communication between B cells and helper T cells. The 
development of both humoural and cell-mediated responses requires interaction of T 
cells with an antigen that has been processed and presented together with major 
histocompatibility complex (MHC) molecules. Binding of the antigen to the surface 
antibody molecule of a virgin B cell determines the specificity of the resulting antibodies 
as the antigen-binding site on the surface antibody molecule will be identical to the 
binding site on the secreted antibodies.
Even if a macromolecule has the properties that contribute to immunogenicity, its ability 
to induce an immune response will depend on certain properties of the biological 
system that the antigen encounters. Some of these properties include immunogen 
dosage and route of administration and an optimal mixture of the two can induce a 
peak immune response in a given animal. An insufficient dose fails to activate enough 
lymphocytes or induce a state of immunological unresponsiveness or tolerance. 
Conversely, an excessive high dose can also induce tolerance. A single dose of most 
experimental immunogens will not induce a strong response; rather repeated 
administration or boosters, over a period of weeks is usually required. Boosters 
increase the clonal proliferation of antigen - specific T cells or B cells and thus increase 
the lymphocyte populations specific for the immunogen. The immunogens are usually 
administered by a variety of routes such as intravenous, intradermal, intramuscular, 
intraperitoneal and subcutaneous. The administration route strongly influences which 
immune organ and cell populations will be involved in the response. In intravenous 
injections, the antigen is carried first to the spleen, whereas antigens administered 
subcutaneously move first to local lymph nodes. This affects the subsequent immune 
response.
Adjuvants are substances that when mixed with an antigen and injected enhance the 
immunogenicity of that antigen. They are used to boost the immune response when an 
antigen has low immunogenicity or when only small amounts of antigen are available. 
Precisely how adjuvants increase the immune response is not known. Alum (aluminum 
potassium sulfate) appears to prolong antigen persistence, increase local inflammation 
by inducing granuloma formation and maybe enhance co-stimulatory signals. When an 
antigen is mixed with alum, the salt precipitates the antigen. This results in a slower 
release of antigen from the injection site, so that the effective time of exposure to the 
antigen increases from a few days without adjuvant to several weeks with adjuvant. 
The alum precipitate also increases the size of the antigen, increasing the likelihood of
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phagocytosis. When alum stimulates the local inflammatory response, it attracts both 
phagocytes and lymphocytes. This infiltration of cells often results in formation of a 
dense macrophage-rich mass of cells called a granuloma. Because the macrophages 
in a granuloma are activated, this mechanism also enhances TH cell activation. 
Chemical coupling of a hapten to a large protein (carrier) yields an immunogenic 
hapten-carrier conjugate. When this is injected, animals produce antibodies specific for 
1) the hapten, 2) unaltered epitopes on the carrier protein, and 3) new epitopes formed 
by combined parts of both the hapten and carrier. As mentioned before, a hapten 
cannot function as an immunogenic epitope. But when multiple molecules of a single 
hapten are coupled to a carrier protein, the hapten becomes accessible to the immune 
system and can function as an immunogen.
The theories presented in this section regarding the immune system and vaccine 
design were all taken into account when making the derivatives (in the appendix) and 






2.0 Effects of nicotine and cotinine on dopamine release using 96-well plate
assay.
2.1 Introduction
As discussed in the Introduction section 1.6.2, cotinine has been shown to have 
various effects in relation to nicotine addiction and its actions on nAChRs. The aim of 
this chapter is to investigate the effect of cotinine on dopamine release in the striatum 
in comparison and in conjunction with nicotine. A high throughput method using a 96- 
well plate assay developed by Puttfarcken et al (2000) was used in this study with 
variations. This is a static release system carried out in 96-well filter plates, with a 
support membrane to separate tissue slices from the bathing medium (containing the 
released transmitter) that can be removed by vacuum filtration. The pharmacological 
data presented for nicotine-evoked [3H]-dopamine release (Puttfarcken et al 2000), are 
comparable to results obtained from conventional superfusion systems, therefore this 
method is useful for rapid determination of the effects of agonists and antagonists on 
[3H]-dopamine release. The advantages of using minces as described in section 2.3.3 
are its speed and ease of preparation.
Previous studies have estimated that approximately 85% of mouse striatal nAChRs are 
a4p2 on synaptosomes on DA terminals (Marks et al 1998, Whiteaker et al 2000). 
Sharpies et al (2000) and Puttfarcken et al (2000) have suggested the involvement of 
a4p2 nAChRs in [3H]-dopamine release in rats. The role of other nAChR subtypes in 
dopamine release has been suggested by the finding that aCTMII-sensitive nAChRs 
account for 40% of nicotine-evoked dopamine release in mouse striatum (Grady et al 
2002, Kulak et al 1997, Kaiser et al 1998), suggesting the involvement of a3 and/or a6- 
containing nAChRs (Champtiaux et al 2002). Kaiser & Wonnacott (2000) showed that 
antagonism of aCTMII was additive with that of a7-selective antagonists. They 
concluded that a7 nAChRs on striatal glutamate terminals elicit glutamate release, 
which in turn acts at ionotropic glutamate receptors on dopamine terminals to stimulate 
dopamine release.
Several antagonists were used to study which nAChRs are involved in nicotine and 
cotinine -evoked [3H]-dopamine release in this assay. The antagonists used were:
1) Mecamylamine which is a non-selective nAChR antagonist.
63
2) a-Conotoxin Mil was originally defined as a potent antagonist at a3p2 nAChRs 
expressed in Xenopus oocytes, with inhibition of responses occurring in the 
subnanomolar range (Cartier et al 1996). Since its isolation from the venom of the fish- 
hunting cone snail Conus magus, it is now synthesized commercially and has been 
used in several functional studies in native systems. Using a-Conotoxin Mil in the 
studies examining dopamine release from rodent striatal dopaminergic neurons, has 
led to the identification of two distinct populations of nAChRs (Kulak et al 1997, Kaiser 
et al 1998). This toxin partially blocks [3H]-dopamine release from rat striatal 
synaptosomes stimulated with nicotine (Kulak et al 1997) or anatoxin-a (Kaiser et al
1998). This was interpreted as evidence for the heterogeneity of presynaptic nAChRs 
on dopamine terminals, with one population containing an a3p2 interface. Although 
recent reports have suggested that the population may contain an a6p2 inerface 
(Champtiaux et al 2002). Therefore, the selectivity of a-Conotoxin Mil may be more 
complicated than originally thought.
3) a-bungarotoxin is isolated from the venom of the snake Bungarus multicinctus and is 
a potent and selective pseudoirreversible antagonist at a7 nAChRs (Davies et al 1999). 
This toxin has been used to inhibit a7 nAChRs in a wide variety of functional studies, 
ranging from superfusion (Kaiser & Wonnacott 2000) to electrophysiology (Gray et al 
1996). The disadvantage of its use in functional studies is the long pre-incubation time 
needed (1h) when using nanomolar concentrations, which may adversely affect some 
tissue preparations. However, this problem may be overcome by increasing its 
concentration with a shorter pre-incubation period.
4) Dihydro-p-erythroidine (DHpE) was derived from seeds of the Erythrina spp.. It has 
been shown to inhibit p2 nAChR subunits in low concentrations (Crooks et al 1995). 
Many pharmacological studies have used this compound as a selective antagonist at 
a4p2*nAChRs (Alkondon & Albuquerque 1993). However, its selectivity at this subtype 
is questionable, as it has been shown to inhibit other subtypes of heteromeric nAChRs 
expressed in Xenopus oocytes with a concentration range of 0.19 to 1.3 pM (Harvey et 
al 1996).
The experiments presented in this chapter were conducted by myself and two 





Rats used were male Sprague Dawley rats with a weight range of 250-300 grams. 
Four were housed per cage, in a smoke-free environment with food and water available 
ad libitum.
2.2.2 Drugs and Chemicals
Cotinine, (-)-nicotine, dihydro-p-erythroidine (DHJ3E), mecamylamine, nomifensine and 
pargyline were purchased from Sigma Chemical Company Ltd., Poole, Dorset, UK. 
Alpha-bugarotoxin (a-bungarotoxin) was purchased from Molecular Probes, Eugene, 
UK. Alpha-conotoxin Mil (aCTMII) was purchased from Tocris, Bristol, UK. [7,8-3H]- 
dopamine (41-45 Ci/mol) was purchased from Amersham International, Amersham, 
Bucks., UK. Microscint™ 40 (liquid scintillation cocktail) and Optiplate™-96 (opaque, 
top-count specific, 96-well plates) were purchased from Packard Bioscience Company, 
Groningen, Netherlands. Millipore Multiscreen™ BV clear plates were purchased from 
Millipore Corporation, Bedford, UK.




Buffer 1: Krebs-bicarbonate (188mM NsCI, 2.4mM KCI, 2.4mMCaCI2, 1.2mM MgS04, 
1.2mM KH2P04, 25mM NaHC03, pH 7.4). This was gassed with 95% 0 2/ 5% C 02 for 
1 hour. Pargyline (10pM), glucose (0.9 g) and ascorbic acid (0.09 g) were added (pH 
7.4). This buffer is used in the first stage of the assay.
Buffer 2: Nomifensine (50nM) was added to buffer 1. Nomifensine is a dopamine re­
uptake inhibitor and is used to prevent [3H]-dopamine being taken up into the tissue 
once it has been released by the tissue to allow for measurement. Buffer 2 was used 
in the preparation of the drugs used in the assay, as well as incubating the filter plates 
for 30 minutes at 37°C prior to the experiment. The drugs to be used in the assay were 
prepared prior to the experiment and transferred into nunc 96-well plates.
Sucrose-HEPES (0.32M sucrose, 5mM HEPES) was used to hold brain tissue prior to 
striatal mince preparation.
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2.3.2 Dissection of the striatum
Four striata (a striatum from the left and right hemisphere of the brain) from two rats 
were used per experiment. The rats were killed by cervical dislocation and 
decapitation (schedule 1 method).
2.3.3 Preparation of striatal minces
The striata were sliced using a Mclllwain tissue chopper to create 250|im x 250pm 
tissues minces. This was done by chopping the tissue 3 times, each time rotated by 
60°. The minces were then triturated in 5ml buffer 1 and incubated for 4 minutes at 
37°C. The minces were then washed 3 times in 5ml buffer 1 over 15 minutes at 37 °C.
2.3.4 Pre-loading of tissue with r3H1-dopamine
[3H]-dopamine (50nM) was added to the 5ml suspended minces and incubated at 37°C 
for 30 minutes, with regular agitation. The minces were then washed 5 times in buffer 
2 over 30 minutes at 37°C and re-suspended in 10ml buffer 2.
2.3.5 Stimulation of tissue
The buffer soaking the filter plate was removed using vacuum filtration and the striatal 
minces were distributed evenly over the 96-well filter plate (100pl per well). This was 
then vacuum filtered, leaving the minces on the filter. The drugs used for pre­
incubation were added (70pl per well) and incubated for the required duration (the 
standard time was 5 minutes unless otherwise stated), at 37°C. 8 wells were used per 
drug condition.
The solution was vacuum filtered into an opaque Optiphase plate (basal step). The 
drugs used for stimulation of tissue (70pl per well) were added and incubated for the 
required duration (the standard time was 5 minutes unless otherwise stated), at 37 °C. 
The solution was vacuum filtered into another opaque Optiphase plate (release step). 
The filter plate was frozen at -20°C overnight.
2.3.6 Measurement of radioactivity
Scintillation fluid was added (170pl per well) to both Optiphase plates and radioactivity 
was measured using Microbeta machine.
After the filter plate has been frozen overnight the filters were taken out of each well 
and placed in individual scintillation vials. Scintillation fluid (4ml) was added to each 




The ratio of the [3H]-dopamine released in the release step to the basal step was 
calculated which gives the degree of drug-evoked release. This was then compared to 
the total amount of radioactivity contained within the tissue and the final release was 
calculated using the equation below:
% Release = Stimulated release / (Stimulated release + Tissue) x 100
Previously efficiencies of the microbeta (34.5%), and scintillation counter (53.6%) were 
calculated and these were taken into account when calculating release.
Curve fitting for the nicotine and cotinine dose response experiments were carried out 
using the Hill Equation below:
f = t / (1+(K/X)*n) + s
where:
K = EC50 value (agonist concentration which evokes a half-maximal response) 
s = minimum agonist concentration 
t = maximum agonist concentration 
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2.4 Results
2.4.1 Dose response for nicotine and cotinine evoked f3H1-dopamine release
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Figure 2.1: Dose response curves for nicotine and cotinine evoked f3H]-dopamine 
release.
Striatal minces were pre-loaded with pHJ-dopamine and buffer 2 only was used to pre-incubate 
the tissues (5 minutes). In the basal stage nicotine (1nM - 100/jM) or cotinine (1/jM -  10mM) 
were used to stimulate the tissue (5 minutes). Nicotine-evoked (—) and cotinine-evoked (—) 
dopamine release were calculated. 8 wells per drug treatment were used in each experiment 
and this was repeated in 3 experiments (n=3).
[3H]-dopamine release evoked by nicotine or cotinine ranged between 0.6% and 10.2% 
of the total amount of [3H]-dopamine at the start of the release stage. The EC50 value 
was calculated which denotes the drug concentration that evokes 50% of the maximum 
[3H]-dopamine released. Nicotine (EC50 = 381 nM) requires a thousand fold lower 
concentration than cotinine (EC50 = 342jiM) to evoke the same %[3H]-dopamine 
release. This is in accordance with the observation that cotinine has a thousand fold 
lower affinity for nAChR than nicotine (Quick & Lester 2002).
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GCMS analysis of the cotinine used in these experiments shows 0.0022% impurity of 
nicotine present. This is insufficient to account for the shift in potency.
2.4.2 Characterization of nicotine and cotinine - evoked r3H1-dopamine release
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Figure2.2: Effect of mecamylamine on nicotine and cotinine evoked fHJ-dopamine 
release.
Striatal minces were pre-loaded with pHJ-dopamine. Pre-incubation with buffer 2 (5 minutes) 
and stimulation with cotinine (1mM) H  and nicotine (10pM) H  (5 minutes). Incubation with 
mecamylamine (20pM) g  ,with both cotinine and nicotine-evoked pHJ-dopamine release was 
blocked. 8 wells per drug treatment were used in each experiment and this was repeated in 3 
experiments (n=3).
Figure 2.2 shows both nicotine and cotinine -  evoked [3H]-dopamine release were 
blocked by the non-selective nicotinic antagonist mecamylamine. This suggests both 
nicotine and cotinine have an agonist effect on [3H]-dopamine release via nAChRs.
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Figure 2.3: Effect o f cotinine on nicotine -  evoked f3H]-dopamine.
Striatal minces were pre-loaded with fHJ-dopamine. Pre-incubation with buffer 2 (5 minutes) 
and stimulation with nicotine (10/jM) ®  and cotinine (100/uM) ®  (5 minutes) showed fH ]-  
dopamine release similar to that seen in figure 2.2. When pre-incubated with cotinine (10/uM - 
1mM) and stimulated with both nicotine (1 0/jM) and cotinine (10pM -1mM) g  nicotine evoked 
pH]-dopamine release decreased with increasing cotinine concentrations. 8 wells per drug 
treatment were used in each experiment and this was repeated in 3 experiments (n=3). * = 
significantly different (p<0.05), using one way analysis of variance (ANOVA) test with Dunnet 
post hoc -  multiple comparisons versus control group (10pM nicotine alone). + = significantly 
different (p<0.05), using one way analysis of variance (ANOVA) test with Turkey post hoc -  all 
pair-wise multiple comparison.
Figure 2.3 shows pre-exposure to cotinine produces a significant decrease in nicotine 
(10pM) -  evoked [3H]-dopamine release at 100pM and 1mM concentrations. This 
suggests that cotinine is antagonising the actions of nicotine. As both nicotine and 
cotinine -  evoked [3H]-dopamine release were blocked by the non-selective nicotinic 
antagonist mecamylamine (figure 2.2), the most likely explanation is that prior exposure
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to low concentrations of cotinine can desensitise the nAChRs. This is further 
discussed in the discussion (section 2.5).





Pre-incubation: Buffer D H B E lp M  Buffer  D H IiE lp M -------
Stimulation: .........N ic lO jjM .........................C o tlO m M   D H B E lp M
+ D H B E I M M  + D H B E  l pM
Figure 2.4: The effect o f dihydro-p-erythtoidine (DHpE) on nicotine and cotinine -  evoked 
pH]-dopamine release.
Striatal minces were pre-loaded with pH]-dopamine. Pre-incubation with buffer 2 (5 minutes) 
and stimulation with nicotine (10/jM) | ]  and cotinine (10mM) H  (5 minutes) showed pH]- 
dopamine release similar to that seen in figure 2.2. When pre-incubated with DHpE (1pM) and 
stimulated with both nicotine (10pM) and DHpE (1pM) ^nicotine-evoked pH]-dopamine release 
decreased significantly. When pre-incubated with DH/3E (1pM) and stimulated with both 
cotinine (10mM) and DHpE (1pM) g  nicotine-evoked fH]-dopamine release also decreased 
significantly. Pre-incubation and stimulation with DHpE (1pM) alone M  showed no pH]- 
dopamine release. 8 wells per drug treatment were used in each experiment and this was 
repeated in 3 experiments (n=3). * = Significantly different from nicotine alone (p<0.05) using 
Student’s unpaired t-Test. + = Significantly different from cotinine alone, p<0.05 using Student’s 
unpaired t-Test.
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DHpE is a p2* nAChR antagonist (Harvey et al 1996, Alkondon & Albuqurque 1993), 
and was used in this experiment to determine whether the p2* subunit is involved in 
nicotine and cotinine - evoked dopamine release. Figure 2.4 shows p2* is one of the
receptors involved in nAChR evoked pHjdopamine release from dopaminergic 
terminals. Nicotine shows a 89% reduction in nicotine evoked pHjdopamine release in 
the presence of DHpE compared to a 54% reduction for cotinine in the presence of 
DHpE, however it does not produce complete antagonism as seen by mecamylamine 
in figure 2.2. The antagonism shown by DHpE is greater against nicotine than cotinine. 
This may be due to the high concentration of nicotine used, which may be causing a 
desensitisation of the receptors during pre-incubation in this assay and therefore 
adding to the reduction of the dopamine response by the actions of the antagonist 
DHpE.
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2.4.4.2  gConotoxin Mil
16 1 
15 -
pre-incubation: Buffer 200nM aCTMII Buffer ..........200nM aCTMII_____
stimulation: 10pMnic 200nM aCTMII 10mMcot ............200nM aCTMII ........
+10pMnic +10mMcot
Figure 2.5: The effect of aConotoxin Mil (aCTMII) on nicotine and cotinine -  evoked fH ] -  
dopamine release using 96-well plate assay.
Striatal minces were pre-loaded with pHJ-dopamine. Pre-incubation with buffer 2 (5 minutes) 
and stimulation with nicotine (10/jM) g  and cotinine (10mM) g  (5 minutes) showed fH ]-  
dopamine release similar to that seen in figure 2.2. When pre-incubated with aCTMII (200nM) 
and stimulated with both nicotine (10/jM) and aCTMII (200nM) [ j]  , nicotine-evoked fH ]-  
dopamine release decreased significantly. When pre-incubated with aCTMII (200nM) and 
stimulated with both cotinine (10mM) and CTMII (200nM) nicotine-evoked pHJ-dopamine 
release also decreased significantly. Pre-incubation and stimulation with aCTMII (200nM) alone 
showed no f  H]-dopamine release. 8 wells per drug treatment were used in each experiment 
and this was repeated in 4 experiments (n=4). * = Significantly different from nicotine alone 
(p<0.05) using Student’s unpaired t-Test. + = Significantly different from cotinine alone, p<0.05 
using Student’s unpaired t-Test.
aCTMII has been shown to be an a 3/a6p2* nAChR antagonist (Cartier et al 1996, 
Harvey et al 1997, Kaiser et al 1998), and was used in this experiment to determine 
whether the a3/a6p2* subunits are involved in nicotine and cotinine - evoked dopamine 
release. Figure 2.5 shows a a /a ^ *  is one of the receptors involved in nAChR evoked
3
[ HJdopamine release from dopaminergic terminals. Nicotine shows a 62% reduction in
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nicotine evoked [3 H]dopamine release in the presence of aCTMII compared to a 34% 
reduction for cotinine in the presence ofaCTMII, however it does not produce complete 
antagonism as seen by mecamylamine in figure 2 .2 .
2.4.4.3 a-Bunqarotoxin
14 n
pre-incubation: Buffer 1pM a  Bgt Buffer IpM aB gt IpM aB gt
stimulation: 10pMnic Ip M a B g t 10mMcot Ip M aB gt IpM aB gt
+10pM nic +10mMcot
Figure 2.6: The effect o f a-Bungarotoxin (aBgt) on nicotine and cotinine -  evoked f3H]- 
dopamine release using 96-well plate assay.
Striatal minces were pre-loaded with pHJ-dopamine. Pre-incubation with buffer 2 (5 minutes) 
and stimulation with nicotine (10p M a n d  cotinine (10mM) ®  (5 minutes) showed ?H]- 
dopamine release similar to that seen in figure 2.2. When pre-incubated with aBgt (1juM) and 
stimulated with both nicotine (10/uM) and aBgt (1 p M ^  , nicotine-evoked pHJ-dopamine release 
did not show a significant change. When pre-incubated with aBgt (1pM) and stimulated with 
both cotinine (10mM) and aBgt (1/jM) ^nicotine-evoked fHJ-dopamine release also showed no 
significant change. Pre-incubation and stimulation with aBgt (1/jM) alone H showed very little 
pHJ-dopamine release. 8 wells per drug treatment were used in each experiment and this was 
repeated in 3 experiments (n=3).
aBgt has been shown to be an a7 nAChR antagonist (Davies et al 1999), and was 
used in this experiment to determine whether the a7 subunits are involved in nicotine 
and cotinine - evoked dopamine release. However, under these conditions (figure 
2.6), it does not show any significant effect. This may suggest a7 is not involved in
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3
nicotine and cotinine - evoked [ HJdopamine release in the striatum contrary to Kaiser 
& Wonnacott (2000). However these results may be due to aBgt’s slow binding 
kinetics (Sharpies & Wonnacott 2000, Davies et al 1999), and the short pre-incubation 
time of this assay, which may have been insufficient to allow aBgt to elicit an effect.
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2.4.4.4 Optimisation of assay
This experiment was conducted as part of the optimisation of the assay before all 
experiments with aCTMII in this chapter were conducted. aCTMII is known to adhere 
to the surface of the wells during incubation. Addition of BSA in the buffer was 


















...Buffer... 200nMaCTMII ...Buffer. 
 1 |jM nic.
.200nMaCTMIL 
10mM cot  200nMaCTMII
+200nMaCTMII +200nMaCTMII aCTMII
Figure 2.7: Effect of assay buffer witf(  and without £v] BSA (0.01%) on nicotine and 
cotinine -  evoked fHJ-dopamine release using 96-well plate assay.
Striatal minces were pre-loaded with pHJ-dopamine. Pre-incubation with buffer 2 or 200nM 
aCTMII (5 minutes) and stimulation with nicotine (1pM) or cotinine (10mM) (5 minutes) showed 
BSA reduces the nicotine and cotinine -  evoked pHJ-dopamine release. BSA also increased 
the ability of aCTMII to block nicotine and cotinine -  evoked pHJ-dopamine release. However, 
aCTMII still blocked nicotine and cotinine -  evoked pHJ-dopamine release effectively without 
the addition of BSA. 8 wells per drug treatment were used in this experiment and this was only 
done once to acquire the effect of BSA.
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As BSA was shown to reduce the effects of nicotine and cotinine -  evoked [3H]- 
dopamine release and aCTMII was shown to still be effective without BSA, it was 
concluded that BSA was not necessary for use in assays with aCTMII.
2.5 Discussion
2.5.1 Pharmacology
Nicotine has been shown in this study to evoke dopamine release in rat striatal minces 
in a dose dependent manner (figure 2.1). This is in accordance with previous 
published data by Dwoskin et al (1999), as well as in our laboratory; dopamine release 
in the striatum has been observed, in response to a local application of nicotine via the 
microdialyisis probe (Marshall et al 1997). The dose response curve for cotinine (figure 
2.1) follows the same sigmoidal pattern as seen for nicotine (figure 2.1, Dwoskin et al
1999), in which the curve is shifted to the right. The EC5o values show that 1000-fold 
higher concentration of cotinine is required to elicit the same dopamine release as 
produced by nicotine. This is in accordance with the report that cotinine has a 1000- 
fold lower affinity for nicotine binding sites on nAChRs, than nicotine (Sharpies & 
Wonnacott 2001, Abood et al 1981).
Both nicotine and cotinine - evoked dopamine release were shown to be inhibited by 
mecamylamine (figure 2.2), which is a non-selective nAChR antagonist (Dwoskin & 
Crooks 2001), suggesting that both drugs evoke dopamine release via nAChRs.
To find out which nAChRs are involved in the actions of nicotine and cotinine -evoked 
dopamine release, in this assay, 3 competitive antagonists which work on a variety of 
nAChRs were used. Competitive antagonists interact reversibly with the nAChR at or 
close to the agonist binding site, stabilising the receptor in a conformation with the 
channel closed and preventing access for agonists. This inhibition is surmountable 
with increasing agonist concentration.
DHpE is a purely competitive antagonist for neuronal nAChRs. At low concentrations, 
it has been shown to inhibit nAChR subtypes containing p2 (see section 2.1, Crooks et 
al 1995). In this assay, DHpE has shown a significant inhibition of the nicotine and 
cotinine-evoked dopamine release (figure 2.5), suggesting that p2 subunits are 
involved in this mechanism, which is in accordance with literature (Zoli et al 2002, 
Sharpies et al 2000).
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a-Conotoxin Mil has previously been reported to act on a6p2 * subunits (see section 
2.1, Zoli et al 2002, Sharpies et al 2000). a-Conotoxin Mil was shown to inhibit both 
nicotine and cotinine -  evoked dopamine release in this assay (figure 2.5), suggesting 
involvement of the a6*p2* subunits in both the actions of nicotine and cotinine.
A slight decrease in nicotine and cotinine - evoked dopamine release is seen when a- 
bungarotoxin is present in the pre-incubation and stimulation stages (figure 2.6). This 
however, is not significant. This may suggest a7 subunits are not involved in this 
mechanism, however, as seen in previous publications (see section 2.1), a7 has been 
shown to be present in the striatum and has been shown to act on a7 subunits on 
glutamate terminals which are indirectly involved in nicotine -  evoked dopamine 
release within the striatum (Kaiser & Wonnacott 2000). Also a-Bungarotoxin has been 
reported to act on a7 nAChR subunits by McGehee & Role (1995). There is however
3
evidence that shows a7 nAChRs do not appear to mediate [ H]dopamine release from 
striatal synaptosomes as the a7-selective antagonists a-bungarotoxin and a-conotoxin 
Mil are without effect (Rapier et al 1990, Grady et al 1992, Kulak et al 1997). However, 
it has previously been noted that 50nM methyllcaconitine, a potent a7-selective
3
antagonist, produced a partial inhibition of anatoxin-a-evoked [ HJdopamine release 
from striatal synaptosomes (Kaiser & Wonnacott 2000), in agreement with the earlier 
observation of Clarke & Reuben (1996). Therefore, the lack of dopamine release 
inhibition by this antagonist, in this assay, may be explained by its slow association 
binding kinetics. Typically a pre-incubation of one hour with the toxin would be 
necessary to achieve a complete blockade using a low concentration of a-bgt (10nM) 
(Sharpies & Wonnacott 2001, Davies et al 1999). A higher concentration may be 
needed to evoke a response in this assay, a7 components may only appear at 100 pM 
of nicotine (Wonnacott el at 2000). Relating this information to this assay, pre­
incubation of 5 minutes of a 1 pM concentration of a-bgt may not be sufficient to elicit 
an inhibition on nicotine and cotinine -  evoked dopamine release.
Nicotine-evoked dopamine release was decreased when striatal minces were pre- 
incubated and stimulated with cotinine in a dose-dependent manner (figure 2.3). This 
suggests that cotinine is acting as an antagonist towards the actions of nicotine. 
However as figures 2.1. and 2.2 suggest, cotinine can also act as an agonist on 
nAChRs. As previously published, pre-treatment of synaptosomes with nanomolar 
concentrations of nicotine has shown a decrease in the ability of acute nicotine 
stimulation to evoke dopamine release (Marks et al 1993). This behaviour has been
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attributed to nAChR desensitisation. This is when prolonged stimulation results in 
receptors entering a temporary inactive state (See section 1.2.1.5). This 
desensitisation theory can be attributed to exposure to cotinine causing desensitisation 
in this assay.
2.5.2 Implications of cotinine vaccine
This desensitisation theory is important in the hypothesis of the vaccine project (see 
section 1.8 & 1.9). As discussed in the introduction, the effects of cotinine are 
contradictory in the literature. The results in this chapter have been able to add to the 
theory of cotinine acting as an agonist on nAChRs. However, by desensitisation these 
receptors, it produces a decrease in nicotine - evoked dopamine release. If a cotinine 
specific vaccine can retain cotinine in the blood and therefore reduce its concentration 
in the brain, then nicotine will be able to produce a larger effect, resulting in reducing 





3.0 Production and verification of conjugates -  Trial 1
3.1 Introduction
The aims of this trial were to conjugate the derivatives summarized in the appendix 
section 7.4 onto the carrier molecule ovalbumin, to allow for increased immunogenicity 
(see section 1.6.4 & 7.1). The conjugates were then formulated with adjuvant to 
increase the immune response, and injected into rats to examine the immune 
response. Blood nicotine and cotinine concentrations were also determined to 
demonstrate effect of vaccination after chronic nicotine treatment with osmotic 
minipump.
3.2 Materials
All chemicals were obtained from standard commercial suppliers and all equipment 
used is present at the University of Bath.
Buffers: Phosphate buffer; 100mM Na2HP04, 100mM NaH2P04.
Phosphate buffer saline (PBS); 150mM NaCI, 100mM Na2HP04, 100mM 
NaH2P 04.
3.3 Conjugation of N-alkvl pyridvl cotinine (cotcooh) and N-alkvl pvridvl nicotine 
(niccooh) to ovalbumin
3.3.1 Methods
Conjugation reactions for both N-alkyl pyridyl cotinine and N-alkyl pyridyl nicotine are 
performed simultaneously and with the same protocol except for areas stated in the 
text.
The derivative (4mg) was dissolved in 4 drops of water and stirred (pH blow 6). Ten­
fold molar excess 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) 
(27.4mg for niccooh, 26.2mg for cotcooh) over derivative was added and stirred at 
room temperature for 5 minutes. Eighty-fold molar excess derivative was added to the 
derivative (8mg ovalbumin in 2ml phosphate buffer pH 7.4) and stirred overnight at 
room temperature. The solution was then dialysed against PBS(pH 7.4) at 4°C for 8 
hours with 2 changes of PBS.
The chemical reaction between the derivatives and ovalbumin is shown in figure 3.1.
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R ,------U— O H
protein
Figure 3.1: Conjugation of derivative containing a carboxyl group (N-alkyl pyridyl 
cotinine and N-alkyl pyridyl nicotine) with a carrier protein (ovalbumin).
The first stage of the reaction is the attachment of EDC to the carboxyl group of the derivative, 
producing an active site (R1 represents the remaining structure of the nicotine or cotinine 
derivatives). In the second stage of the reaction, the amine groups present in ovalbumin then 
react with the active site of the derivative to produce a carbodiiamide bond resulting in an 
ovalbumin-nicotine or ovalbumin-cotinine conjugate. There can be up to 15 derivative 
attachments per ovalbumin molecule.
3.3.2 Results
3.3.2.1 Conjugation was estimated photometrically
The conjugated product was tested by spectrophotometry using phosphate buffer as 
blank and 4mg/ml ovalbumin in phosphate buffer as control. The product was 
measured at 260nm and 280nm, and the ratio calculated. This was done to show a 
general picture of whether any conjugation had occurred.
|  h 2N ^>rotein^
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Chemicals tested A.260nm A.280nm Ratio
Ovalbumin alone 1.458 2.302 0.633
A/-alkyl pyridyl cotinine conjugate 3.478 3.245 1.07
A/-alkyl pyridyl nicotine conjugate 3.347 3.175 1.05
Table 3.1: Spectrophotometry results showing mean absorbance measured at X260nm 
and X280nm and the calculated ratio.
The OD260 values (figure 3.1) have increased significantly for both conjugates 
compared to that of ovalbumin alone. This is due to the addition of the pyridyl ring 
structures present in the derivatives, to ovalbumin, which are detected at the 260nm 
range. This has in turn increased the ratio. The increase in the OD280 values 
compared to ovalbumin alone, may be caused by the presence of the pyridyl ring 
structure which is also detected at this wavelength due to the overlap in the spectra. 
The results show the derivatives have been conjugated onto the carrier molecule 
although this test alone is inconclusive.
3.3.2.2 Conjugation was estimated by SDS-PAGE electrophoresis
To qualitatively determine the conjugation of the derivatives to ovalbumin, 
electrophoresis gels were run, stained with Coomasie blue, or used in Western Blotting 
for both conjugates. SDS-PAGE electrophoresis is used for separation of proteins by 
apparent molecular weight using an electric current. In the Coomasie blue staining 
technique, the separated proteins are dyed to allow for recognition. In the western 
blotting technique, separation is followed by electrophoretic transfer onto a suitable 
membrane, where the proteins are immobilized. This enables the membranes to be 
probed with specific antibodies, and subsequent secondary antibodies, to reveal the 
presence of individual proteins.
The gels were run under standard conditions as described in literature (Harlow, Lane, 
Antibodies - a laboratory manual, by Cold Spring Harbor Laboratory 1998).
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Recipes for the SDS gels used were as follows:
SDS Gel 7.5%
4.95 ml distilled H20  
2.5 ml 1.5M Tris pH 8.8 
100 pi 10% SDS 
10% AMPS
2.55 ml Acrylamide / Bisacrylamide
Stacking gel
2.5 ml distilled H20
1 ml 0.5M Tris pH 6.8
10% AMPS 
5 pi TEMED
0.4 ml Acrylamide / Bisacrylamide
(Acrylamide/Bisacrylamide 30% stock ‘Protogel’; National Diagnostics)
5 pi TEMED
Gels were cast in the Bio-Rad mini-Protean II SDS gel system between clean glass 
plates and 1 mm spacers. Once the 7.5% SDS gel had set, stacking gel was applied 
with a 10 sample well comb and allowed to set.
Sample preparations already made up in Laemmli buffer (1:1, 20pl), (Laemmli buffer; 
2%SDS, 100mM Dithiothreitol (DDT), 6mM Tris pH 6.8, 0.01% bromophenol blue), 
were thawed and 20pl were then loaded onto the gel along with BioRat marker (5pl). 
Ovalbumin in phosphate buffer (4mg/ml) was used as control. This was run for 10 
minutes at 80V and 200V for 45 minutes in a Bio-Rad mini-protean II system with 80ml 
of 5X electrode buffer (0.12M Tris, 1.2M glycine 0.5% SDS, diluted in distilled H20  to 
give 400ml).
3.3.2.3 Electrophoresis gel was stained with Coomasie Blue
One gel from section 3.3.2.2 was stained with Coomasie blue for 4 hours using method 
described in literature (Harlow, Lane, Antibodies - a laboratory manual, by Cold Spring 
Harbor Laboratory 1998).
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Figure 3.2: SDS-PAGE gel stained with Coomasie blue showing N-alkyl pyridyl cotinine 
and N-alkyl pyridyl nicotine conjugates, compared with untreated ovalbumin.
Samples (20pl) of N-alkyl pyridyl cotinine-ovalbumin conjugate (Cot) and N-alkyl pyridyl 
nicotine-ovalbumin conjugate (Nic) and ovalbumin alone (Oval) were subjected to SDS-Page as 
described in section 3.3.2.2. Molecular weight standards (left hand well) were run in parallel. 
Gels were stained with Coomasie blue for 4 hours. Same samples are shown in duplicate on 
the gel.
The staining (figure 3.2) suggests that conjugation has occurred as there is a slight rise 
in the bands at 40-50 KDa compared to the ovalbumin alone wells. This is accounted 
for as ovlabumin has a MW of 46 KDa and the rise in the band is caused by the 
addition of several derivatives onto the ovalbumin molecule. There are several lines 
between the 80-100kDa regions, which are not present in the ovalbumin only wells. 
This may have been caused by the conjugation of two ovalbumin molecules together, 
as the MW is approximately double that of one ovalbumin molecule. This gel is not 
very accurate as there is an over loading of the wells with conjugate and ovalbumin. 
This was a preliminary experiment and due to constraints of time, it was not repeated 
to get better band definition. It was used purely as a quick observation to decide 
whether to move onto immunisation.
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3.3.2.4 Western Blotting was conducted on electrophoresis gel
Western blotting was conducted using method described in literature on one gel from 
section 3.3.2.2 (Harlow, Lane, Antibodies - a laboratory manual, by Cold Spring Harbor 
Laboratory 1998), with the following changes.
The gel was blotted using Sigma semi-dry blotting transfer equipment onto 
nitrocellulose (Schleicher and Schuell, Dassel, Germany) previously soaked in transfer 
buffer (0.05M Tris, 0.05M glycine, 0.0375% SDS, 20% methanol), at 80 mA for 40 
minutes. The methanol prevents the gel swelling and keeps proteins adsorbed to the 
nitrocellulose membrane.
After blotting, the non-specific binding sites were blocked in 4% non-fat milk powder 
(Bio-Rad Laboratories Inc) / PBS for 1 hour on a shaker at room temperature. The 
membranes were probed with primary antibodies (sheep anti-cotinine antibody 4jil in 
20ml blotto;1% Marvel / PBS + 0.05% Tween-20) on a shaker at 4°C overnight. The 
blots were washed 3 times for 5 minutes with PBS then incubated on a shaker at room 
temperature for 1 hour with HRP conjugated secondary antibodies (anti-sheep horse 
raddish peroxidase, 4pl in 20ml blotto), diluted to manufacturers’ recommended 
concentration. Secondary antibodies were removed and blots were washed a further 3 
times with PBS. Electro-chemiluminescence (ECL) reagent (Amersham Pharmacia 
Biotech AB, Uppsala Sweden) was prepared according to instructions, (1:1 solution 1 
and 2, to give 7 ml/blot), and applied to blots for 1 minute. Excess ECL reagent was 
removed and the membranes were then wrapped in plastic film and secured in a film 
holder, blots were then exposed to photographic film to visualise, typically exposure 










Figure 3.3: Diagram of semi-dry blotting apparatus. (Picture by Dr Amy Bradly)
Blotting paper soaked in transfer buffer sandwiches the nitrocellulose membrane and the SDS 
gel containing the elecrophoretically separated proteins. A current is applied through the 
electrodes causing the proteins to migrate out of the gel matrix onto the nitrocellulose 
membrane.
Figure 3.4: Western blot o f N-alkyl pyridyl cotinine and N-alkyl pyridyl nicotine 
conjugates, compared with untreated ovalbumin.
Samples (20pi) o f N-alkyl pyridyl cotinine (Cot) and N-alkyl pyridyl nicotine (Nic) conjugates and 
ovalbumin alone (Ova) were subjected to SDS-Page and western blot using sheep anti-cotinine 
antibodies as primary antibody, as described in section 3.3.2.4. Molecular Weight standards 







The results (figure 3.4) show that sheep anti-cotinine antibody has recognized the 
nicotine and cotinine conjugates but not the ovalbumin alone. This shows conjugation 
has occurred, although the sheep anti-cotinine antibody can not distinguish between 
the nicotine and cotinine conjugates. This is not cause for alarm at this stage as 
commercial antibodies may produce such results. The bands are in similar regions as 
presented in the Coomasie blue gel in figure 3.2, however better results can be 
obtained with less loading of the wells with conjugate to obtain better band definition. 
Due to time constraints this blott was not repeated.
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3.4 Conjugation of trans-4-thiol cotinine (cotsh) to ovalbumin
3.4.1 Conjugation methods
Before the conjugation reaction couid be performed, trans-4-thiol cotinine was tested to 
find out whether oxidation of the sulfhydryl group had occurred, despite the derivative 
being stored under nitrogen. To do this and also to quantify the conjugated product at 
the end of the experiment, Ellmans’ Reagent (5,5’-dithiobis-(2-nitrobenzoic acid) was 
used, which reacts with the sulfhydryl groups on the derivative, to produce a 
chromophore with maximum absorbance at 412nm. This assay will estimate the total 
numbers of peptide sulfhydryls present before and after conjugation.
Imject Maleimide Activated Immunogen Conjugation Kit was used to perform the 
conjugation. This experiment was conducted in 3 stages.
1. Conjugation buffer (200jil) provided in the conjugation kit was added to all wells in a 
microwell plate. Hapten solutions (10pl) were added in duplicate wells. The hapten 
solutions were cysteine standards used for the standard curve (a range from 3.0mM, 
2.5mM, 2.0mM, 1.5mM, 1.25mM, 1.0mM, 0.75mM, 0.5mM, 0.25mM in conjugation 
buffer). The derivative (3.6mg/ml) was dissolved in conjugation buffer. 10pl was added 
in separate duplicate wells. Conjugation buffer (10|il) was added in separate duplicate 
wells as control. Ellmans’ Reagent (20jil, 1 mg/ml reagent in conjugation buffer) was 
then added to all wells. The plate was incubated for 15 minutes at room temperature 
and absorbance was measured at 412nm using a microwell plate reader.
2. Pre-activated ovalbumin molecule (0.6mg/ml) provided in the conjugation kit was 
dissolved in deionised water and the derivative (20 pi) made in stage 1 was added. 
The solution was incubated at room temperature for 2 hours. This was then dialysed 
against PBS at 4°C for 8 hours with 2 changes of PBS.
3. The Ellmans’ test was conducted in the same manner as in stage 1, using 20pl of 
the conjugated solution produced in stage 2.
3.4.2 Conjugation was estimated photometrically - results
Standard curves showing absorbance at 412nm for cysteine solutions over a range of 












y  0.40 
0.35 
5  0.30 
j§  0.25 







0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
Protein concentration (M)
Figure 3.5: Standard curve showing absorbance at 412nm for cysteine solutions over a 
range of concentrations from stage 1 o f the Ellmans’ test.
The sulfhydryl group absorbance reading before conjugation was 0.784 nm, giving a 3.39M 
concentration of sulfhydryl groups present.
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Figure 3.6: Standard curve showing absorbance at 412nm for cysteine solutions over a
range of concentrations from stage 3 o f the Ellman’s test.
The activated ovalbumin conjugated to trans-4-thiol cotinine produced an absorbance reading of
0.003 nm, giving a 0.008M concentration of sulfhydryl groups present after conjugation.
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The standard curves allowed for the calculation of the concentration of derivative 





Before conjugation 0.784 3.39
After conjugation 0.003 0.008
Table 3.2: Spectrophotometry results showing mean absorbance measured at A412nm 
and concentration of sulfydryl derivative, present before and after conjugation to 
ovalbumin.
The concentration of derivative was 3.39M before conjugation, which decreased to 
0.008M after conjugation to ovalbumin. This is because the free sulfhydryl derivatives 
which are recognized in the Ellmans’ test, were no longer present due to reaction with 
the ovalbumin molecule as shown in figure 3.7. However, these results alone are 
inconclusive. _
protein
Figure 3.7: Conjugation o f derivative containing a sulfhydryl group (Trans-4-thiol 
cotinine) with a carrier protein (ovalbumin).
Activated ovalbumin from Imject Maleimide Activated Immunogen Conjugation Kit contains the 
active site (R1 represents the remaining structure of the nicotine or cotinine derivatives), which 
reacts with the sulfhydryl group on the derivative producing a maleimide bond, resulting in an 
ovalbumin-cotinine conjugate.
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3.4.3 Conjugation was estimated by SDS-PAGE electrophoresis and coomasie 
blue staining
To qualitatively determine the conjugation of the derivative to ovalbumin, 
electrophoresis gels were run, and stained with Coomasie blue, using the same 
protocol as for the A/-alkyl pyridyl cotinine and A/-alkyl pyridyl nicotine molecules (see 
Section 3.3.2.2 & 3.3.2.3).
t h i o l
Figure 3.8: SDS-PAGE gel stained with Coomasie blue showing trans-4-thiol cotinine 
conjugate, compared with untreated ovalbumin.
Sample (20pi) of trans-4-thiol cotinine conjugate (thiol) and ovalbumin alone (Ova) were 
subjected to SDS-Page as described in section 3.3.2.2. Molecular Weight standards (left hand 
well) were run in parallel. Gels were stained with Coomasie for 4 hours.
The staining (Figure 3.8) shows that conjugation has occurred as there is a definite rise 
in the band in the thiol column, meaning an increase in the molecular weight of the 
conjugated molecules compared to the ovalbumin alone caused by the attachment of 
several derivatives. This band is broad, perhaps due to varying numbers of sulfhydryl 
groups attached to the ovalbumin molecule or due to the overloading of the wells wfth 
the conjugate as seen in the ovalbumin well. Due to time constraints this experiment 
was not repeated. There are also bands present around the 80-100Kda MW as seen 
in figure 3.2 perhaps due to the conjugation of two ovalbumin molecules together.
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3.4.4 Western Blotting was conducted on electrophoresis gel
To qualitatively determine the conjugation of the derivative to ovalbumin, 
electrophoresis gels were run, and western blotting conducted with the same protocol 




Figure 3.9: Western blot of trans-4-thiol cotinine conjugate, compared with untreated 
ovalbumin.
Samples (20pi) of which trans-4-thiol cotinine conjugate (Thiol) and ovalbumin alone (Ova) were 
subjected to SDS-Page and western blot using sheep anti-cotinine antibodies as primary 
antibody, as described in section 3.3.2.4. Molecular Weight standards (left hand well) were run 
in parallel.
The western blot (Figure 3.9) shows that the sheep anti-cotinine antibody has 
recognized the cotinine conjugate but not the ovalbumin alone. This shows 
conjugation has occurred. Again the band seen is broad which can be improved with 
less loading of the wells. This was not done due to time constraints.
3.5 Formulation of vaccines
The N-alkyl pyridyl cotinine, N-alkyl pyridyl nicotine and trans-4-thiol derivatives 
conjugated to ovalbumin were formulated for vaccination into rats. Ovalbumin alone 
was used as control conjugate. Rats injected with saline alone were also tested as 
control. All vaccines were made in the same manner. Alum (10mg/ml) from 
GlaxoSmithKline was used and diluted to 4mg/ml in PBS. Alum was added to
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conjugate drop wise while vortexing over 1min. This was left for 30 minutes at room 
temperature, in which time vortexing every 10 minutes for 1 minute each time. An 
experiment plan is shown in more detail in table 3.3.
3.6.1 Injection regime
The injection regime used was recommended by Dr Pascal Mettens from 
GlaxoSmithkline and taken from Heida et al (2000) with variations (Also see section 
1.7). The same regime was applied for all animals. Injections were given 
subcutaneously. Following immunization, minipumps were used to study the effect of 
chronic nicotine administration for a 14-day period.
Injection regime for 34 rats (This is explained further in table 3.3):
Day 1 Bleed & first injection
Day 21 Bleed & second injection
Day 35 Bleed & first booster
Day 43 Bleed & minipump insertion
Day 57 Kill & brain dissection & blood collection
The rats used varied in weight between 220g and 290g at the start of the experiment. 
This was the closest range of weight possible with the rats available. The rats were 6-7 
weeks old at the beginning of the experiment, which is the age in which the parental 
antibodies are no longer able to cause any effect on the production of antibodies 
against this vaccine.
It was noted that no difference was seen in rat behaviour or locomoter activity after 
injections and minipump insertion.
3.7 Surgical Procedure
All surgical procedures that are described in this thesis conform to UK Home Office 
Regulations and were performed under project licence number PPL 30/2112 .
3.7.1 Materials & Animals
Male Sprague-Dawley (SD) rats, weighing 220-290g from the University of Bath 
breeding colony were used, (-)nicotine base was obtained from Sigma Chemicals Co. 
(Poole, Dorset, UK). Alzet™ osmotic minipumps (Model 2001) were purchased from 
Charles River Laboratories (UK). Wound clips were from Scientific Laboratory 
Supplies (Nottingham, UK). Other miscellaneous surgical equipment and chemicals 
were obtained from standard sources.
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3.7.2 Methods
3.7.2.1 Blood taken for antibody titre determination
The rats were injected subcutaneous with corresponding vaccines and bleeding was 
done via tail lateral vein, under general anaesthetic (Isoflurane). Approximately 200pl 
of blood was taken at the time of each bleed. This was heated at 37°C for 30 minutes, 
centrifuged at 4°C, 1500G, for 30 minutes, serum taken off and centrifuged again at 
4°C, 1500G, for 30minuies. The finai serum was taken off, 0.01% sodium azide added 
and frozen at -70°C.
3.7.2.2 Chronic nicotine treatment of rats bv 14-dav osmotic minipumps
The rats previously immunized with cotinine and control vaccine were chronically 
treated with (-)nicotine delivered via osmotic minipumps for 14 days, 4mg (-)nicotine 
base/kg/day. Minipumps were loaded with either nicotine base in saline or saline as 
control, with the pH adjusted to 7.4 with conc. HCI. The concentration of nicotine in the 
pump was calculated according to the following equation:
4ma/kg/dav x estimated weight of rat on day 7 
24hrs x Pumping Rate of Minipump/hr (in ml)
The answer gives the concentration of free base nicotine to be used in mg/ml.
Pumping rate of the minipumps used was 0.00049 ml/hour. The nicotine was inserted 
into the minipump and % efficiency of filling the pump was calculated by:
Weight of pump after filling -  weight of pump before filling
maximum volume of minipump available (229pl) x 100.
All minipumps were within 97-100% filled. All nicotine solutions were made in PBS pH
7.4, and filtered with 0.2|il filter. For control rats, minipumps filled with only PBS were 
used.
Animals were placed under isoflourane anaesthesia (3% isoflourane: 1.41/m in 0 2), and 
minipumps implanted dorsally, 2-3cm behind the shoulder blades. This area was 
shaved with electric clippers and swabbed with 70% ethanol / 0.5% hibitane. A 1.5cm 
incision was made and blunt dissection performed to create a subcutaneous skin 
pocket large enough to accommodate the minipump. The minipump was swabbed with 
isopropanol and inserted, with the delivery portal facing towards the tail of the animal.
95
Antibiotic powder (Cicatrin™) was puffed into the wound and the incision closed using 
2-3 wound clips. The minipumps start releasing nicotine after 4 hours of being in the 
rat therefore the time was noted and rats were sacrificed 14 days after this time. When 
the rats were sacrificed the minipump was taken out and checked to see if the 
membrane inside had collapsed therefore nicotine delivered, and the delivery tube not 
blocked. All minipumps used were shown to have worked at the end of the experiment. 
Behaviour of the animal was monitored repeatedly throughout the 14 days. At the end 
of the 14 days the animals were sacrificed using a schedule 1 method. Trunk blood 
was taken for serum nicotine and cotinine concentration analysis (section 3.9) and 
antibody titre analysis (section 3.8).
3.7.2.3 Blood taken for nicotine and cotinine concentration determination
This was done after the rats are killed and trunk blood was collected in ependorf tubes 
containing 10|il of 20 units/ml heparin. Blood was kept on ice and centrifuged at 2500 
rpm for 15 minutes. The serum was removed, and re-centrifuged in the same manner. 
The final sera were frozen at -20°C and sent to ABS Laboratories for analysis. ABS 
Laboratories determined the nicotine and cotinine concentrations in the serum by Gas 
Chromatography.






3 Saline Saline - 150pl - Nicotine
3 Saline Saline - 150pl - Saline
5 Ovalbumin 120pg in 30pl 120pl-4mg/ml Nicotine
5 Ovalbumin 120pg in 30pl 120pl-4mg/ml Saline
3 /V-alkyl pyridyl nicotine 120pg in 30pil 120pl-4mg/ml Nicotine
3 A/-alkyl pyridyl nicotine 120pg in 30pl 120|il-4mg/ml Saline
3 A/-alkyl pyridyl cotinine 120pg in 30pl 120|il-4mg/ml Nicotine
3 /V-alkyl pyridyl cotinine 120pg in 30pl 120|il-4mg/ml Saline
3 Trans-4-thiol cotinine 120pg in 30pl 120pl-4mg/ml Nicotine
3 Trans-4-thiol cotinine 120|ig in 30pl 120pl-4mg/ml Saline
Table 3.3: Experiment plan showing number of SD rats used in each treatment group, 
amount of conjugate and adjuvant used and osmotic minipump treatment.
Each injection is made up of conjugate, saline and alum as described in this table. The injection 
regime is shown in section 3.6.1. There is no difference in composition of the solution 
administered in the injections or boosters. The difference is only in name relating to when in the 
injection regime, vaccination is conducted.
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3.8 Enzvme-Linked Immunosorbent Assay (ELISA)
3.8.1 Materials
Maxisorp 96-well plates (Nunclon), were used for ELISA antibody titre determination. 
Carbonate buffer -1  tablet in 100ml deionised water.
Saturation buffer -  PBS,Tween 20 (0.1%), Decomplemented Newborn Calf 
Serum (4%), BSA(1%).
3.8.2 Methods & Results
3.8.2.1 Measurement of antibody titres towards ovalbumin in sera from rats 
injected with ovalbumin
This experiment was done to determine the amount of antibodies produced towards 
ovalbumin, in control animals, which were injected with only ovalbumin.
Methods
Maxisorp 96 well plates were coated with ovalbumin (10pg/ml in carbonate buffer, 
50pl), and left overnight at 4°C. Plates were emptied and saturated with saturation 
buffer plus caseine (1%) (100pl, pH 7.4) for 1 hour at 37°C. Sera from ovalbumin- 
injected rats were serially diluted (1:2 times each time) starting from 1:200 dilutions in 
saturation buffer.
50(il of each dilution was added to the wells and incubated at 37°C for 1 hour. Plates 
were washed 3 times with PBS-Tween (0.1%). Biotinylated anti-rat Ig from sheep was 
prepared (1:3000) in saturation buffer and added to wells (50pl). This was incubated 
for 1 hour 15 minutes at 37°C. Plates were washed 3 times with PBS-Tween (0.1%) 
and incubated with streptavidine-biotinylated HRP (1:1000 in saturation buffer, 50pl), 
for 30 minutes at 37°C. Plates were washed 5 times with PBS-Tween (0.1%)and 
incubated with single component TMB peroxidase (50pl) for 10 minutes in the dark. 
Sulphuric acid was then added (0.4 N, 50pl) and absorbance measured using a plate 














Day 43 Day 1
Figure 3.10: Mid-point antibody titres from rats vaccinated with ovalbumin alone.
The titres were measured in sera from rats on days 1 before injection and day 43 after injection
with ovalbumin alone, and tested by ELISA using ovalbumin-coated wells. There are 10 rats in
each group.
The results (figure 3.10) are expressed as midpoint titres using SoftMaxPro software. 
No titres were produced for rats on day 1 as expected. These results show mean 
antibody titres of 110082±27175 from 10 rats injected with control vaccine containing 
ovalbumin only, from sera taken on days 43. The titres obtained against ovalbumin are 
high as expected, and shows that ovalbumin alone is producing a good immune 
response. There is a large standard error which is normal in animal studies and can be 
associated to inter-animal variations. Sera from day 1 show no antibody titres against 
ovalbumin as expected. Only sera from days 1 and 43 were tested to keep costs 
down. This shows the immune response after all injections were made.
3.8.2.2 Measurement of titres towards conjugates in sera from rats injected with 
each conjugate
This was done in four assays to determine the best ELISA method for obtaining 
accurate antibody titres. The first method was to coat the 96-well plates with the 
conjugate, the second method was to determine whether the titres obtained were from
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the effects of ovalbumin or from the conjugates, ie. Are antibodies raised towards the 
target conjugate? The third method was to coat the 96-well plates with derivative only, 
and the fourth method was a sandwich ELISA.
3.8.2.2.1 Conjugate coated 96-well plates 
Method
The method is the same as in section 3.8.2.1 with the following variations:
Maxisorp 96 well plates were coated with conjugates ie. Derivatives attached to 
ovalbumin (10pg/mi in carbonate buffer, 50pl), and left overnight at 4°C. Plates were 
also coated with ovalbumin in the same way as mentioned in section 3.8.2.1. Serum 
from rats injected with the three conjugates, were serially diluted (1:2 times each time) 
starting from 1:200 dilutions in saturation buffer. 50pl of each dilution was added to the 
wells and incubated at 37°C for 2 hour.
Results
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Figure 3.11: Mid-point antibody titres from rats vaccinated with N-alkyl pyridyl nicotine 
(niccooh), N-alkyl pyridyl cotinine (cotcooh) and trans-4-thiol cotinine (cotsh).
The titres were measured in sera from rats on day 43 after injection with the three vaccines and 
tested by ELISA using ovalbumin-coated wells■  and corresponding conjugate coated wells ■  
There were 6 rats in each group with the bars illustrating mean titre and symbols representing 
each rat.
The results show (figure 3.11) all sera demonstrate antibodies raised against 
ovalbumin on plates coated with ovalbumin. When sera were tested on plates coated
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with the corresponding conjugate, all plates again demonstrated titres. These titres are 
largely due to antibodies raised against ovalbumin. However, for N-alkyl pyridyl 
nicotine and N-alkyl pyridyl cotinine sera, there is a fall in titres tested on conjugate 
coated plates compared to the corresponding ovalbumin coated plates. This may be 
because all antibodies raised against ovalbumin alone or conjugate are not detected in 
this assay. It is not possible to distinguish whether the titres shown are towards 
ovalbumin alone or from the conjugate. The point to note here is the increase in titres in 
the trans-4-thiol cotinine injected sera tested on the conjugate coated plates compared 
to ovalbumin coated plates. This demonstrates that antibodies have been raised 
against the conjugate as well as ovalbumin alone, however this assumption is not 
conclusively proven in this experiment and is in need of further investigation. This 
effect of antibodies raised against ovalbumin is tested further in section 3.8.2.2.2.
3.8.2.2.2 Effect of ovalbumin on measurement of antibody titres in plates coated 
with conjugate.
This experiment was conducted to examine the effect of antibodies raised against 
ovalbumin, on the antibody titres produced against the conjugates (see section 1.7.6). 
This was done by binding ovalbumin antibodies in the sera to ovalbumin coated plates, 
removing the remaining serum from those wells and placing it in conjugate coated 
plates. The ELISA was then conducted to find out whether this one fold dilution of 
ovalbumin antibodies had any effect on the titres shown for the conjugate.
Methods
Maxisorp 96 well plates were coated with ovalbumin (10|ig/ml in carbonate buffer, 
50pl), and left overnight at 4°C. Plates were emptied and saturated with saturation 
buffer plus caseine (1%) (100pl, pH 7.4) for 1 hour at 37°C. Serum from rats injected 
with the three conjugates, were serially diluted (1:2 times each time) starting form 1:20 
dilutions in saturation buffer. 50pl of each dilution was added to the wells and 
incubated at 37°C for 2 hour. The serum was then taken out of the wells and placed on 
new plates coated with derivatives conjugated to ovalbumin [96 well plates were coated 
with conjugates (10pg/ml in carbonate buffer, 50pl), and left overnight at 4°C. All 
plates were emptied and saturated with saturation buffer plus caseine (1%) (1 OOjal, pH 
7.4) for 1 hour at 37°C]. These new plates were then incubated for 1 hour at 37°C and 
washed 3 times with PBS Tween-20 (0.1%). Biotinylated anti-rat Ig from sheep was 
prepared (1:3000) in saturation buffer and added to the wells (50pl). This was 
incubated for 1 hour 15 minutes at 37°C. Plates were washed 3 times with PBS Tween
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(0.1%) and incubated with streptavidine-biotinylated HRP (1:1000 in saturation buffer, 
50pl), for 30 minutes at 37°C. Plates were washed 5 times with PBS Tween-20 
(0.1%)and incubated with single component TMB peroxidase (50fil) for 10 minutes in 
the dark. Sulphuric acid was then added (0.4 N, 50pl) and absorbance measured by a 




80000 -  
70000 -  
60000 -
Q)
f  50000 -c o
-jb 40000 -  
5
30000 -  
20000  -  
10000 -  
0 -
niccooh cotcooh cotsh
Figure 3.12: Mid-point antibody titres from rats vaccinated with N-alkyl pyridyl nicotine 
(niccooh), N-alkyl pyridyl cotinine (cotcooh) and trans-4-thiol cotinine (cotsh).
The titres were measured in sera from rats on day 43 after injection with the three vaccines and 
tested by ELISA using corresponding conjugate coated wells |  and corresponding conjugate 
coated wells with one fold ovalbumin dilution ® There were 6 rats in each group with the bars 
illustrating mean titre and symbols representing each rat.
The results (figure 3.12) show a marked decrease in titres with the one fold dilution for 
all sera tested on plates coated with their corresponding conjugates, compared to 
ELISA with no ovalbumin dilution. This suggests some of the ovalbumin antibodies 
have been taken out of the sera at the first plate stage, however a large amount may 
still remain which may be eliminated if more dilutions were done. This method does
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not give accurate antibody titres generated towards the conjugates. Therefore, a more 
accurate ELISA method was investigated in section 3.8.2.2.3.
3.8.2.2.3 Derivative coated 96-well plates
This experiment was conducted using only derivatives, therefore eliminating coating of 
ovalbumin onto ELISA wells. The antibody titres obtained will therefore be for the 
derivative only and not ovalbumin.
Methods
The method is the same as in section 3.8.2.1 with the following variations. Maxisorp 96 
well plates were coated with the three derivatives N-alkyl pyridyl nicotine (niccooh), N- 
alkyl pyridyl cotinine (cotcooh) and trans-4-thiol cotinine (cotsh), (1pg/ml in carbonate 
buffer, 50pl) and left overnight at 4°C. Sera from rats injected with the three 
conjugates were serially diluted (1:2 times each time) starting from 1:20 dilutions in 
saturation buffer. 50pl of each dilution was added to the corresponding wells and 
incubated at 37°C for 2 hour.
Results
These results (figure 3.13) show that there were no antibody titres measured from sera 
injected with N-alkyl pyridyl nicotine or N-alkyl pyridyl cotinine conjugates tested on 
plates coated with corresponding derivatives. This suggests that no antibodies 
specifically recognizing the N-alkyl pyridyl nicotine and N-alkyl pyridyl cotinine 
derivative sections of the conjugates were produced. Antibodies towards and trans-4- 
thiol cotinine were produced as shown in figures 3.13, 3.14, 3.15. Titres were 
produced as early as day 21 and reached their maximum on day 43. There was a 
reduction in titres after minipump treatment on day 57, although this was not significant. 
This reduction is an encouraging sign as it may be due to an antibody-conjugate 
complex being produced, therefore reducing the amount of antibodies being detected, 
as the antibody-conjugate complex is not likely to be detected by ELISA. These titres 
however are very low and are not sufficient for further neurochemical studies.
Figure 3.14 demonstrates the antibody titre curve on days 21, 35, 43 and 57, for a 
sample rat shown in figure 3.13. This illustrates both the changes in antibodies over 
time and the success of the cotinine derivative in stimulating the production of 
antibodies which recognise cotinine.
Figure 3.15 demonstrates the mid-point antibody titres for the same sample rat as in 
figure 3.13, on a linear scale on days 21, 35, 43 and 57. This illustrates the changes in 













Figure 3.13: Mid-point antibody titres from rats vaccinated with trans-4-thiol cotinine.
The titres were measured for sera taken on days 21, 35, 43 and 57. The sera were tested by 
ELISA using trans-4-thiol cotinine derivative-coated wells. There were 6 rats in each group with 










Figure 3.14: Antibody titre curve for one rat vaccinated with trans-4-thiol cotinine.
The titres were measured for sera taken on days 21, 35, 43 and 57. The sera were tested by 
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Figure 3.15: Mid-point antibody titre from one rat vaccinated with trans-4-thiol cotinine.
The mid-point titres were measured for sera taken on days 21, 35, 43 and 57. The sera was 
tested by ELISA using trans-4-thiol cotinine derivative-coated wells.
3.8.2.2.4 Sandwich ELISA
This experiment was done to determine whether a sandwich ELISA would give more 
conclusive antibody titres.
96 well plates were coated with commercial anti-cotinine IgG (10pg/ml in carbonate 
buffer, 50jil), and left overnight at 4°C. Plates were emptied and saturated with 
saturation buffer plus caseine (1%) (100jil, PH 7.4) for 1 hour at 37°C. The three 
different derivatives (1pg/ml in carbonate buffer, 50pil) were added to the plates and 
incubated for 1 hour at 37°C. The plates were washed 3 times with PBS Tween-20 
(0.1%). Sera from rats injected with one of the three conjugates were serially diluted 
(1:2 times each time) starting from 1:20 dilutions in saturation buffer. 50pl of each 
dilution was added to the wells and incubated at 37°C for 1 hour. Plates were washed 
3 times with PBS Tween-20 (0.1%). Biotinylated anti-rat Ig from sheep was prepared 
(1:3000) in saturation buffer and added to the wells (50pl). This was incubated for 1 
hour 15 minutes at 37°C. Plates were washed 3 times with PBS-Tween (0.1%) and 
incubated with streptavidine-biotinylated HRP (1:1000 in saturation buffer, 50pl), for 30 
minutes at 37°C. Plates were washed 5 times with PBS Tween (0.1%) and incubated
Method
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with single component TMB peroxidase (50jil) for 10 minutes in the dark. Sulphuric 
acid was then added (0.4 N, 50fil) and absorbance measured by a plate reader at 













100 -  
ft •o -  f  ■
niccooh cotcooh cotsh
“ "1
Figure 3.16: Mid-point antibody titres from rats vaccinated with N-alkyl pyridyl nicotine
(niccooh), N-alkyl pyridyl cotinine (cotcooh) and trans-4-thiol cotinine (cotsh).
The titres were measured in sera from rats on day 43 after injection with the three vaccines and
tested by sandwich ELISA. There were 6 rats in each group with the bars illustrating mean titre
and symbols representing each rat.
These results (figure 3.16) show no antibody titres for N-alkyl pyridyl nicotine (niccooh) 
and N-alkyl pyridyl cotinine (cotcooh) conjugates. There are antibodies raised against 
the trans-4-thiol cotinine (cotsh) conjugate, hence confirming results in figure 3.13. 
Figure 3.17 illustrates a correlation between mid-point titres illustrated in figure 3.15 for 
rats injected with trans-4-thiol vaccine on day 43 and sera tested on ELISA coated with 
derivative, and the same sera tested by sandwich ELISA. The sandwich ELISA shows 
a lower average mid-point titre than the derivative coated ELISA, suggesting that the 
derivative coated ELISA method gives the most accurate results. Therefore it was 
used in all antibody titre determination experiments in the rest of the project.
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Figure 3.17: Mid-point antibody titres from rats vaccinated trans-4-thiol cotinine (cotsh).
The titres were measured in sera from rats on day 43 after injection with trans-4-thiol cotinine 
and tested by sandwich ELISA (A) and derivative coated ELISA (B). There were 6 rats in each 
group with the bars illustrating mean titre and symbols representing each rat.
Control
Sera from a group of rats with saline injections were also tested as control, on both 
ovalbumin coated and derivative coated plates. The methods were the same as 
described in sections 3.8.2.2.3 and 3.8.2.1. The results showed no production of 
antibodies, as expected, towards ovalbumin or the derivatives.
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3.9 Results of rat serum analysis for nicotine and cotinine concentrations in rats
treated with nicotine bv osmotic minipump.
The aim of this experiment was to measure the concentration of nicotine and cotinine in 
rat serum treated with nicotine minipump with the different vaccines. Dopamine 
release experiments were planned for this set of vaccinated rats, however due to the 
very low antibody titres obtained, these experiments were deemed too expensive to 
conduct.
/accine Type [Nicotine] ng/ml [Cotinine] ng/ml
Saline 90.1±17.2 (n=3) 461.4±67.4 (n=3)
Ovalbumin 98.1 ±12.9 (n=5) 461.0±55.0 (n=5)
A/-alkyl pyridyl nicotine 92.4±12.4 (n=3) 443.1 ±64.0 (n=3)
A/-alkyl pyridyl cotinine 77.6±26.4 (n=3) 433.0±15.6 (n=3)
Trans-4-thiol cotinine 67.9±31.5 (n=3) 573.3±21.5 (n=3)
Table 3.4: Nicotine and cotinine concentrations in sera from rats immunized with 4 
different vaccines and treated with nicotine by osmotic minipump.
The results show (table 3.4), rats receiving saline had negligible levels of serum 
nicotine (mean 1.0 ± 0.2) and cotinine (mean 15.8 ± 4.8) in all vaccine types.
Nicotine treatment produced levels of nicotine and cotinine in the expected range in 
non- vaccinated and control vaccinated rats. (Sanderson etal 1993).
The cotinine concentration for the trans-4-thiol cotinine vaccine showed an increase 
compared to the saline and ovalbumin only control vaccines, (this was not significant 
using Student’s unpaired t-Test). However, the slight increase is an encouraging sign 
as it may be due to an antibody-cotinine complex being produced, therefore cotinine 
(metabolised after chronic nicotine treatment) is retained in the blood probably by the 
precipitation mechanism of antibodies as described in section 1.7.4).
The cotinine concentration in the blood does not vary significantly in the presence of 
the N-alkyl pyridyl nicotine and N-alkyl pyridyl cotinine vaccines, compared to 
ovalbumin alone or saline vaccine. This may be because high antibody titres were not 
produced in response to these derivatives. Another reason may be that the antibodies 
did not recognise nicotine or cotinine respectively from those conjugates.
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In contrast to cotinine, nicotine concentrations showed some variation between groups 
of conjugates. For the A/-alkyl pyridyl nicotine vaccine, the nicotine concentration is the 
same as both control vaccines. This may also be because high antibody titres were not 
produced in response to the derivative, or another reason may be that the antibodies 
did not recognise nicotine.
The N-aIkyl pyridyl cotinine and trans-4-thiol cotinine vaccines do show a slight fall in 
nicotine concentration in the blood (not significant using Student’s unpaired t-Test). 
However, this may be due to inter-animal variation or it may be a consequence of the 
vaccine. If it is a real effect, this could mean antibodies have been produced in high 
enough titres and they recognise nicotine. Alternatively, antibodies may have 
recognised cotinine, retained it in the blood and therefore increased the rate of 




The 3 derivatives discussed in the appendix (section 7.4) were taken forward for 
conjugation to the carrier protein ovalbumin. The qualitative analysis conducted by 
Coomasie blue staining and western blot of the N-alkyl pyridyl nicotine, A/-alkyl pyridyl 
cotinine and trans-4-thiol cotinine conjugates (section 3.3.2.3, 3.3.2.4, 3.4.3, 3.4.4) 
showed that conjugation had occurred. However, quantitative analysis is needed to 
determine how many molecules of the derivatives are attached to each ovalbumin 
molecule. This is important as up to 14 derivative attachments per carrier molecule are 
needed to produce a viable immune response (see section 1.6.4). HPLC work was 
conducted for quantitative analysis, however due to incomplete hydrolysis of the 
conjugate, I was not able to get accurate results. As this initial trial was performed as a 
learning experience, more quantitative analysis was left until trial 2.
3.10.2 Immunisation
The conjugates were taken forward for injection into animals to determine whether any 
immune response was produced. The four different ELISA methods tested showed 
that the derivative coated plate method identified the highest mid-point titres (section 
3.8.2.2.3). This assay was developed for use in the next trial.
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The N-alkyl pyridyl nicotine and A/-alkyl pyridyl cotinine conjugates showed very low 
antibody titres. This may have been due to insufficient conjugation of derivatives onto 
the carrier molecule, therefore insufficient activation of the humoral and cell-mediated 
responses (as discussed in section 1.6.4). However, trans-4-thiol cotinine conjugate 
vaccine did induce an immune response and gave some encouraging titres. The 
antibodies identified were probably IgG immunoglobulins as these are the most 
abundant antibodies in the blood (see section 1.6.4). This may be due to a more 
robust conjugation of derivative to earner molecule by maleimide bonds. Mid-point titres 
of approximately 10,000 are needed to produce a sufficient antibody response to allow 
for studies on the effects of the vaccine in the animal in relation to nicotine addiction as 
shown by Heida et al (1997). However, titres obtained in this trial were low and not 
sufficient to conduct neurochemical studies.
3.10.3 Effects of nicotine
Heida et al (2000) showed an increase in blood nicotine levels after nicotine 
vaccination, caused by the binding and accumulation of nicotine to the antibodies in 
serum. There was a trend in this trial of an increase in cotinine levels in the sera 
(discussed in section 3.9), however the results were not significant and this was 
repeated in the next trial to allow for better interpretation of the actions of the vaccine. 
Trans-4-thiol cotinine derivative was taken forward to the next trial, where modifications 
were introduced to increase the immune response.
3.10.4 Conclusions
This first trial allowed for the right conjugate (trans-4-thiol cotinine) to be taken forward 
to the next trial and lessons were learnt on possible methods of improving the antibody 





4. Optimisation of injection regime and neurochemical study-Trial 2
4.1 Introduction
Several changes were made to trial 1 to enhance the immune response. As mentioned 
in section 3.10, trans-4-thiol cotinine was the only conjugate taken forward for this trial. 
A new conjugation method was used to allow for the attachment of this derivative to a 
new carrier protein, tetanus toxoid (150KDa). This was done to enhance the number of 
derivative attachments on to the carrier molecule. Three concentrations of conjugate 
were injected into rats to determine which dose elicited the best immune response. 
The adjuvant was changed from Alum to GlaxoSmithKline adjuvant AS2V to increase 
the immune response.
4.2 Materials
All chemicals were obtained from standard commercial suppliers and all equipment 
used was present at the University of Bath.
Buffers: Phosphate buffer; 100mM Na2HP04, 100mM NaH2P 04.
Phosphate buffer saline (PBS); 150mM NaCI, 100mM Na2HP04, 100mM 
NaH2P04.
4.3. Conjugation of Trans-4-thiol cotinine (cotsh) to Tetanus Toxoid (TO
4.3.1 Activation of Tetanus Toxoid
The first step was to activate the lysine groups in the TT molecules (14-16 lysines have 
previously been activated using TT by GSK team), to enable the presentation of an 
active site for conjugation with sylfhydryl group in trans-4-thiol cotinine.
TT (5mg/ml in phosphate buffer pH 7) was stirred at room temperature, with SGMBS (5 
jimol) for 2 hours, Final volume 2ml). This was then purified by FPLC (PD-10 desalting 
column -  Amersham Pharmacia Biotech ). Phosphate buffer (pH 6.8) was used to 
elute the activated TT at a flow rate of 40ml/hr. 15 fractions of 4 ml each were taken 
and absorbance was measured at 280nm. The fractions showing the desired TT in the 
profile reading on basis of increased UV absorption were pooled. The Lowry assay 
was conducted to determine the protein concentration.
4.3.2 Protein determination bv Lowrv Assay
Protein was determined using the Lowry assay (Lowry et al 1959). A Bovine Serum 
Albumin (BSA) standard curve was constructed using triplicate samples of BSA
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dissolved in PBS (pH 6.8) over a concentration range of lOjig/ml -  200 pg/ml. TT 
samples were diluted 1:10, 1:20 and 1:40 in PBS (pH 6.8) in triplicate. Each sample 
(200 pi of BSA standards and TT samples) was placed in LP4 tubes and 10% SDS 
(200 pi) and assay reagent (1% CuS04, 2% Na/K, 2% NaCOa/NAOH 0.1 N, 1ml) were 
added. The tubes were vortexed and incubated for 10 minutes at room temperature. 
Folin’s Reagent (100pl) was added to each tube, vortexed and incubated for 30 
minutes at room temperature. Protein was determined by measurement of optical 
density at 750nm versus blank (assay buffer plus Folin’s Reagent) using Helios 
Gamma spectrophotometer.
4.3.3 Determination of the number of activated sites on TT bv Ellmans’ Assay
This was done to determine the number of activated sites on TT. Samples (100pl) of 
phosphate buffer (blank -  100 mM, pH 6.8), activated TT from section 4.3.1 and 
unmodified TT were assayed in triplicate. 2-mercaptoethanol (1mM, pH 8, 50pl) was 
added to all samples and incubated for 30 minutes (37°C). Ellmans’ Reagent (100mM, 
pH 8, 100pl) and PB (100mM, pH 8, 1ml) were added to all samples and incubated for 
15 minutes at room temperature. Optical density (OD) was measured at 412nm using 
a Helios Gamma spectrophotometer and the number of activated sites calculated as 
below:
(Blank OD -  modified TT OD) / (Molar extinction coefficient of TNB (reported to be 
14150M'1cm'1) x concentration of sulfhydryl solution*
Concentration of sulfhydryl solution * = protein concentration from Lowry Assay x 1000 
/ MW of TT x final volume
The final number of activated sites is calculated by taking away the number of activated 
sites on the unmodified TT (<1), from the number of activated sites on the activated TT.
Results: The number of activated sites on TT was calculated to be 15.
4.3.4 Coupling of modified TT to trans-4-thiol cotinine (cotsh)
The concentration of trans-4-thiol cotinine needed was calculated by multiplying the 
concentration of modified TT from section 4.3.1, by molecular weight of trans-4-thiol 
cotinine. This is then added drop-wise to the solution of activated TT, and incubated 
for 1 hour at room temperature while stirring (TT-cotsh). To prepare the control, a
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sample of modified TT from section 4.3.1 was added to cysteine (4mg/ml in PBS 
150mM, pH 6.8) and incubated for 1 hour at room temperature (TT-cysteine). The TT- 
cotsh sample was dialysed for 2 hours using Slide A-lyzer discs (3500MWCO - Pierce) 
against phosphate buffer (2mM, pH 6.8) with 3 buffer changes. Cysteine (4mg/ml in 
phosphate buffer 100mM, pH 6.8) was then added to quench the unattached sites 
present on TT-cotsh, and incubated for 30 minutes at room temperature while stirring. 
TT-cotsh and TT-cysteine preparations were then dialysed overnight (4°C) using 
dialysis membrane (12-14KDa -  Medicell International), against phosphate buffer 
(2mM, pH 6.8) with 3 buffer changes. Aliquots (100pl) of TT-cysteine and TT-cotsh 
before and after quenching were set-aside for Lowry Assay. The volumes of the TT- 
cysteine and TT-cotsh were then measured and these samples were filtered using a 
millex filter (0.22pm) in a sterile environment. The volume after filtration was also 
measured (needed for calculations using Lowry and Ellman’s tests as described in the 
following paragraph).
Lowry Assay was conducted on TT-cysteine and TT-cotsh after filtration samples (as 
described in section 4.3.2). Ellmans’ test was also conducted on the following 
samples; TT-cotsh before quenching, TT-cotsh before and after filtration, TT-cysteine 
before and after filtration (as described in section 4.3.3), to determine the number of 
activated sites still remaining. These sites are not detected when trans-4-thiol cotinine 
or cysteine are attached, therefore the number of attachments per TT molecule can be 
derived. In the trans-4-thiol cotinine samples, to find out whether these attachments 
are trans-4-thiol cotinine or cysteine from the quenching step, a comparison of number 
of attachments was made between the samples of before and after quenching.
Results: In the TT-cotsh sample, 15 attachments of trans-4-thiol cotinine were made 
per TT molecule. This is in accordance with number of attachments acquired by GSK 
who in their own work have shown to illicit a high immune response (literature not 
available to public).
4.4 Formulation of vaccines
The adjuvant was changed from Alum to GlaxoSmithkline adjuvant AS2V to increase 
the immune response. AS2V has been shown by GSK to illicit a high immune response 
(literature not available to public).
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All vaccines were made in the same manner. The correct amount of TT-cotsh 
conjugate (1pg, 5jig, 25pg) and TT-cysteine conjugate (25pg) used as control vaccine, 
were made up in PBS (200mM) and mixed with adjuvant in a 1:1 ratio. Adjuvant was 
added to conjugate drop wise while vortexing over 10 seconds. This was incubated for 
10 minutes at room temperature while stirring. The vaccine was vortexed before 
injection.
4.5. Injection regime
The injection regime used was recommended by Dr Pascal Mettens from 
GlaxoSmithkline and taken from Heida et al (2000) with variations. This was changed 
from trial 1 to study the effect of more boosters on the amount of antibodies produced. 
Due to the limitation of animal numbers, the second booster was only conducted on the 
1pg and 25pg TT-cotsh vaccine groups. The minipumps were used to deliver a 
constant rate of nicotine applied to the rats over a 7-day period. This is different in 
comparison to the 14-day minipump treatment of trial 1. This change was made to 
reduce the number of days of the animal treatment, however the other protocols related 
to the minimpup procedure were the same (section 3.7.2.2).
Day 1 Bleed & first injection
Day 21 Bleed & second injection
Day 35 Bleed & third injection
Day 49 Bleed
Day 78 Bleed & first booster
Day 98 Bleed & 7 day osmotic minipump insertion
Day 105 Kill -  bleed & brain dissection for dopamine release assay -  5pg/ml
vaccine group and control 
Day 184 Bleed & second booster for 1 pg and 25pg vaccine groups 
Day 205 Bleed
Day 226 Bleed
Rats were 6-7 weeks old at the beginning of the experiment, which is the age in which 
the parental antibodies are no longer able to cause any effect on the production of 
antibodies against this vaccine. The rats used varied in weight between 220g and 
290g at the start of the experiment. This was the closest range of weights possible 
with the rats available. There were 10 rats per vaccine group. In the 5pg/ml vaccine 
group which were treated with osmotic minipumps, 5 rats were treated with saline and 
5 with nicotine (4mg/ml/kg/day).
114
It was noted that no difference was seen in rat behaviour or locomoter activity after 
injections and minipump insertion.
All further procedures undertaken are the same as described in section 3.6 and 3.7.
4.6 Enzvme-Linked Immunosorbent Assay (ELISA)
The protocol described in section 3.8.2.2.3 - Derivative coated 96-well plate ELISA, 
was used with variations, to determine antibody titres using TT-cotsh and TT-cysteine 
vaccinated rat sera. The plates were coated with trans-4-thiol cotinine (1 jig/ml in 
carbonate buffer, 50pl) and the serum was serially diluted (1:2 times each time) starting 
from 1:100 dilutions in saturation buffer.
An ELISA was conducted using TT-coated maxisorp 96 well plates using the same 
protocol as section 3.8.2.2.3, to determine antibody titres produced against TT. The 
results were too high to calculate the mid-point titres. As the aim of this project was to 
study the effect of the antibodies specifically raised against cotinine, as well as the high 
cost of TT, this experiment was not optimised to determine titres against TT.
4.6.1 Immune response for trans-4-thiol cotinine -  Tetanus Toxoid conjugate - 
1uq
Antibodies towards trans-4-thiol cotinine were produced as shown in figure 4.1. Titres 
were produced as early as day 21 but were too low to measure mid-point titres, 
therefore only those from day 35 onwards were used. Average titres reached their 
maximum on day 105 and decreased for the remaining injection period. The titres 
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Figure 4.1: Mid-point antibody titres from rats vaccinated with 1/ug Tetanus Toxoid 
Trans-4-thiol cotinine.
The titres were obtained from sera taken on days 35, 49, 78, 98, 105, 184, 205 and 226. The 
sera were tested by ELISA, using trans-4-thiol cotinine derivative coated wells, n -  10 for each 
group with the line illustrating mean mid-point titre, and symbols representing mid-point titre for 
each rat.
4.6.2 Immune response for trans-4-thiol cotinine -  Tetanus Toxoid conjugate - 
5ug
Antibodies towards trans-4-thiol cotinine were produced as shown in figure 4.2. Titres 
were produces as early as day 21 but were too low to measure mid-point titres 
accurately, therefore only those from day 35 onwards were used. Average titres 
reached their maximum on day 105. The titres obtained are high and within a reported 
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Figure 4.2: Mid-point antibody titres from rats vaccinated with 5pg Tetanus Toxoid - 
Trans-4-thiol cotinine.
The titres were obtained from sera taken on days 35, 49, 78, 98, 105. The sera were tested by 
ELISA, using trans-4-thiol cotinine derivative coated wells, n = 10 for each group with the line 
illustrating mean mid-point titre, and symbols representing mid-point titre for each rat.
4.6.3 Immune response for trans-4-thiol cotinine -  Tetanus Toxoid conjugate - 
25ug
Antibodies towards trans-4-thiol cotinine were produced as shown in figure 4.3. Titres 
were again produced as early as day 21 but were too low to measure mid-point titres 
accurately, therefore only those from day 35 onwards were used. Average titres 
reached their maximum on day 105. The titres obtained are high and within a reported 
range (Heida et al 2000).
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Figure 4.3: Mid-point antibody titres from rats vaccinated with 25pg Tetanus Toxoid - 
Trans-4-thiol cotinine.
The titres were obtained from sera taken on days 35, 49, 78, 98, 105, 184, 205 and 226. The 
sera were tested by ELISA, using trans-4-thiol cotinine derivative coated wells, n = 10 for each 
group with the line illustrating mean mid-point titre, and symbols representing mid-point titre for 
each rat.
4.6.4 Summary of immune response for Trans-4-thiol cotinine -  Tetanus Toxoid 
conjugate - 1 . 5  and 25uq
A summary of the dose response experiment to determine which vaccine gave the 
highest mid-point titre antibody production is illustrated in figure 4.4. In each case, the 
highest mid-point titre was observed on day 105. Comparison of these values (figure 








Figure 4.4: Mid-point antibody titres from rats vaccinated with 1, 5 and 25pg Tetanus 
Toxoid -  trans-4-thiol cotinine.
Comparison of the mid-point titres obtained on day 105. The sera were tested by ELISA using 
trans-4-thiol cotinine derivative coated wells, n = 10 in each group with the bars illustrating 
mean mid-point titre, and symbols representing mid-point titres for each rat.
4.6.5 Competitive ELISA to determine the specificity of antibodies produced
4.6.5.1 Optimisation of derivative coating concentration for ELISA plate
The first step in determining the specificity of antibodies present in sera was to optimise 
the competitive ELISA method. This was done to determine the optimal concentration 
of trans-4-thiol cotinine derivative for coating the ELISA plates. To do this, a variety of 
concentrations of trans-4-thiol cotinine (0.001 -1pg/ml) were tested, using the normal 
ELISA method as described in section 3.8.2.2.3, with a sample serum from a rat 













- m - 0.01 pg/ml
- #--- 0.001 pg/ml
■ 0.001 pg/mi
Sera Dilution
Figure 4.5: Antibody titres from serum from a sample rat using ELISA plate coated with 
varying concentrations (0.001-1 pg!ml) o f the derivative cotsh.
The serum from a rat vaccinated with 5/ug TT-cotsh on day 98 was used. Each concentration of 
derivative coating was done in duplicate shown as two curves per concentration.
The most suitable coating concentration is the lowest needed concentration to give a 
full antibody titre curve. From Figure 4.5 it can be determined that this concentration 
lies between 0.1 -0.01 jig/ml.
Therefore another ELISA was conducted within this range with a more concise 
gradient. The concentrations used were 0.1, 0.05, 0.025 and 0.01 ng/ml (figure 4.6).
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Figure 4.6: Antibody titre from serum from a sample rat using ELISA plate coated with 
varying concentrations (0.1-0.01 pg/ml) o f the derivative cotsh.
The serum from a rat vaccinated with 5/ig TT-cotsh on day 98 was used. Each concentration of 
derivative coating was done in duplicate shown as two curves per concentration
From Figure 4.6 it can be seen that the most suitable concentrations are 0.05 fig/ml 
and 0.025 ng/ml. However, it is difficult to distinguish which concentration is most 
suitable of the two as they show a similar profile.
Therefore a competitive ELISA was conducted using ELISA plates coated with both 
concentrations of derivative to distinguish which concentration gave the best titre 
readings (figure 4.7). Nicotine and cotinine were used as competitor drugs (1mM- 
1nM). The method for competitive ELISA is described in section 4.6.5.2.
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Figure 4.7: Antibody titres from serum from a sample rat using a competitive ELISA.
The serum from a rat vaccinated with 5pg TT-cotsh on day 98 was used. The ELISA plate 
was coated with two concentrations (0.05 and 0.025jjg/ml) o f the derivative trans-4-thiol 
cotinine.
Cotinine (A) and nicotine (B) were used as competitor drugs (1mM-1nM). The method for 
competitive ELISA is described in section 4.6.5.2.
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Figure 4.7 shows clear competition of antibody detection by cotinine compared to a 
lack of effect by nicotine, except at high concentrations which are not present in blood 
after chronic nicotine treatment (figure 3.4). This is probably caused by antibody- 
cotinine complexes being formed, which are not detectable by ELISA.
The ELISA plates coated with 0.05 pg/ml trans-4-thiol cotinine show a slightly higher 
titre. A larger n number would be needed to give a conclusive result, however due to 




The competitive ELISA was done on sera from rats injected with 5pg TT-cotsh vaccine 
on day 98. The other sera were not tested due to cost and time constraints, however 
this will give a good indication on the specificity of the antibodies raised against the 
vaccine. The control vaccine was not tested, as any antibodies raised against TT- 
cysteine are not likely to affect the actions of cotinine, as they are not able to recognize 
cotinine.
The highest sera dilutions from the linear part of the curve obtained from previous 
ELISAs were incubated with 7 ten-fold dilutions of competitors (1mM -  1nM). The 
competitors used were nicotine, cotinine, nornicotine, norcotinine, trans-3- 
hydroxycotinine, nicotine-1-oxide and cotinine-N-oxide (purchased by GSK). These 
are all metabolites of nicotine (see chapter 1, section 1.3.1.2). Sera and competitors 
were incubated at 4°C overnight. A normal ELISA was then done (as described in 
section 3.8.2.2.3) with the following variations; after the 0.05pg/ml trans-4-thiol cotinine 
coated plates were incubated with casein and washed as normal, 100pl of the sera- 
competitor solution were added in duplicate. There was no serial dilution of the serum 
as one specific dilution was taken at the beginning of the experiment. This was 
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Figure 4.8: Competitive ELISA to determine specificity o f antibodies in sera in relation to 
nicotine and some of its metabolites.
The sera used are from 5/jg TT-cotsh vaccinated rats on day 98. The sera were tested by using 
0.05/ug/ml trans-4-thiol cotinine derivative coated wells, n = 10 rats for each competitor.
The competitive ELISA (figure 4.8) illustrates that the antibodies obtained from 
vaccination with 5pg TT-cotsh vaccine show specificity for cotinine over all metabolites 
tested. Norcotinine does show slight competition with the vaccine, however this is not 
an important finding. Although norcotinine has been shown to be present and 
metabolised in rat brain, there is no literature to suggest it has any pharmacological 
activity (Crooks & Dwoskin 1997, Ghosheh et al 2001).
There seems to be a difference in inhibition between figures 4.7 and 4.8. In figure 4.7 
the inhibition seems to start occurring with 100pM competitor, whereas in figure 4.8, 
the curve seems to start occurring with 1pM competitor. The point to note is that in
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figure 4.7, the highest absorbance reached is 2.5 and the curve seems to start going 
down at 2.0. At this absorbance of 2.0, figure 4.8 shows inhibition at the same 
concentration (100pM). I suggest that the problem lies with why the highest absorption 
levels of 3.5 are not reached. This maybe because the serial dilution in figure 4.7 was 
only begun at 1:20, and not 1:100 as in figure 4.8. This may mean that more antibody 
are present in the sera and therefore more inhibitor needed to have the same effect. 
This is of course only a hypothesis and needs further investigation. Experimental error 
could also account for this difference and as figure 4.7 is n=1, more experiments are 
needed to clarify this point.
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4.7 Results of rat serum analysis for nicotine and cotinine concentrations in rats 
treated with nicotine osmotic minipump.
The aim of this experiment was to determine the effect of vaccination on rat serum 
nicotine and cotinine concentrations. Rats vaccinated with TT-cotsh (5pg) and TT- 
cysteine (25pg) were chronically treated with nicotine or saline by osmotic minipump, 
on days 98-105. The same procedures for bleeding, osmotic minipump preparation, 
surgical procedures and sera cotinine and nicotine concentration determination were 
used, as described in section 3.6 and 3.7. Cotinine and nicotine concentration 
measurements were done by gas chromatography at ABS laboratories. In short, this 
technique separates out the components within the sera and the concentration of 
cotinine and nicotine are detected. The cotinine levels detected will include the 
antibody-bound cotinine as separation experiments such as hydrolysis are not 
conducted previous to gas chromatography.
TT-CO TSH  vaccinated rats 
TT-cysteine vaccinated rats
[Nicotine]
Figure 4.9: Nicotine and cotinine concentration in serum from rats immunized with 5/jg 
TT-cotsh vaccine and TT-cysteine (control), and treated with 7-day nicotine osmotic 
minipump.
Nicotine was administered at a rate o f 4mg/kg/day. Sera were taken on day 105. n = 5 rats per 
minipump treatment group. * = Significantly different from corresponding control TT-cysteine 
vaccine (p <0.05 p = 0.0129) using student’s unpaired t-test.
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Rats receiving saline had negligible levels of serum nicotine (mean 1.0 ± 0.5ng/ml) and 
cotinine (mean 3.75 ± 0.5ng/ml) in both vaccine groups.
Nicotine treatment produced levels of nicotine (77.3 ± 15.2) and cotinine (403.4 ± 95.1) 
in the expected range for the nicotine dose used, in control vaccinated rats (figure 4.9) 
(Sanderson etal 1993).
The cotinine concentration for the TT-cotsh vaccine sera (901 ± 124) increased 
significantly compared to the control vaccine (403.4 ± 95.1), when treated with nicotine 
(figure 4.9). This result is as expected, possibly due to the cotinine specific antibodies 
binding to cotinine in the blood producing an antibody-conjugate complex, and 
therefore retaining cotinine in the blood (Heida et al 1997).
4.8 Effect of vaccination on nicotine-evoked dopamine release from striatal 
minces
The rats vaccinated with 5pg TT-cotsh were treated with 7-day nicotine or saline 
osmotic minipumps on day 98-105. The two striata from each animal were dissected 
and the effect of this nicotine treatment on nicotine-evoked dopamine release was 
measured.
The same procedures for osmotic minipump preparation and surgical procedures were 
used as described in section 3.6 and 3.7. The 96-well plate [3H]-dopamine release 
assay described in sections 2.2 and 2.3 was used.
There was a significant increase in nicotine - evoked [3H]-dopamine release when rats 
were chronically treated with nicotine compared to saline, in both TT-cotsh and TT- 
cysteine vaccinated rats (figure 4.10). However in this experiment there is no 
significant change in nicotine -  evoked [3H]-dopamine release between TT-cotsh and 
TT-cysteine vaccinated rats (p=0.059). The statistics show that significance in this 
case is close and with further experiments and an increase in the number of rats in the 
experiment, significance may be reached. This is further investigated in the next trial. 
Nicotine - evoked [3H]-dopamine release was unaffected by vaccination in saline 
treated rats.
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Nicotine minipump Saline minipump
treatment treatment
Figure 4.10: Effect o f chronic nicotine treatment on nicotine -  evoked f3H]-dopamine 
release using 96-well plate assay.
Rats were chronically treated with nicotine or saline osmotic minipump for 1 days. Striatal 
minces were pre-loaded with fHJ-dopamine. Pre-incubation with nicotine (100juM, 5 minutes) 
and stimulation with nicotine (100pM, 5 minutes) produced fHJ-dopamine release. 8 replicates 
were used for each condition and this was done for 4-6 rats per group.
* = Significantly different from control TT-cysteine vaccinated rats treated with saline minipump 
(p<0.05) using Student’s unpaired t-Test.
# = Significantly different from TT-cotsh vaccinated rats treated with saline minipump (p<0.05) 
using Student’s unpaired t-Test.
f  = Not quite significant from corresponding TT-cotsh vaccinated rats treated with nicotine 
minipump (p=0.059) using Student’s unpaired t-Test.
4.9 Discussion
4.9.1 Have the improvements from trial 1 been effective?
The change in carrier molecule from Ovalbumin to Tetanus toxoid was shown to be a 
successful strategy as the desired number of attachments of derivative (15 cotsh per 
TT molecule), were made and this was successfully determined using Lowry and 
Ellmans’ tests. The more cotinine epitopes present on the conjugate vaccine, the 
higher the recognition of cotinine by the immune response, therefore increasing the 
amount of antibodies produced. There is a correlation between size of a 
macromolecule and its immunogenicity as discussed in the introduction (section
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1.6.4.5), therefore increasing the size of the antigen by adding a larger carrier molecule 
(TT) compared to ovalbumin in trial 1 has improved the immune response. The change 
in adjuvant from Alum to GSK AS2V was also a successful strategy as in conjunction 
with the increase in derivative attachments and change of carrier molecule, the immune 
response was increased dramatically (average mid-point titres >1:10000) to desired 
levels where it has been shown to produce adequate drug-specific binding affinity 
(Hieda et al 1997). This was done in a vaccine against nicotine where titres at this 
level have been shown to elicit binding of a substantial fraction of a single dose of 
nicotine in serum.
The successful optimisation of the competitive ELISA method allowed for the 
determination of the specificity of the antibodies to detect cotinine alone. As shown in 
figure 4.8, nicotine and the other metabolites tested were not recognized by the 
cotinine antibodies present in the sera. The metabolites used in this trial were chosen 
as they were easily obtained and may contribute to the actions of nicotine in relation to 
nicotine addiction. For example nornicotine has been shown to increase dopamine 
release in a calcium-dependent manner from superfused rat striatal slices (Dwoskin et 
al 1993). It is important to obtain an immune response towards the cotinine molecule 
only, as the metabolites of nicotine have a similar structure to cotinine (as seen in 
figure 1.5), and the identification of the oxygen molecule on the pyrolydine ring in 
cotinine, by the immune cells is paramount in enabling a specific response. The 
specificity of the antibody therefore enables us to determine only the effect of the 
reduction of cotinine to the brain and not other mechanisms that may contribute to 
nicotine addiction. In conclusion the results show a proof of concept for the initial aims 
of this project: cotinine specific antibody titres are produced in the desired quantity due 
to the production of a viable cotinine vaccine.
The 5 jig TT-cotsh conjugate produced the highest mid-point titres in comparison to the 
1 and 25 pg TT-cotsh conjugates (figure 4.4). An insufficient dose fails to activate 
enough lymphocytes or induce a state immunologic unresponsiveness or tolerance. 
This could explain the reduced immune response for the 1 pg conjugate. Conversely, 
an excessive high dose can also induce tolerance, which could explain the reduced 
immune response in the 25 pg conjugate. In each conjugate concentration, the highest 
mid-point titre was observed on day 105. The 1 and 25 pg vaccines did show a fall in 
antibody titres on day 184 which then increased by day 205 but did not reach the 
maximum titre previously achieved, and progressively fell once again by day 226. This
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suggests that one booster alone does not produce a long lasting effect in this immune 
response but the second booster activates the memory response. This is probably 
caused by the long-lived memory cells, which are produced along with the relatively 
short-lived effector cells of the primary immune response, after the second booster. 
These memory cells proliferate rapidly when exposed again to the same antigen, giving 
rise to a new clone of memory cells as well as new effector cells, demonstrated here by 
the increase of antibody titres after the second booster. The fall in antibody titres is 
probably caused by the actions of the immune cells, by getting rid of this foreign 
molecule (explained further in section 1.6.4.3).
This pattern needs to be further investigated to determine improvements in the 
vaccination regime to produce a high and long lasting immune response.
4.9.2 Effects of nicotine
The significant increase in blood cotinine, but not nicotine, concentrations after chronic 
nicotine treatment, seen in TT-cotsh vaccinated rats in comparison to control 
vaccinated rats suggests an antibody-cotinine complex formation in sera. Therefore 
cotinine is retained in the blood probably by the precipitation mechanism of antibodies 
as described in section 1.6.4.4). This is an important finding, suggesting that the 
specific antibodies produced towards cotinine are acting on free cotinine in the blood. 
This is similar to results obtained in the production of a nicotine vaccine (Hieda et al 
1997), where nicotine concentrations were increased in sera after nicotine treatment. 
In this project, I was not able to determine specific binding concentrations for cotinine 
to the antibody due to practical constraints but this is a crucial piece of information to 
allow for complete characterization of the immune response.
There was a significant increase in nicotine - evoked [3H]-dopamine release when rats 
were chronically treated with nicotine compared to saline, in both TT-cotsh and TT- 
cysteine vaccinated rats (figure 4.10). A search of the literature reveals that few 
reports exist regarding the effect of chronic nicotine treatment on dopamine release in 
vitro, with examination of dopamine release in vivo regarded as a more suitable system 
(DiChiaria 2000). The analysis of dopamine release from rat striatal slices found an 
increase in dopamine release after treatment with nicotine by daily injection (Yu & 
Wecker 1994). In contrast, Marks et al (1993) showed that dopamine release from 
mouse brain synaptosomes declined after chronic nicotine infusion suggesting 
desensitisation / inactivation of nAChRs. Similar results have also been obtained in our 
laboratory.
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The dopamine release assay was conducted to determine whether vaccination causes 
any change in the reported increase in dopamine release after chronic nicotine 
treatment. In TT-cotsh vaccinated animals, following chronic nicotine treatment, there 
was a trend towards increased nicotine-evoked dopamine release, compared with the 
response in tissue form rats receiving the control vaccine. However this failed to reach 
statistical significance, suggesting vaccination does not have an effect on dopamine 
release in the striatum, using this assay. However, increasing the n number of 
animals, and / or the titres achieved during the nicotine treatment may enhance this 





5.0 Neurochemical and Behavioural studies to evaluate the effect of vaccination
-T ria l 3
5.1 Introduction
This final trial was conducted to assess the effect of vaccination against cotinine on a 
variety of parameters. These parameters included the study of mid-point titres, nicotine 
and cotinine concentrations after chronic and acute nicotine treatment, dopamine 
release in the striatum, and locomotor activity. The locomotor activity tests are a new 
addition in this trial and a short review of the literature as well as methodologies used 
are explained in section 5.7, followed by results for the effects of acute and chronic 
nicotine treatment on locomotor activity and a discussion of the results obtained. The 
vaccine used in this trial was prepared in the same manner as trial 2 using the 5pg TT- 
cotsh conjugate and 25pg TT-cystiene conjugate as control (section 4.3 and 4.4). 
However the number of trans-4-thiol cotinine attachments to TT was 11 per TT 
molecule compared to 15 per TT molecule in trial 2. This change in the vaccine may 
cause an effect on the immune response however, it could not be improved due to time 
and financial limitations.
5.2 Injection regimes
There were two groups of rats used in this study. One group (regime 1) was used to 
study the effect on nicotine-evoked dopamine release and blood cotinine and nicotine 
concentrations after chronic nicotine treatment using 7-day osmotic minipumps. The 
injection regime was kept as similar to the injection regime in trial 2 as possible 
allowing for differences in access to the animals at the time. The second group 
(regime 2) was used to study locomotor activity and blood nicotine and cotinine 
concentrations after acute nicotine injection. The injection regime was changed in this 
group to examine any differences that may occur in the immune response with a 
different injection regime (allowing 4 weeks between the second injection and first 
booster). This was also done for convenience, to allow for experiments in both 
injection regimes to be conducted in the same period of time.
Regime 1
Day 1 -  First injection 
Day 21 -  Second injection 
Day 35 -  Third injection & bleed 
Day 84 -  First Booster & bleed 
Day 91 -  Minipump insertion & bleed




Day 1 - First injection
Day 21 - Second injection 
Day 35 - Third injection & bleed 
Day 95 - First Booster & bleed 
Day 116 - Bleed 
Day 119 - Start of Locomotor 
activity experiment 
Day 143 - End of locomotor 
activity experiment 
Day 150-Bleed 
Day 170 - Second Booster
Day 184 - Acute nicotine injection, 8 hours later rats were killed - blood taken for 
[nicotine & cotinine] analysis 
The rats used varied in weight between 220g and 290g at the start of the experiment. 
This was the closest range of weight possible with the rats available. The rats were 6-7 
weeks old at the beginning of the experiment which is the age in which the parental 
antibodies are no longer able to cause any effect on the production of antibodies 
against this vaccine. There were 10 rats per vaccine group in regime 1 and 14 rats per 
vaccine group in regime 2. In regime 1 vaccine group which were treated with osmotic 
minipumps, 5 rats were treated with saline and 5 with nicotine (4mg/kg/day).
It was noted that no difference was seen in rat behaviour or locomoter activity after 
injections and minipump insertion.
All further procedures undertaken are the same as described in section 3.6 and 3.7.
In regime 2 vaccine group, which were studied for locomotor activity, 7 rats were 
injected with saline, and 7 rats were injection with nicotine (0.4 mg/kg). Further details 
are described in section 5.8.
5.3 Enzvme-Linked Immunosorbent Assay (ELISA)
The protocol described in section 3.8.2.2.3 -  derivative-coated 96-well plate ELISA was 
used with variations, to determine antibody titres using TT-cotsh and TT-cysteine 
vaccinated rat sera. The plates were coated with trans-4-thiol cotinine (1pg/ml in 
carbonate buffer, 50pl) and the serum was serially diluted (1:2 times each time) starting 
from 1:100 dilutions in saturation buffer.
An ELISA was also conducted in this trial using TT-coated maxisorp 96 well plates 
using the same protocol as section 3.8.2.2.3, to determine antibody titres produced
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against TT. The results were too high to calculate the mid-point titres (as explained 
further in section 4.6).
5.3.1 Immune response for trans-thiol cotinine -  Tetanus Toxoid conjugate (5uq) 
from injection regime 1
Antibodies towards trans-4-thiol cotinine were produced as shown in figure 5.1. Titres 
were produced as early as day 21 but were too low to measure mid-point titres, 
therefore only those from day 35 onwards were used. Average mid-point titres reached 
a maximum on day 91 and remained at this level until day 98. The titres obtained are 
high, however they are lower than the titres obtained in trial 2 (figure 4.4). This may 
have been caused by the lower number of derivative attachments (11cotsh per TT) on 
the carrier molecule compared to the number of attachments in trial 2 (15 cotsh per TT) 
as explained in section 5.1. Another reason for the fall in immune response may be the 
efficacy of the adjuvant used. GSK have shown that the efficacy of AS2V adjuvant was 
decreased after three months from production, and in this trial AS2V was made one 
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Figure 5.1: Mid-point antibody titres from rats vaccinated with 5pg TT-cotsh.
The titres were obtained from sera taken on days 35, 84, 91. The sera was tested by ELISA 
using trans-4-thiol cotinine derivative coated wells, n = 10 rats for each group with the bars 
illustrating mean mid-point titre, and symbols representing mid-point titre for each rat.
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5.3.2 Immune response for TT-cotsh conjugate (5uq) from injection regime 2
Antibodies towards trans-4-thiol cotinine were measured as shown in figure 5.2. Titres 
were produced as early as day 21 but were again, too low to measure mid-point titres, 
therefore only those from day 35 onwards were used. Average mid-point titres reached 
their maximum on day 116 and remained at this level until day 150. The titres obtained 
are high, however the average titres are lower than the titres obtained in trial 2. 
Individual rat titres do reach those obtained in trial 2 in the 1:10000 region. The 
decreased in average titres may have, been caused by the lower number of derivative 
attachments on the carrier molecule Tetanus Toxoid, or the possible lower efficacy of 
AS2V adjuvant explained further in section 3.3.1. Antibody titres were not able to be 
obtained on day 184, 14 days after the second booster, as it was not possible to take 
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Figure 5.2: Mid-point antibody titres from rats vaccinated with 5pg TT-cotsh.
The titres were obtained from sera taken on days 35, 95, 116, 150. The sera were tested by 
ELISA using trans-4-thiol cotinine derivative coated wells, n = 10 rats for each group with the 
bars illustrating mean mid-point titre, and symbols representing mid-point titre for each rat.
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5.4 Results of rat serum analysis for nicotine and cotinine concentrations in rats
chronically treated with nicotine by osmotic minipump.
Rats vaccinated with TT-cotsh (5pg) and TT-cysteine (25pg) were chronically treated 
with nicotine (4mg/kg/day) or saline by osmotic minipump, on days 91-98. The same 
procedures for bleeding, osmotic minipump preparation, surgical procedures and sera 






Figure 5.3: Nicotine and cotinine concentration in serum from rats immunized with 5^g 
TT-cotsh vaccine and TT-cysteine (control), and treated with 7-day nicotine osmotic 
minipump in regime 1.
Nicotine was administered at a rate of 4mg/kg/day. Sera were taken on day 98. n = 5 rats per 
minipump treatment group.
* = Significantly different from corresponding rats vaccinated with TT-cysteine (control) (p <0.05 
p = 0.0129) using student’s unpaired t-test.
Rats receiving saline had negligible levels of serum nicotine (mean 2.0 ± 0.226ng/ml ) 
and cotinine (mean 6.35 ± 1.627ng/ml) in both vaccine groups.
Nicotine treatment produced levels of nicotine (152.6 ± 13.6) and cotinine (720.6 ± 
75.8) in the expected range for the nicotine dose used, in control vaccinated rats (figure 
5.3) (Sanderson et al 1993). The cotinine concentration for the TT-cotsh vaccine sera 
(1312.4 ± 70.93) increased significantly compared to the control vaccine (720.6 ± 75.8),
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when treated with nicotine (figure 5.3). This result is as expected, possibly due to the 
cotinine specific antibodies binding to cotinine in the blood producing an antibody- 
conjugate complex, and therefore retaining cotinine in the blood (Heida etal 1997).
5.5 Results of rat serum analysis for nicotine and cotinine concentrations in rats. 
8 hours after nicotine injection.
Rats vaccinated with TT-cotsh (5pg) and TT-cysteine (25pg) from regime 2, were 
acutely treated with nicotine (0.4mg/kg) or saline by subcutaneous injection, on day 
184. Eight hours after injection, the rats were killed and blood was taken for nicotine 
and cotinine concentration determination (see section 3.7 for procedures). There were 
7 rats per injection group. This experiment was done to show if vaccination causes an 
effect on acute nicotine treatment.
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Figure 5.4: Nicotine and cotinine concentration in serum from rats immunized with 5/jg 
TT-cotsh vaccine and TT-cysteine (control), and treated with nicotine injection (0.4mg/kg) 
in regime 2.
Acute nicotine treatment (0.4mg/kg) was administered by subcutaneous injection on day 184, 
and sera were taken eight hours after injection, with 7 rats per nicotine or saline treatment 
group. * = Significantly different from corresponding rats vaccinated with TT-cysteine (control) 
vaccine (p <0.05 p = 0.0129) using student’s unpaired t-test.
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Rats receiving saline had negligible levels of serum nicotine (mean 2.0 ± 0.226ng/ml) 
and cotinine (mean 6.35 ± 1.627ng/ml) in both vaccine groups.
Nicotine treatment produced levels of nicotine (12.3 ± 1.9) and cotinine (167.2 ± 8.5) in 
the expected range for the nicotine dose used, in control vaccinated rats (Sanderson et 
al 1993).
The cotinine concentration for the TT-cotsh vaccine sera (365.2 ± 43.3) increased 
significantly compared to the control vaccine (167.2 ± 8.5), when treated with acute 
nicotine (0.4mg/kg) (figure 5.4). This result shows that vaccination was acting within 
eight hours after introduction of nicotine into the system, allowing for metabolism of 
nicotine to cotinine. The cotinine specific antibodies may then have bound to cotinine 
in the blood, in large amounts to allow the production of antibody-conjugate complexes, 
which retained cotinine in the blood in large enough quantities to produce a significant 
increase in cotinine concentration (Heida et al 1997).
5.6 Effect of vaccination on nicotine- evoked dopamine release in the striatum
The rats vaccinated with 5pg TT-cotsh were treated with 7-day nicotine or saline 
osmotic minipumps in regime 1 on days 31-38. The two striata from each animal were 
dissected and the effect of this nicotine treatment on nicotine-evoked dopamine release 
was measured.
The same procedures for osmotic minipump preparation and surgical procedures were 
used as described in section 3.6 and 3.7. The 96-well plate [3H]-dopamine release 
assay described in sections 2.2 and 2.3 was used. The nicotine concentration used in 
these experiments was 10pM.
There was a significant increase in nicotine - evoked [3H]-dopamine release when rats 
were chronically treated with nicotine compared to saline, in TT-cotsh vaccinated rats 
(figure 5.5). This is in accordance with results obtained in trial 2 (figure 4.10).
There was a significant decrease in nicotine - evoked [3H]-dopamine release when rats 
were chronically treated with nicotine compared to saline, in TT-cysteine vaccinated 
rats (figure 5.5). This is in contradiction with results obtained in trial 2 (figure 4.10). 
However in this experiment there is no significant change in nicotine -  evoked [3H]- 
dopamine release between TT-cotsh and TT-cysteine vaccinated rats (p=0.058). The 
statistics show that statistical significance in this case is close and with further 











Figure 5.5: Effect o f chronic nicotine treatment on nicotine -  evoked fHJ-dopamine  
release.
Striatal minces were pre-loaded with pHJ-dopamine. Pre-incubation with nicotine (10/uM, 5 
minutes) and stimulation with nicotine (10/uM, 5 minutes) showed pHJ-dopamine release after 
chronic nicotine treatment by 7-day osmotic minipump. 8 wells per treatment were used in each 
experiment and this was done for 5 rats per group from regime 1.
f  = Significantly different from control TT-cysteine vaccinated rats treated with saline minipump 
(p<0.05) using Student’s unpaired t-Test.
* = Significantly different from corresponding TT-cotsh vaccinated rats treated with saline 
minipump (p<0.05) using Student’s unpaired t-Test
5.7 Effect of vaccination on nicotine -  evoked locomotor activity
5.7.1 Introduction
Under a regime of daily exposure to nicotine, tolerance to the depressant effect on 
locomotor activity begins to develop after a single exposure, and is clearly present after 
a week (Shoaib et al 1994, Domino 2001). Sensitisation to the locomotor stimulation
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produced by nicotine takes longer to develop, with a clear effect visible after 10 days or 
more (Shoaib & Stolerman 1992, Whiteaker et al 1995, Kelsey et al 2002).
Enhanced locomotor response to nicotine in animals pretreated with the drug prior to 
test day is associated with potentiation of its effects on dopamine secretion in the 
nucleus accumbens (Benwell & Balfour 1992). Pre-treatment with nicotine causes a 
regionally selective sensitisation of its stimulatory effects on the mesoaccumbens 
dopamine system, which has been implicated in the locomotor stimulant response to 
nicotine and its ability to reinforce self-administration . The sensitisation evoked by 
daily injections of nicotine is associated with a regionally selective down-regulation of 
the control of mesoaccumbens dopamine neurons by inhibitory autoreceptors and 
depends on co-stimulation of NMDA glutamatergic receptors. It is suggested that the 
sensitisation is related to enhanced burst firing of mesoaccumbens neurons, which 
results in an enhancement of dopamine release into the extracellular space between 
the cells where it acts upon putative extrasynaptic dopamine receptors. (Balfour et al 
1997). There are some studies which suggest that up-regulation of the nicotinic 
acetylcholine receptors may be responsible, in part, for the sensitisation to nicotine 
(Shoaib et al 1997). This study was done to examine the effects of nicotine on 
locomotor activity in vaccinated vs non-vaccinated rats, as well as the effect of nicotine 
sensitisation on locomotor activity in vaccinated vs non-vaccinated rats. This study 
was carried out in the Department of Pharmacy and Pharmacology at the University of 
Bath, in conjunction with Dr Paul J Mitchell.
5.7.2. Methods 
STUDY GROUPS
TT - COTSH vaccinated rats - Saline injections (n=7)
Nicotine injections (n=7)
TT - Cysteine vaccinated rats- Saline injections (n=7)
Nicotine injections (n=7)
Rats were placed in the locomotor activity chamber for 60 minutes prior to injection to 
habituate the rats to the new environment. Locomotor activity was monitored 
immediately upon introduction to the activity chamber and for 90 minutes after injection 
of nicotine or phosphate buffer (total time = 150 minutes) (Figure 5.6). Nicotine 
hydrogen tartrate in phosphate buffer (100mM, 0.4mg/kg, pH 7.4) or phosphate buffer 
as control (100mM, pH 7.4) was administered by subcutaneous injection.
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The locomotor cages had 11 infrared beams in the surround. Breaking of the beams 
was registered on the computer, allowing for measurement of line crosses and 
repeated breaking of the beam. The number of line crosses was the measurement 
used to quantify locomotor activity. Cage crosses were measured at 5-minute epochs 
and 30-minute blocks were analysed. Rats were housed in cages of 4 for the duration 
of the trial, with unlimited access to food and water, in rooms where the temperature is 
maintained at 20 ± 1°C and humidity at 50 ± 10%. There was a regular light-dark cycle 
with lights on from 0.700 -  19.00 hours. All behavioural experiments were carried out 
during the light phase of the cycle with 1 rat per locomotor activity chamber.
60minutes 90 minutes
T t  T
Start recording Injection Stop recording
Figure 5.6: Time course of each locomotor activity recording.
Locomotor activity was monitored immediately upon the introduction of rats to the activity 
chamber and for 90 minutes after injection of nicotine or phosphate buffer (total time = 150 
minutes).
Day 1 Day 2 Day 3 Day 4
Group 1 Saline Nicotine Saline Start
Sensitisation
Group 2 Saline Saline Nicotine Start
Sensitisation
Table 5.1: Experiment plan demonstrating which treatments were administered on
specific days prior to the sensitisation experiment.
Locomotor activity was measured in rats with saline injections on day 1, to determine base rate 
activity and habituate all rats to the experimental procedures. Locomotor activity measured on 
days 2 and 3 are to study the effect of acute nicotine treatment, allowing for all rats to be tested 
with both nicotine and saline to increase the number of animals in each group. Beginning on 
day 4, the effect of sensitisation on locomotor activity was measured for 21 days, in rats in the 
two groups with nicotine or saline treatment (7 days/week).
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The dosing and recording was done as shown in table 5.2:
Mon Tues Wed Thurs Fri Sat Sun
Dose V V V T V V
Recording V - 1 - V - -
Table 5.2: Experiment plan for a sample week, showing dosing and recording regime.
All rats were treated with nicotine (0.4mg/kg) or phosphate buffer by subcutaneous injection 
everyday for three weeks, and locomotor activity was measured on Monday, Wednesday and 
Friday. There were 9 sessions in total.
5.7.3 Results
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Figure 5.7: Effect o f acute nicotine treatment on locomotor activity in rats vaccinated 
with TT-cotsh and control TT-cysteine.
Rats vaccinated with TT-cotsh and TT-cysteine were treated with 4mg/kg nicotine or saline and 
locomotor activity was measured as described in section 5.7.2. n = 14
i .




There is a high level of activity when animals are first placed in the locomotor chamber 
(60-35 pre) in all groups, which decreases in the next 30 minutes as the animals are 
habituated to the new environment. Acute nicotine induced hyperactivity is seen in 
vaccinated and non-vaccinated animals. The same hyperactivity is not seen in saline 
treated animals (Figure 5.7). Immunisation with cotinine vaccine shows no significant 
difference in nicotine induced locomotor activity compared to control vaccinated 
animals.
5.7.3.2 Chronic nicotine treatment produced sensitisation
The results are represented per half hour of locomotor activity measurement over the 9 
sessions of tests as described in section 5.7.2, in the TT-cotsh and TT-cysteine 








1 2 3 4 5 6 7 8 9
Session
■  Novae sal
■  Novae nic
□  V ac  sal
□  V ac  nic
Figure 5.8: Effect of chronic nicotine treatment on locomotor activity in rats vaccinated 
with TT-cotsh and control TT-cysteine.
Rats vaccinated with TT-cotsh and TT-cysteine were treated with 4mg/kg nicotine or saline and 
locomotor activity was measured as described in section 5.7.2. The graph represent locomotor 
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Figure 5.9: Effect of chronic nicotine treatment on locomotor activity in rats vaccinated 
with TT-cotsh and control TT-cysteine.
Rats vaccinated with TT-cotsh and TT-cysteine were treated with 4mg/kg nicotine or saline and 
locomotor activity was measured as described in section 5.7.2. The graph represent locomotor 
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Figure 5.10: Effect of chronic nicotine treatment on locomotor activity in rats vaccinated 
with TT-cotsh and control TT-cysteine.
Rats vaccinated with TT-cotsh and TT-cysteine were treated with 4mg/kg nicotine or saline and 
locomotor activity was measured as described in section 5.7.2. The graph represent locomotor 
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Figure 5.11: Effect of chronic nicotine treatment on locomotor activity in rats vaccinated 
with TT-cotsh and control TT-cysteine.
Rats vaccinated with TT-cotsh and TT-cysteine were treated with 4mg/kg nicotine or saline and 
locomotor activity was measured as described in section 5.7.2. The graph represent locomotor 
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Figure 5.12: Effect of chronic nicotine treatment on locomotor activity in rats vaccinated 
with TT-cotsh and control TT-cysteine.
Rats vaccinated with TT-cotsh and TT-cysteine were treated with 4mg/kg nicotine or saline and 
locomotor activity was measured as described in section 5.7.2. The graph represent locomotor 
activity measured in the 65-90 minute period after nicotine or saline treatment, n - 7
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The statistical analysis for figures 5.10, 5.11 and 5.12 are shown below. This was 
done to allow the reader to be able to compare the figures easily.
* One-way ANOVA post hoc showed significance in comparison to respective saline group 
(p<0.5)
** One-way ANOVA post hoc showed significance in comparison to respective saline group
(p<0.01)
*** One-way ANOVA post hoc showed significance in comparison to respective saline group
(p<0.001)
t  Repeated measures ANOVA post hoc p <0.05 in comparison to session 1
Figures 5.8 and 5.9 show a high level of activity when animals are first placed in the 
locomotor chamber (60-35 pre-treatment) in all groups, which decreases in the next 30 
minutes as the animals are habituated to the new environment.
In the first 30 minutes after nicotine treatment (figure 5.10), nicotine induces significant 
hyperactivity in vaccinated and non-vaccinated animals. This does not occur in 
animals treated with saline. There is a period of development in the nicotine-induced 
increase of locomotor activity between sessions 1 to 3 for 30 minutes post dosing 
(figure 5.10). The increase in response to nicotine only reached significance in 
vaccinated animals in session 3, 30 minutes post treatment (figure 5.10) and is 
maintained mainly until 60 minutes post treatment (figure 5.11), however some 
hyperactivity is seen in session 5, 65-90 minutes post treatment (figure 5.12).
There is no evidence for differences in locomotor activity between vaccinated and non- 
vaccinated animals throughout the acute nicotine treatment. However, baseline activity 
in vaccinated animals is predominantly lower than in non-vaccinated animals, in the 
habituation sessions (60-5 minutes pre-treatment, figure 5.8, 5.9), and consistently 
lower in chronically treated animals (figure 5.10, 5.11, 5.12).
In summary, although nicotine -  induced locomoter activity has been shown in this 
experiment, vaccination does not seem to cause an effect.
5.8 Discussion
5.8.1 Immunisation
The overall immune response in this trial was lower than in trial 2 for both injection 
regimes, possibly due to the lower number of derivative attachments to tetanus toxoid.
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However mid-point titres from Regime 2 reached a higher level at the end of the 
experiment (day 150), compared to regime 1 (day 98), however this did include an 
extra booster of the vaccine (section 5.2). Further study is needed to examine both 
regimes more closely with the vaccine used in trial 2, to determine which injection 
regime activates the most robust immune response.
5.8.2 Effect of nicotine
The significant increase in blood cotinine but not nicotine concentrations after both 
acute and chronic nicotine treatment, seen in TT-cotsh vaccinated rats in comparison 
to control vaccinated rats, suggests antibody-cotinine complex formation in sera. 
Therefore cotinine is retained in the blood probably by the precipitation mechanism of 
antibodies as described in section 1.7.4. This is similar to results obtained in the 
production of a nicotine vaccine (Hieda et al 1997), where nicotine concentrations were 
increased in sera after nicotine treatment.
There was a significant increase in nicotine - evoked [3H]-dopamine release when rats 
were chronically treated with nicotine compared to saline, in TT-cotsh vaccinated rats 
which is in accordance with results obtained in trial 2. However, nicotine has evoked a 
decrease in dopamine release compared to saline in non-vaccinated animals which is 
in accordance with Marks et al (1993). Therefore there seems to be a trend towards a 
larger difference in nicotine-evoked dopamine release and saline treatment in 
vaccinated animals compared to non-vaccinated animals. This decrease in dopamine 
release in non-vaccinated rats may be due to inactivation of nAChRs caused by 
nicotine treatment.
However in this experiment there is no significant change in nicotine -  evoked [3H]- 
dopamine release between TT-cotsh and TT-cysteine vaccinated rats (p=0.058). The 
statistics show that statistical significance in this case is close and with further 
experiments and an increase in the number of rats in the experiment, significance may 
be reached. These results are in accordance with the hypothesis of the cotinine 
vaccine project ie: cotinine is retained in blood causing a reduction in cotinine reaching 
the brain, allowing for nicotine to have a larger effect on dopamine release.
The nicotine induced locomoter activity was not affected by cotinine vaccination. This 
may be due to the low antibody titres during the locomotor activity experiments. 
Enough cotinine may not have been retained in the blood to have a significant effect on 
locomotor activity. Optimisation of the immune response and a repeat of these
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locomotor experiments are necessary to determine whether the cotinine vaccine 
causes a behavioural change in rats. Passive immunisation of rats with nicotine 
vaccine (Pentel et al 2000) completely prevented nicotine-induced increases in 
locomotor activity measured 25 hours after nicotine injection, therefore reducing the 
amount of nicotine reaching the brain can cause an effect on locomotor activity. It 
would be interesting to find out if an increase in the actions of nicotine through 






The socio-economic consequences of nicotine addiction are vast as explained in the 
introduction. Many methods are adopted to treat nicotine addiction, including 
therapeutic intervention and counselling, the long term success rates have been limited 
and there continues to be a need for more effective treatments. A novel approach that 
has gained a significant degree of interest in recent years is the use of vaccines 
designed to raise antibodies against this drug of abuse and prevent its entry into the 
brain, therefore this concept would be targeting the drug and not the brain.
Cotinine was chosen as the target molecule for the vaccine. The hypothesis behind 
this target is that cotinine is produced in the body by the metabolism of nicotine.
Specific antibodies to cotinine in the blood eliminate the compound before it reaches 
the brain. This will in turn stop the antagonistic actions of cotinine (through initial 
agonism causing desensitisation of nicotinic AchRs) on nicotine in the brain. Therefore 
nicotine will have a larger desired effect on the smoker, which in turn will encourage the 
smoker to consume fewer cigarettes. This is better for the health of the smoker and 
also with the aid of other therapies such as NRT, the smoker may have a better chance 
of successfully quitting.
The effects of cotinine and/on nicotine in the rat brain were first studied in chapter 2, as 
there is conflicting evidence in the literature regarding its mechanism of action 
(described in detail in the introduction). In the 96-well plate assay used to test the 
effects of various drugs on dopamine release in the striatum, nicotine and cotinine were 
shown to act as agonists on nAChRs in a dose-dependent manner, and cotinine 
showed a 1000-fold lower potency than nicotine, and probably caused desensitisation 
of the receptors when used in conjunction with nicotine. This conclusion was made as 
a decrease in nicotine-evoked dopamine release was seen when cotinine was used in 
conjunction with nicotine. This is in accordance with previous published data (Dwoskin 
et al 1999, Marshall et al 1997, Sharpies & Wonnacott 2001, Abood et al 1981). This 
finding backs up the cotinine vaccine hypothesis. Removing or reducing the cotinine 
concentration in the brain by antibodies in the blood, will reduce the antagonism of 
cotinine on nicotine-evoked dopamine release as well as possibly affecting other 
mechanisms of nicotine addiction related to nAChRs. This will in turn increase the 
effects of nicotine on the addiction pathway allowing for the reduction of the need for 
nicotine by smokers. With other forms of nicotine cessation such as NRT, smokers will 
in this way be aided in their quit attempt.
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The effects of cotinine on nAChRs in the striatum of rats were also studied to acquire a 
better understanding of the mechanism of action of cotinine. It was established that 
cotinine acts on nAChRs in the striatum, as mecamylamine which is a non-selective 
nAChR antagonist, was able to block dopamine release produced by cotinine 
stimulation. This is also in accordance with literature (Dwoskin & Crooks 2001).
To study which nAChRs are involved in this mechanism various antagonists were used 
and it was concluded that p2 and a6p2* subtypes are involved in cotinine-evoked 
dopamine release. This finding is also in accordance with literature (Zoli et al 2002, 
Sharpies et al 2000). In this assay a7 was not shown to be involved in cotinine-evoked 
dopamine release, which is contradictory to published evidence (see section 2.1 and 
2.5), however this may have been due to the limitations of the assay which is explained 
in full in section 2.5.
Three derivatives were made as described in the appendix, targeting both cotinine and 
nicotine. They were then conjugated to ovalbumin in chapter 3. It was however, not 
possible to conclusively determine whether conjugation had occurred and if so how 
many derivatives were attached per ovalbumin molecule. This was because of the lack 
of time and expertise at the beginning of the project. However, the conjugates were 
moved on to the immunisation stage to see the effect of the vaccine on the immune 
response. After immunization of SD rats with these vaccines, only trans-4-thiol cotinine 
produced measurable mid-point titres, however the titres were too low to be used to 
study the effects of the vaccine in neurochemical experiments. This may have been 
due to insufficient conjugation of derivatives onto the carrier molecule, therefore 
insufficient activation of the humoral and cell-mediated responses (as discussed in 
section 1.6.4).
The concentrations of nicotine and cotinine were studied in this initial trial after chronic 
nicotine treatment via osmotic minipump, however as anticipated, the vaccines did not 
produce significant changes in blood nicotine or cotinine levels. The other vaccines 
may not have been able to illicit an immune response due to the insufficient 
conjugation of derivatives on the carrier molecule. Heida et al (2000) showed an 
increase in blood nicotine levels after nicotine vaccination, caused by the binding and 
accumulation of nicotine to the antibodies in serum. There was a trend in this trial of an 
increase in cotinine levels in the sera (discussed in section 3.9), however the results 
were not significant and this was repeated in the next trial to allow for better
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interpretation of the actions of the vaccine. Trans-4-thiol cotinine derivative was taken 
forward to the next trial, where modifications were introduced to increase the immune 
response. In trial 1 an ELISA assay was optimised to detect antibody titres and it was 
determined that coating the wells with the derivative produced the most accurate 
analysis of antibody titre, in comparison to coating with conjugate or using a sandwich 
ELISA. This assay was used for the rest of the project.
The trans-4-thiol cotinine vaccine was taken forward to trial 2 for optimisation. This was 
done by changing a variety of parameters:
• There is a correlation between size of a macromolecule and its immunogenicity 
as discussed in the introduction (section 1.6.4.5), therefore increasing the size 
of the antigen by adding a larger carrier molecule (TT) compared to ovalbumin 
in trial 1 improved the immune response.
• It was also determined that 5pg of the vaccine was the optimal concentration 
producing the highest mid-point titres. Therefore this concentration was used 
for the rest of the project.
• Conjunction with the increase in derivative attachments to the new carrier 
molecule, resulted in a dramatic increase in the immune response (average 
mid-point titres >1:10000) to desired levels where it has been shown to produce 
adequate drug-specific binding affinity (Hieda et al 1997). It was determined 
that 15 derivatives per tetanus toxoid molecule were attached which is in the 
desired region to illicit a high immune response.
• More boosters were also administered. The high levels of titres produced were 
probably caused by the long-lived memory cells, which are produced along with 
the relatively short-lived effector cells of the primary immune response, after the 
second booster. These memory cells proliferate rapidly when exposed again to 
the same antigen, giving rise to a new clone of memory cells as well as new 
effector cells, demonstrated here by the increase of antibody titres after the 
second booster.
• The change in adjuvant from Alum to GSK AS2V was also a successful 
strategy.
• High mid-point titres towards cotinine were obtained in this trial and after 
development of a competitive ELISA, the antibodies produced were shown to 
be specific to cotinine in comparison to nicotine and other nicotine metabolites 
which have been shown to have an effect on nicotine addiction. For example 
nornicotine has been shown to increase dopamine release in a calcium-
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dependent manner from superfused rat striatal slices (Dwoskin et al 1993). The 
specificity of the antibody therefore enables us to determine only the effect of 
the reduction of cotinine to the brain and not other mechanisms that may 
contribute to nicotine addiction. The nicotine vaccines made by Pentel group 
(1997), De Villier et al (2002) or the Xenova vaccine have not shown specificity 
of antibody to their chosen drug to this degree.
This improved vaccine produced a positive result on blood cotinine concentrations after 
chronic nicotine treatment. It was shown that cotinine was retained in the blood.
This is similar to results obtained in the production of a nicotine vaccine (Hieda et al 
1997), where nicotine concentrations were increased in sera after nicotine treatment. 
This retention of cotinine in the blood probably causing a reduction in the concentration 
of cotinine in the brain, in accordance with the project hypothesis as explained earlier.
In trial 3, two injection regimes were used to allow for dopamine release and locomotor 
activity studies. The vaccine used in this trial was the same as in trial 2, however only 
11 derivatives per carrier molecule were shown to be conjugated. This may have been 
due to decomposition of the derivative before conjugation, as a long period had 
elapsed since the production of the derivatives at the beginning of the project. This 
contributed to less robust results in this trial. For example, Lower mid-point titres were 
obtained in trial 3 compared to trial 2. Another factor which may have contributed to 
this was the fall in efficacy of adjuvant used due to long period of storage after its 
production. However, cotinine was still retained in the blood after acute and chronic 
nicotine treatment as seen in trial 2.
There was a significant increase in nicotine - evoked [3H]-dopamine release when rats 
were chronically treated with nicotine compared to saline, in both TT-cotsh and TT- 
cysteine vaccinated rats in trial 2. However in trial 3 there was a significant increase in 
nicotine - evoked [3H]-dopamine release when rats were chronically treated with 
nicotine compared to saline, in TT-cotsh vaccinated rats (same as trial 2) but, nicotine 
evoked a decrease in dopamine release compared to saline in non-vaccinated animals 
which is in accordance with Marks et al (1993). Therefore there seems to be a trend 
towards a larger difference in nicotine-evoked dopamine release and saline treatment 
in vaccinated animals compared to non-vaccinated animals. This decrease in 
dopamine release in non-vaccinated rats may be due to inactivation of nAChRs caused 
by nicotine treatment.
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The analysis of dopamine release from rat striatal slices found an increase in dopamine 
release after treatment with nicotine by daily injection (Yu & Wecker 1994). In contrast, 
Marks et al (1993) showed that dopamine release from mouse brain synaptosomes 
declined after chronic nicotine infusion suggesting desensitisation/inactivation of 
nAChRs. Similar results have also been obtained in our laboratory.
The nicotine evoked dopamine release experiments produced contradictory results 
between chapter 4 and 5. However, the vaccine did produce a trend in changing the 
effect of nicotine on dopamine release in the striatum, which may preliminarily suggest 
that the hypothesis of the vaccine can be plausible i.e.; cotinine is retained in the blood, 
reducing the amount reaching the brain, which in turn is imposing an effect on 
dopamine release in the brain. This pathway has been shown to be involved with 
reward in nicotine addiction, concluding that this vaccination has the potential of having 
an effect on nicotine addiction
Unfortunately the vaccine did not cause a significant effect on locomotor activity both 
with acute and chronic nicotine treatment. However, the low antibody titres were 
perhaps responsible for the lack of significance in the difference between locomotor 
activity in vaccinated and non-vaccinated rats. The cotinine concentration in the brain 
may not have been reduced to a large enough degree to produce a significant change 
in nicotine-induced locomotor sensitisation.
This project has given a proof of concept for the cotinine vaccine. It has shown that a 
vaccine specific for cotinine has been produced giving some preliminary results on the 
effect of immunization on biological and neurochemical parameters.
6.2 Future perspective
The cotinine vaccine project is at its preliminary stages. After obtaining specific 
antibodies towards cotinine, there are countless areas of examination of the immune 
response.
One route to take should be to obtain the concentration of antibodies in the blood after 
immunization and the binding affinity of the antibody for the antigen as these are 
important parameter to investigate. They may allow for the understanding of the 
actions of the antibodies produced against cotinine, and the effectiveness of the 
antibodies in retaining cotinine in the blood and for how long. Such experiments were 
conducted by Heida et al (1997) who demonstrated that the nicotine binding capacity of
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anti-nicotine antibodies after active immunisation (1.3 pmol/L) exceeded the venous 
plasma levels of nicotine (up to 0.26 pmol/L) and was nearly equal to the arterial 
plasma levels reported in humans after smoking one or two cigarettes (Benowitz et al 
1983, Henningfield et al 1993). Fourty minutes after intravenous administration of 
nicotine 0.03 mg/kg, there were 4 to 6 fold greater concentrations of nicotine in the 
plasma of immunised animals but there were no differences in brain levels of nicotine. 
However, when nicotine levels were examined at a more clinically relevant time point (3 
minutes after intravenous nicotine administration), brain nicotine levels were reduced 
by 36%, while plasma concentrations raised 3 to 6 fold (Heida et al 1999). The 
pharmacokinetics were similar even after five repeated doses of nicotine (Keyler et al 
1999), or after long-term exposure to nicotine before and during immunisation (Heida et 
al 2000). Preclinical studies of the Xenova TA-NIC™ (a nicotine derivative coupled to 
rec cholera toxin B) vaccine produced high titres of nicotine-specific antibodies in mice 
and altered the pharmacokinetic distribution of a nicotine challenge. Specifically one 
minute after an intravenous injection, nicotine levels in the brain decreased while 
plasma levels increased. They concluded that the antibodies may have the capacity to 
block the psychoactive effects of nicotine.
It would also be important to study what happens to the bound cotinine in the body. 
Does it cause an effect in other parts of the body? Measurement of antibody-cotinine 
complex as well as cotinine and nicotine in different organs between vaccinated and 
non-vaccinated animals is one way of achieving this. In 2003 Satoskar et al showed 
that vaccination against nicotine reduces nicotinic distribution to the brain not only by 
sequestering nicotine in serum but also by redirecting tissue distribution 
disproportionately away from the brain, such that nicotine concentrations are reduced 
to a greater extent in the brain than in other tissue. They also showed that maternal 
vaccination against nicotine reduced nicotine distribution to foetal brain in rats (Keyler 
et al 2003).
The De Villier vaccine also showed that immunization against nicotine altered the 
distribution but not half-life of nicotine (de Villiers et al 2004). Therefore studying the 
pharmacokinetics of nicotine and cotinine in cotinine vaccinated animals is also an 
important area to study to get a better understanding of its actions in the body. Will the 
half -life of cotinine remain the same? If so will the antibodies be able to retain and aid 
in the elimination of cotinine effectively as cotinine has a much longer half-life 
compared to nicotine.
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Another area of investigation could be the characterization of the immunoglobulins 
activated by the vaccine as this would be useful to understand the immune response 
more thoroughly. It would also be important to study the time period in which the 
immune response is effective. Pentel et al (1997) used an injection regime over 5 
weeks and similar time periods were used in the other nicotine vaccines. Would 
boosters be needed throughout the life of the “ex-smoker” to prevent relapse or would it 
only be an effective tool during cessation?
The animal species can be changed to find out effect of vaccination on other species 
as well as examining whether a better immune response can be obtained.
A large array of neurochemical and behavioural examinations can been conducted to 
study the effect of the cotinine vaccine on nicotine addiction. For example, locomotor 
activity tests must be conducted again with a higher immune response in the animals to 
find out the effect of vaccination against cotinine on nicotine-evoked sensitisation. 
Passive immunisation of rats with nicotine vaccine (Pentel et al 2000) showed 
attenuated nicotine-induced increases in systolic blood pressure and completely 
prevented nicotine-induced increases in locomotor activity measured 25 hours later.
Other behavioural experiments can also be conducted. For example in nicotine- 
dependent rats, passive administration with nicotine vaccine prevented nicotine 
reversal of abstinence signs (Malin 2001). These experiments were done using 
passive immunisation however, with active immunisation with the cotinine vaccine we 
can use the same behaviour experiment to study the effect of reduced cotinine on 
abstinence symptoms. Will these symptoms be reduced?
Self-administration experiments can be conducted to examine whether the cotinine 
vaccine does produce a reduction in nicotine intake in vivo in animals who have been 
previously “addicted” to nicotine. This would provide a good insight into the actions of 
the vaccine on the complex behavioural components of nicotine addiction. This was 
tested using passive immunization against nicotine which attenuated nicotine 
discrimination using a two lever operant chamber (Malin et al 2002). The De Villier 
vaccine also showed that vaccinated rats do not re-instate nicotine self-administration 
behaviour when exposed to nicotine (Lindblom et al 2002).
Microdialysis experiment would be a good tool to study the effect of vaccination on 
different neurotransmitter actions involved in nicotine addiction such as dopamine and
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noradrenaline release in the areas of the brain which are involved in the addiction 
pathway including the NAcc core and shell. De Villiers et al (2002) showed a reduction 
in the outflow of dopamine in the NAcc shell with their nicotine vaccine. The questions 
below were raised in the introduction and microdialysis experiments are one tool to 
examine these questions:
• Will the decrease in cotinine in the brain have an effect on excitatory inputs into 
the VTA via glutamatergic transmission from the prefrontal cortex?
• Will the inhibitory inputs into the VTA via GABAergic neurons have an effect on 
the addiction pathways?
• Will the decrease in cotinine and the subsequent larger effect of nicotine show 
different characteristics on the dopamine released in the Nacc shell and core 
and therefore on the hedonic properties of nicotine?
• The aversive effects of nicotine may also be altered with the decrease of 
cotinine and the subsequent increase of nicotine effect in the brain.
Long term trials should also be set up to examine the effect of vaccination on the 
longer term parameters of nicotine addiction such as withdrawal and craving in animal 
models.
Of course, the effect of the cotinine vaccine would be most interestingly studied in 
humans to find out whether it provides a positive and effective tool to combat nicotine 












Figure 7.1: Chemical structure of Cotinine molecule. Cotinine is the major metabolite of 
nicotine. It has a similar structure with added oxygen molecule to position 8 on the pyrolidine 
ring. It accounts for 70-78% of metabolised nicotine, with a half-life of 16-20 hours in humans.
Immunogenicity (refer to section 1.6.4 in Introduction) is the ability of a molecule to 
induce an immune response and is determined by both the intrinsic chemical structure 
of a molecule and whether or not the host animal can recognize the compound. For a 
compound to elicit a primary antibody response and a strong secondary response, it 
must contain an epitope that can bind to the cell-surface antibody of a virgin B cell and 
it must promote cell-to-cell communication between B cells and helper T cells. When 
an immunogen is too small in size, as the cotinine hapten is in this project, the T helper 
cells are often not activated resulting in no response from the immune system. To 
remedy this problem, the immunogen must be conjugated to a carrier protein. The 
first step to making a vaccine for cotinine is the successful conjugation of cotinine onto 
an immunogenic carrier protein in order to induce an antibody response in vivo. To do 
this, the cotinine molecule (figure 7.1) must be derivatised so it can be easily linked to 
the carrier protein. This is the focus of the appendix.
One consideration in producing this cotinine vaccine is to be able to successfully obtain 
a patent for an anti-cotinine vaccine, and to do this the induced antibodies must 
predominantly recognize cotinine as opposed to nicotine. This would then avoid 
infringing the existing patents in the area of nicotine vaccines.
Cotinine itself could be linked to an immunogenic carrier protein via a number of 
different positions on its structure (positions 1, 5, 6 or 10) (figure 7.1). As the key 
differentiation factor from nicotine is the carbonyl group on the pyrolidine ring, the ideal 
linkage site would be on the pyridine ring at position 1, 5 or 6. Once conjugated via 
one of these sites, the pyrolidine ring would be presented to the body’s immune system 
and therefore increase the chances of obtaining a cotinine specific antibody response.
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Unfortunately it is not possible to predict on paper which linkage would yield the best 
immune response therefore work was done on several different linkage sites. The 
actual nature of the linker should be 4-6 carbons in length to adequately expose the 
cotinine hapten to the immune system. Ideally at the end of the linker there should be 
a sulfhydryl group which will enable the cotinine-linker conjugate to bind to the protein 
via a maleimide bond. This type of chemical linkage lends itself well to large-scale 
vaccine manufacture. However for initial studies there could be a carboxyl group at the 
end of the linkage which can then be linked to the protein via a carbodiiamide bond.
The production of the derivatised cotinine and nicotine molecules were undertaken by 
Dr. Sham Ramaya and Professor Tim Gallagher at University of Bristol.
7.2 Materials
All commercially obtained reagents were purified and dried according to accepted 
procedures (Purification of Laboratory Chemicals, Perrin, Armarego & Perrin, 2nd 
Edition). Infrared spectra (vmax) were recorded in the range of 3500-3100 cm'1 using a 
Perkin-Elmer spectrophotometer as a thin film on NaCI plates. Nuclear Magnetic 
Resonance (NMR) spectra were recorded at the specified field strength and in the 
solvent indicated using standard pulse techniques on a Joel GX 270, Lambda 300 or a 
Joel GX 400 spectrometer. All samples were dissolved in deuterochloroform using 
tetramethylsilane (TMS) as an internal reference. Chemical shifts are quoted in parts 
per million (ppm) downfield from TMS. Coupling constants (J) are quoted in Hz. Mass 
spectra (m/z) (electron ionisation (El) or chemical ionisation (Cl) were obtained using a 
Fisons/VG Analytical Autospec System at the University of Bristol. Flash column 
chromatography was carried out on silica gel (Merck 9385) or 60 H silica gel (Merck 
TLC). Thin layer chromatography (TLC) was carried out using Merck glass-backed 
Kieslegel 60 F254 plates. Chromophoric compounds were visualized by UV light (254 
nm) and subsequently staining with alkaline potassium permanganate solution. 
Evaporation of solvents was carried out on a Buchi rotary evaporator. All chemicals 
were obtained from Aldrich.
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7.3 Methods and Results




Figure 7.2: Synthetic reaction for generating 2- and 6-amino nicotine from nicotine.
This synthesis was carried out as a preliminary stage for the attachment of a viable 
linker on the 6 position of the nicotine pyridine ring.
This method (figure 7.2) was based on literature method of Casida et al (1999). 
Sodium amide (3.1g, 0.08 mol) was added portion wise, to a solution of (-)-nicotine 
(4.95cm3,0.03 mol) in p-xylene (dry, distilled from P20 5, 12.5cm3). The mixture was 
then heated at 130°C for 12 hours. The resulting brown mixture was cooled to room 
temperature, and concentrated hydrochloric acid was added carefully until pH1. The 
organic phase was extracted with ether (3x50cm3), and the aqueous phase was made 
again alkaline (pH 14) with 20% aq NaOH and then extracted with ether (3x50cm3). 
The combined extracts were dried (Na2S04), filtered and concentrated in vacuo to give 
a brown slurry. Purification in order to separate this product from the corresponding 2- 
amino isomer was done by flash chromatography using 0-50% methanol / 
dichloromethane as eluant gave 6-amino nicotine (2.81 g, 51%) as a brown oil.
8h (300 MHZ, CDCI3) 7.97 (1 H, d, J2.4, H-2), 7.49 (1 H, dd, J2.4, 8.5, H-4), 6.52 (1 H, 
d, J 8.5, H-5), 4.47 (2 H, br s, NH2), 3.22 (1 H, t d, J 1.9, 9.3), 2.93 (1H, d d, J 7.5, 9.3), 
2.25-1.80 (5 H, m), 2.14 (3 H, s, CH3).
7.3.2 Synthesis of 6-Amino Cotinine
CH
CH
Figure 7.3: Synthetic reaction for generating 6-amino cotinine from 6-amino nicotine.
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This synthesis was carried out as a preliminary stage for the attachment of a viable 
linker on the 6 position of the cotinine pyridine ring.
This method (figure 7.3) was based on literature method: Acheson et al (1979). 
Bromine (2.26 cm3) in acetic acid (2.8 cm3) and water (0.6 cm3) were added over one 
hour to a stirred solution of 6-amino nicotine (1.13g, 6.38 mmol) in concentrated acetic 
acid (11.3 cm3) and water (2.8 cm3). After one hour at room temperature, water (45 
cm3) was added and the mixture stirred and heated to 85°C for 15 minutes, and then 
cooled to room temperature.
Concentrated acetic acid (4.5 cm3), concentrated hydrochloric acid (2.3 cm3) and water 
(1.1 cm3) were added, followed by zinc dust (3.96g) which was added portion wise. 
The mixture was stirred at room temperature for 12 hours. After filtering, the solution 
was basified using aqueous ammonia 0.88. Extraction with chloroform (4 x 50 cm3), 
drying the combined extracts over Na2S04, filtering and removing the solvents in vacuo 
gave a yellow-brown oil. Recrystallisation of the crude product from benzene gave 6- 
amino cotinine as a pale yellow solid (416 mg, 34%).
6h (270 MHz, CDCI3) 7.93 (1 H, d, J2.2, H-2), 7.28 (1 H, d d, J2.2, 8.5, H-4), 6.56 (1 H, 
d, J 8.5, H-5), 4.72 (2 H, br s, NH2), 4.44-4.39 (1 H, m), 2.70-2.40 (3 H, m), 2.64 (3 H, 
s, CH3), 1.94-1.78(1 H, m).
Problems were encountered in purifying 6-amino nicotine, therefore attempts were 
made to oxidize the mixture of 2- and 6-aminonicotine directly to the target 6- 
aminocotinine which was isolated in 41% yield.
7.3.3 N(6)-(Alkvl) 6-Amino Cotinine
N bromohexanoic acid




Figure 7.4: Synthetic reaction for addition of carboxyl group on 6-amino cotinine.
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The aim of this experiment was to attach a carboxyl group at the end of a 6-carbon 
linker to produce a viable derivative.
The above reaction did not proceed using 6-bromohexanoic acid in Methanol, and only 
gave back starting material. Using 1 equivalent of K2C 03 also failed to give the desired 
product. Using 2 equivalents of K2C 03 also gave starting material, and then warming 
the reaction mixture to 40°C overnight also gave back starting material.
Similarly, we failed to isolate the A/-alkylated product when 5-bromopentanoic acid was 
used, with and without added K2C 03 (1, 2 equivalents K2C 03 , and heating to 40°C 
overnight). Under all conditions only starting material was isolated.
Literature suggests that direct alkylation of 2-aminopyridine takes place at the pyridine 
nitrogen. However, there are reports that when NaNH2 is used as base, the amino NH2 
undergoes alkylation.
Following some work done by Beresnevichyus (1992), on 2-amino pyridines, the 
following reaction was tried. The reaction involved the addition of acrylic acid to a 
refluxing solution of 6-aminocotinine in toluene. Unfortunately, when purifying using an 
ion exchange column (Amberlite resin), no carboxylic acid containing product was 
isolated. We cannot assume that this did not occur, only that it was not isolated.
The reaction (figure 7.5) was repeated, this time evaporating off the solvent and 
analysed by iH NMR. To a boiling solution of 6-amino cotinine (100mg, 0.5 mmol) in 
toluene (1cm3), acrylic acid (0.04 cm3, 0.6mmol) was added and the boiling continued 
for another hour. During the heating an oil separates out. The reaction mixture was 
cooled to room temperature, and the solvent removed in vacuo. Water (5cm3) and 
dichloromethane (5cm3) was added, and the aqueous phase was washed with further 
portions of dichloromethane ( 3 x 5  cm3). The organic extracts were combined and the 
solvent removed in vacuo. Purification by flash chromatography using 2% methanol/ 
dichloromethane as eluent, gave the 6-amino cotinine conjugate (12mg, 9%) as a 
colourless oil.
5h (270 MHz, CDCI3) 8.66 (1 H, br s, NH), 8.36 (1 H, d, J 8.5, H-5), 8.21 (1 H, d, J 2.2, 
H-2), 8.21 (1 H, d d, J2.2, 8.6, H-4), 6.51 (1 H, d d, J 1.5, 17.0, H-14a), 6.36 (1 H, d d, 
J 9.8, 17.0, H-13), 5.84 (1 H, d d, J 1.5, 9.8, H-14b), 4.54 (1 H, m), 2.70 (3 H, s, CH3), 
2.67-2.46 (3 H, m), 1.97-1.79 (1 H, m); 6c (75MHz, CDCI3) 175.4 (C-8), 163.7 (C-12),
151.5 (C-6), 146.2 (C-2), 136.6 (C-4), 132.5 (C-7), 130.8 (C-13), 128.9 (C-14), 114.5 









Figure 7.5: Synthetic reaction for the production of N(6)-(Alkyl)6-amino cotinine from 6- 
amino cotinine.
We speculated that this product is formed by initial /V-alkylation on the pyridine 
nitrogen, followed by internal acylation, mediated by thermolysis. The structure of the 
product was clear from the NMR data, which showed the alkenyl signals clearly. The 
product represents an unusual and unexpected product that also offers potential in 
terms of the long term objectives of the project. However, it was not taken forward at 
this stage due to the difficulty of its production and low yield.





Figure 7.6: Synthetic production of N-alkyI pyridyl cotinine from cotinine.
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The aim of this experiment was to attach a carboxyl group at the end of a 6-carbon 
linker on position 1 of the cotinine pyridine ring, to enable the cotinine-linker conjugate 
to bind to the carrier molecule via a carbodiiamide bond.
GSK supplied a procedure for alkylation on pyridine nitrogen of nicotine. In this case, it 
was possible to isolate the product using filtration. However, when the procedure was 
applied to cotinine, using 6-bromohexanoic acid as the alkylation agent, the product 
was not easily isolated by filtration. Attempts to precipitate the product directly using 
hexane, petrol 40-60°C, ethanol, ether and ethyl acetate failed to give a suitable solid, 
ether and EtOAc gave very fine suspension, which could not be filtered which is why 
this was not satisfactory. Therefore a different procedure was tried.
The reaction (figure 7.6) was conducted under nitrogen, and all glassware was pre­
dried in an oven at 150°C for at least 12 hours prior to use. (-)-Cotinine (200mg,
1.1 mmol) was dissolved in dry methanol (1cm3, distilled from CaH2) and cooled to 0°C  
in an ice bath and 6-bromohexanoic acid (244mg, 1.25 mmol) in dry methanol was 
added drop wise. The solution was then allowed to stir at room temperature for 24 
hours. The solvent was then removed in vacuo, and water (5cm3) and CH2CI2 (5cm3) 
were then added to the residue. The aqueous phase was washed with CH2CI2 ( 6 x 5  
cm3), until the aqueous phase only showed one baseline product by TLC in methanol. 
The water was removed (freeze drier) to give the A/-aIkyIpyridyI cotinine conjugate 
(90mg, 27%) as a colourless oil.
[Found; (M+), 291.1718. Ci6H230 3N2 requires (M+) 291.1709]; 5H (270 MHz, CDCI3) 
8.84 (2 H, d, J6.3), 8.47 (1H, d, J7.9), 8.09 (1 H, d d, J6.3, 7.9), 5.03 (1 H, m), 4.62 (2 
H, t, J 7.3), 2.72-2.54 (6 H, m), 2.36 (2 H, t, J 7.3), 2.09-1.88 (3 H, m), 1.68-1.56 (2H, 
m), 1.41-1.29 (2 H, m); m/z (El+) 291 [M \ 3%], 176 [M -  ((CH2)5C 02H), 42%].
This yield of 27% could not be increased despite trying longer times (room temperature 
for 48 hours), warming to 40°C for 12 hours and increasing the number of equivalents 
of 6-bromohexanoic acid from 1 equivalent to 2 equivalents.
The corresponding reaction using 5-bromovaleric acid was also tried, but only 5% of 
the desired product was isolated. This is presumably due to the ease with which the 
pyridyl-A/-alkylated product could cyclise. This type of reactivity might suggest that the 
product would not be a stable entity under the conditions required for the project.
The formation of a succinamate ester derivative of the /V-alkyl pyridyl cotinine was then 
attempted. Unfortunately using both DCC and water soluble EDC as coupling agents, 
gave water soluble products that could not be separated. The sensitivity anticipated for 
the succinamate ester precluded further investigation. However, this product was
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taken forward for conjugation to a carrier molecule and injection into rats, to find out
whether it would raise sufficient specific antibodies.





Figure 7.7: Synthetic production of N-alkyl pyridyl nicotine from nicotine.
The aim of this experiment was to attach a carboxyl group at the end of a 6-carbon 
linker on position 1 of the nicotine pyridine ring, to enable the nicotine-linker conjugate 
to bind to the carrier molecule via a carbodiiamide bond.
The reaction (figure 7.7) was conducted under nitrogen, and all glassware was pre­
dried in an oven at 150°C for at least 12 hours prior to use. Nicotine (200mg, 1.2mmol) 
was dissolved in dry methanol (2cm3, distilled from CaH2) and cooled to 0°C in an ice 
bath and 6-bromohexanoic acid (257mg, 1.32 mmol) in dry methanol was added drop 
wise. The solution was then allowed to stir at room temperature for 18 hours. The 
solvent was then removed in vacuo, and water (5cm3) and CH2CI2 (5cm3) were then 
added to the residue. The aqueous phase was washed with CH2CI2 ( 6 x 5  cm3), until 
the aqueous phase only showed one baseline product by TLC in methanol. The water 
was removed (freeze drier) to give the A/-alkylpyridyl nicotine conjugate (425mg, 27%) 
as a sticky red oil.
5h (270 MHz, CDCI3) 8.96 (1H, br.s, H-2), 8.83 (1H, br.d, J 6.2 Hz H-6), (8.58 (1H, br.d, 
J 8.3Hz, H-4), 8.04 (1H, d d, J 6.2, 8.3 H-5).
/V-alkylation of nicotine can be done via the pyridine or pyrrolidine nitrogen. The 
desired product is via alkylation of the pyridine ring. Alkylation of the pyrrolidine ring 
produces an undesired product and a mixture of dueterisomers. The NMR signals 
show this undesired product but could not be isolated. This did not occur in the 
corresponding cotinine derivative. This final product was taken forward for conjugation
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to a carrier molecule and injection into rats, to find out whether it would raise sufficient
specific antibodies.
7.3.6 Incorporation of a thiol moiety into racemic trans-4-cotinine carboxvlic 
acid.
This experiment was conducted to attach a sulfhydryl group at the end of the linker on 
position 10 on the pyrolidine ring, to enable the cotinine-linker conjugate to bind to the 
carrier molecule via a maleimide bond.
The racemic trans-4-cotinine was first coupled using DCC as the coupling agent, but 
the desired product was not isolated. An alternative approach was investigated using 
the corresponding acid chloride. No good evidence was obtained to show that this 
reactive intermediate was either generated or stable under the conditions needed. It 






Figure 7.8: Synthetic production o f trans-4-thiol cotinine from trans-4-cotinine carboxylic 
acid.
This reaction (figure 7.8) was conducted under nitrogen, and all glassware was pre­
dried in an oven at 150°C for at least 12 hours prior to use. {±)-trans-4-Cotinine 
carboxylic acid (200mg, 0.9mmol), 2-aminoethanethiol.HCI (103mg, 0.9 mmol) and 
triethylamine (0.13cm3, 1.8mmol) were dissolved in dry DMF (1.5 cm3). The reaction 
mixture was cooled to 0°C in an ice bath, and EDCI.HCI (174mg, 0.9mmol) was then 
added to the above solution. The reaction mixture was warmed to room temperature 
and stirred for a further 12 hours. The solvent was removed in vacuo, and water (5 
cm3) and CH2CI2 (5 cm3) were added to the residue. The aqueous phase was washed 
with CH2CI2 ( 4 x 5  cm3). The combined organic extracts were dried over Na2S04, 
filtered, and the solvent removed in vacuo. Purification by flash chromatography using 
5% methanol/ dichloromethane as eluent, gave the product (136mg, 54% yield) as a 
colourless oil.
168
[Found; (M+), 279.1045. C13H1702N3S requires (M+) 279.1041]; 5H (400MHz, CDCI3) 
8.58 (1 H, d d, J4.9, H-4), 8.50 (1 H, d, J2.0, H-2), 7.60 (1 H, d t, J2.0, 7.8, H-6), 7.38 
(1 H, d d, J 4.9, 7.8, H-5), 6.77 (1 H, br t, J 5.4, NH), 4.79 (1 H, d, J 6.8, H-7), 3.51-3.35 
(2 H, m, H-9a, H-9b), 2.92-2.68 (5H, m, H-10, H-13a, H-13b, H-14a, H-14b), 2.64 (3 H, 
s, CH3), 1.32 (1 H, t, J 8.3, SH); vmax (thin film)/crrf1 3500-3100 (br NH), 2543 (S-H), 
1684 (C=0); m/z (El+) 279 [M+, 65%]. The product is racemic.
7.4 Discussion















These three derivatives were chosen as they were the most easily obtained and 
produced the largest yields. The A/-alkyl pyridyl nicotine was taken forward to be tested 
for its immunological response, for a nicotine vaccine being considered by GSK. The 
trans-4-thiol cotinine derivative is probably the most viable derivative as it lends itself to 
conjugation to a carrier molecule via a maleimide bond, which is most suitable for large 
scale vaccine production. The linker is on position 10 of the pyrolidine ring, which 
allows for enough space for the epitope to expose the oxygen molecule on cotinine, 
which is the only difference between cotinine and nicotine. Therefore production of 
specific antibodies towards cotinine may be possible. A/-alkyl pyridyl cotinine was 
taken forward as it can be conjugated to a carrier molecule via a carbodiiamide bond, 
which is suitable for this initial study. The linker is on position 1 of the pyridine ring, 
which also allows for the epitope to expose the oxygen on cotinine and production of 
specific antibodies towards cotinine may be possible.
COOH
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